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Preface - Cellular Pharmacology 
 
For more than 100 years, trials in “systemic” or “clinical” pharmacology have been revealing 
the behavior of drug-like molecules in organisms. In this context pharmacology is divided in 
pharmacodynamics and pharmacokinetics. Whereas pharmacodynamics deal with the 
impact of a drug or a combination of those on organisms, pharmacokinetics in turn describe 
the impact of an organism and its metabolic systems on the fate of the drug compound. 
Moreover, in the last decades many biophysical and bioanalytical techniques were 
developed and established to display the exact binding properties of defined binding 
partners, an area of activity that is often named “molecular pharmacology”. Especially high-
throughput screening approaches play a key role in today‟s drug discovery. In cell culture-
based approaches mostly the impact of a molecule on a single response that can be easily 
read out is displayed. Between systemic and molecular pharmacology there is still a large 
gap and the behavior of a molecule in its cellular and subcellular context is misleadingly 
assumed to be rather simple: the compound penetrates the plasma membrane, binds to its 
dedicated target structure and thereby executes its mode of action. In reality, the processes 
are highly complex and there is still an unmet need to untangle the network of a compound‟s 
behavior in its physiological context. In future drug discovery many questions that deal with 
cellular pharmacology will certainly play a crucial role: How does a certain molecule enter the 
cell? Can this be influenced by combinations of drugs or by formulations? Where is the 
molecule located intracellularly? What is its binding profile like in its native environment? 
Does it diffuse freely or is it bound to membranes, proteins or other high-molecular weight 
structures? What is the unbound concentration in the direct environment of the target 
structure? How fast is a molecule degraded, exported or transported within or out of the cell? 
This thesis addresses some of the most relevant questions concerning “cellular 
pharmacology”. In one chapter the modular assembly of peptides conjugated to a chemically 
inert polymeric backbone and the impact of a backbone on the activity of the peptides as well 
as the import efficiency of the conjugates is investigated. These results should support the 
untangling of signal transduction networks. A second chapter concentrates on the effect of 
polymer-conjugation on the peptide stability, a third one on the residence time of peptides 
and conjugates within cells and therefore the time in which these can influence signal 
transduction networks. A forth chapter focuses on the tertiary structure-based mode of action 
of a cell-penetrating peptide derived from the human milk protein human lactoferrin and its 
ability to facilitate the uptake of a cargo. And, finally, one chapter focuses on the intracellular 
binding profile of small molecule anti-cancer drugs.  
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Fig. 0.1. Challenges of cellular pharmacology – a complex network of reversible and 
irreversible processes. (1a-b) extracellular behavior of compound, (1a) interaction with serum 
proteins, (1b) degradation; (2a-c) cellular import, (2a) direct and passive membrane penetration, (2b) 
active/passive transport, (2c) endocytosis; (3) endosomal escape; (4a-c) cellular export, (4a) direct 
and passive penetration, (4b) active export via transporters, (4c) exocytosis; (5) paracellular transport; 
(6a-b) intracellular degradation or metabolism, (6a) cytosolic degradation, (6b) endosomal 
degradation; (7a-d) intracellular binding properties, (7a) binding to specific off-target binding sites, (7b) 
unspecific binding to proteins, (7c) binding to the target protein(s), (7d) interaction with/insertion into 
the membrane; (8) intracellular transport (directed motion/ undirected diffusion); (9) binding activity to 
extracellular receptors; (10) indirect influence on intracellular signal transduction processes by binding 
to cofactors and other binding partners 
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1. Introduction 
 
1.1. Pharmacokinetics on the cellular level 
 
1.1.1. Cellular ADME kinetics - “ALL LIFE IS MOVEMENT” (Leonardo Da Vinci) 
 
ADME kinetics on the cellular level deal with the absorption of molecules into the cell, the 
distribution within the cell and its compartments, the enzyme-mediated metabolism and 
finally the elimination of molecules or their metabolic products out of the cells.  
Uptake into the cell can be facilitated via numerous ways such as endocytosis (Conner and 
Schmid, 2003) followed by endosomal escape, via active transport by ATP-driven 
transporters (Pedersen, 2007), via passive diffusion through channels or by direct 
penetration though the membrane. The distribution and localization of a molecule inside the 
cell can also be controlled by active transport mechanisms, by diffusion, by its 
physicochemical properties such as its size, shape, hydrophobicity or charge or by its 
pharmacodynamic binding profile. Hydrophobicity significantly influences the subcellular 
localization (Verma et al., 2008). In fact, the distribution can have a considerable impact on 
the intracellular local concentration. Furthermore, certain intracellular locations can prevent 
the compound from degradation or in turn accelerate these processes. 
 
 
Fig. 1.1. The four phases of ADME kinetics on the cellular level. 
 
Regarding metabolic processes Phase I and Phase II are distinguished (Oesch et al., 2007; 
Huang et al., 2009; Testa and Kramer, 2009). The Phase I metabolism is characterized by 
cleavage (catalyzed by proteases, protease complexes, esterases, epoxyd hydrolases, etc.), 
by oxidation (catalyzed by the cytochrome P450 (CYP) superfamily, peroxidases, 
dehydrogenases, monooxygenases, monoamine oxidases, etc.) or by reduction (catalyzed 
by reductases or a consequence of the reductive cytoplasm). In this thesis, especially 
proteases and phosphatases play a key role. The Phase II metabolism is characterized by 
the conjugation of other molecules to the compound (catalyzed by gluthathion-S-
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transferases, UDP-glucoronsyltransferases, acetyltransferases, sulfotransferases, kinases, 
etc.). Mostly, these processes inactivate the pharmaceutical active molecule, but in some 
cases a prodrug has to be metabolized to become active, the molecule cannot be entirely 
inactivated or changes its target spectrum (Rautio et al., 2008). In this case the product of 
the metabolic processes is named active metabolite (Testa, 2009; Testa and Kramer, 
2009). The elimination of the therapeutic molecule is facilitated by passive diffusion through 
the cell membrane, via passive channels or via active transport by ATP-driven transporters 
(Multidrug Resistance Proteins (MDRs), Multidrug Resistance-Related Proteins (MRPs), 
etc.). 
 
 
1.1.2. Cellular pharmacokinetic parameters 
 
The usage of pharmacokinetic parameters allows the description of the molecule‟s properties 
regarding its behavior in organisms, tissues and cells.  
In terms of cells the biological half-life t1/2 describes the time in which half of the initial 
concentration c0 of the observed molecule has either left the cell, actively or passively, or is 
metabolized. But, as uptake into the cell is a time-dependent process and the uptake and 
elimination kinetics temporally overlap, the initial concentration can only be estimated. The 
kinetics of the concentration c rather follow a Bateman Equation (see below). Instead of an 
initial concentration the integral of the concentration curve is given as the area under the 
curve AUC. 
The protein-binding coefficient PB describes the fraction of molecules that is bound to 
proteins and is therefore subducted from the free concentration. In systemic 
pharmacokinetics the PB value describes the fraction of molecules in blood serum that is 
protein-bound, mostly to albumins. For cellular pharmacokinetics it is defined here as the 
description of the total protein binding capacity to extra- and intracellular proteins. 
The PB value is mostly related to the hydrophobicity of a molecule, which is quantified by the 
logarithmic octanol/water partition coefficient, the logP value. 
Additionally, the hydrophobicity has a direct impact on the uptake mechanism. Whereas 
hydrophilic molecules have to be taken up via transporters or channels, hydrophobic 
molecules can also enter the cell by direct penetration of the cell membrane. Highly 
hydrophobic molecules, in contrast, tend to accumulate in membrane bilayers. Alternatively, 
the hydrophobicity of a pharmaceutical molecule can be describe by means of the computer-
based approach of calculating the Polar Surface Area (PSA). Here, the area, given in Å2, 
that is covered by polar heteroatoms, is calculated (Ertl et al., 2000), the smaller the PSA the 
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more likely is the molecule cell-permeable.The logP value and the PSA can be calculated via 
open source programms such as. molinspiration (http://www.molinspiration.com/cgi-
bin/properties) (Ertl et al., 2000). The fraction of compound that is absorbed by a cell can 
also be classified by the resorbance factor f. In general, therapeutic molecules are often 
described by the Biopharmaceutics Classification System (BCS). Here, the molecules are 
classified by their ability to penetrate cell membranes and by their solubility in an aqueous 
environment. The molecules are allocated in four BCS classes that can be specified by their 
physicochemical properties (van de Waterbeemd, 1998). 
 
Tab. 1.1. The Biopharmaceutics 
Classification System (BCS): 
 
Class I 
 
high permeability 
high solubility 
 
 
Class II 
 
high permeability 
low solubility 
 
 
Class III 
 
low permeability 
high solubility 
 
 
Class IV 
 
low permeability 
low solubility 
 
 
 
Whereas Class I molecules show an 
unproblematic behavior as they can easily 
enter cells and are well-soluble in 
biological matrices, Class II molecules 
require special treatment regarding to their 
pharmaceutical formulation to enhance 
their solubility in biological systems and 
Class III and Class IV molecules have to 
be modified by means of conjugation to 
other molecules, capping of respective 
active groups or non-covalent formulation 
to enhance their permeability. 
Other parameters that are regularly used in systemic pharmacokinetics as the volume of 
distribution VD and the bioavailability F are less important on the level of single cells and 
are not described here further. In summary, the pharmacokinetics-related usability of a drug 
candidate can be predicted due to its physicochemical properties. One of the first computer-
based approaches with an wide applicability was proposed by Christopher A. Lipinski (Pfizer 
Inc.) (Lipinski et al., 2001). As an alternative, Arup K. Ghose (Amgen Inc.) published a 
frequently cited approach (Ghose et al., 1999).  
 
Tab. 1.2. Physicochemical requirements on a therapeutic molecule 
 Lipinski et al. Ghose et al.  
hydrogen bond donors < 5  
hydrogen bond acceptors < 10  
molecular weight < 500 160 to 480  
logarithmic octanol/water partition coefficient < 5 -0.4 to 5.6  
molar refractivity  40 to 130  
heavy atoms  20 to 70  
 
Both approaches bear several significant drawbacks. On the one hand, the presence of 
cellular transporters and channels, that can also facilitate the efficient uptake of hydrophilic or 
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high-molecular weight compounds, is totally ignored. On the other hand, the possibility of 
chemical modifications and pharmaceutical formulations of compounds possessing 
promising pharmacodynamic properties is not taken into consideration. Experimental and 
predicted pharmacokinetic data and parameters can be found in open source domains such 
as DrugBank (University of Alberta, Alberta, Canada, http://www.drugbank.ca/) or PubChem 
(National Center for Biotechnology Information (NCBI), Bethesda, USA, 
http://pubchem.ncbi.nlm.nih.gov/). Some well-accepted and orally administered drugs such 
as methotrexate (logP -1.8, value based on the PubChem data base) or peptide- and protein-
based drugs such as vancomycin (logP -2.6) would not be classified as useful compounds 
according to the above-mentioned computer-based approaches. Nevertheless, the 
computer-based approaches are a valuable tool to save costs and time as they allow a pre-
selection of possible lead structures without experimental effort. 
The cellular uptake efficiency J of a drug can be characterized by the drug transported per 
unit of time and per membrane surface area. It is dependent on the permeability coefficient 
P, and the concentration gradient between the concentration in the donor compartment 
cD and the concentration in the receiver compartment cR (Goldberg and Gomez-Orellana, 
2003). 
 
)(* RD ccPJ        (1.1) 
 
 
1.1.3. Description of cellular pharmacokinetic processes 
 
Dynamic processes such as the degradation or the metabolism of a molecule are described 
by exponential functions of differing orders. The order depends on the number of rate-limiting 
steps. In pharmacokinetic systems mostly kinetics of the first order are employed as here 
solely the concentration of the drug-like molecule is rate-limiting. Therefore, the reaction rate 
v over the time t is dependent on the substrate concentration [S] and the rate constant k. 
 
][Sk
dt
dS
v        (1.2) 
integrated 
kteSS 0][][         (1.3) 
 
Enzyme activity is quantified by the Michaelis-Menten Equation (Michaelis and Menten, 
1913). In general, Michaelis-Menten kinetics are based on the theory that the formation of 
the high-energetic enzyme-substrate complex ES is not the rate-limiting reaction, but rather 
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the subsequent quasi-irreversible generation of the product P. Thus, the concentration of 
[ES] is not changing within a short time interval and Michelis-Menten kinetics are based on a 
steady-state approximation. 
 
E + S ES E + P
k1 k2
k1'      (1.4) 
 
In Michaelis-Menten kinetics the formation of the product [P] and the decrease of the 
substrate concentration [S] are solely limited by the rate constant of the second reaction step 
k2. The maximal turnover rate vmax of substrate, also named molecular activity or kcat, is given 
by the IUB-conform unit kat (katal: 1 mol/s) or the more widely used unit U (international unit: 
1 mol/min) (Liebecq, 1992). The concentration [S] that is required to achieve a reaction rate 
of 1/2 vmax is represented by the Michaelis-Menten constant Km. 
 
][
][max
SK
Sv
v
m
        (1.5) 
 
If the concentration of the substrate clearly exceeds the capacity of the metabolic system the 
kinetics are only dependent on the rate constant k and follow a linear kinetic profile. Alcohol 
for instance is regularly metabolized linearly and only below a very low concentration the 
kinetic follows the first order. If two limited compounds, e.g. a coenzyme and a 
pharmaceutical compound, react with each other at the enzymatic reaction site the kinetics 
follow a second order. 
Processes that consider the absorption, distribution, metabolism and elimination, all ADME 
parameters, are described by the Bateman Equation.  
 
)(][][ 0
tktk
ae
a ea ee
kk
k
SS      (1.6) 
 
Absorption and distribution kinetics are described by the rate constant ka, whereas 
metabolism and elimination are depicted by ke. The applied dose is represented by [S]0.  
Although most drugs of current therapies target extracellular targets such as receptors (45 
%) or ion channels (5 %) or represent hormones (11 %) (Drews, 2000), they are still 
preferably developed to overcome the intestinal barrier in order to enable oral applicability. 
Therefore, also the for these the capacity to cross membranes and pharmacokinetics in the 
intestinal endothelium are highly important. 
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1.1.4. Enhancement of cellular and tissue uptake  
 
Molecules can be taken up into cells via direct penetration of the membranes, endocytosis, 
transporters or via paracellular transport. As mentioned above the chemical properties of a 
molecule determine its pharmaceutical properties. For drugs of a molecular weight Mw of 
less than 500-700 the cellular uptake efficiency is independent on the molecular weight. In 
contrast, for drugs beyond Mw 700 the uptake efficiency decreases considerably with an 
increasing molecular weight (Donovan et al., 1990a; Donovan et al., 1990b). 
The attachment of lipophilic moieties or the employment of the Eligen system (Malkov et al., 
2005) increase the permeability by the enhancement of lipophilicity and lead to a direct 
penetration of the membrane. 
In order to exploit efficient transport processes, the drug molecules can be conjugated to 
molecular structures that interact with membrane transporters such as glucose (Rouquayrol 
et al., 2002), bile acids (Swaan et al., 1997) or di- or tripeptides (Nielsen et al., 2001).  
Receptor-mediated endocytosis can be induced by conjugation of vitamin B12 (Russell-Jones 
et al., 1995) or an Fc fragment (Spiekermann et al., 2002). 
Finally, the rate of paracellular transport can be enhanced by means of tight junction 
modifications. These occur upon the employment of nitric-oxid donors (Yamamoto et al., 
2001), zonula occludence toxin (Fasano and Uzzau, 1997), Pz-peptides (Yen and Lee, 1995) 
and chitosans (Thanou et al., 2001).  
 
 
1.1.5. Uptake of peptides 
 
According to the rules of Lipinski and Ghose charged high-molecular weight molecules such 
as proteins, peptides, polynucleic acids, peptidoids etc. cannot cross the cell membrane as 
many of the hydrophobic, small molecule drugs can. Notwithstanding, nature has created 
backdoors to overcome this barrier. Numerous peptide-like toxins that are found in poisonous 
mushrooms (e.g. phalloidin, -amanitine) and plants (e.g. ricin) or are secreted by bacteria 
(e.g. cholera toxin) can enter the cytosol effectively, mostly via endocytotic pathways and 
subsequent endosomal escape. 
It was demonstrated that oligo-amino acid sequences, such as poly-L-lysine can facilitate the 
uptake of proteins (Ryser et al., 1978; Shen and Ryser, 1978) and small drugs such as 
methotrexate (Ryser and Shen, 1978). 
In the 1990ies nontoxic peptide sequences that could overcome the plasma membrane were 
found in proteins such as a peptide derived from the third helix of the antennapedia 
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homeodomain from drosophila melanogaster (Derossi et al., 1994), that is also named 
penetratin (Pen/Antp), or the Tat peptide that was derived from the human immunodeficiency 
virus-1 (HIV-1) (Vives et al., 1997). It was recognized that these peptides comprised of 
numerous arginine residues. Therefore, synthetic polyarginine peptides were employed to 
facilitate uptake (Mitchell et al., 2000; Wender et al., 2000). Here, the efficiency of the 
polyarginine peptides depended on the number of arginines, and thus the valency of 
guanidinium groups, plays a crucial role (Kawamura et al., 2006). Interestingly, these 
peptides, mostly named cell-penetrating peptides (CPPs) in Europe and protein transduction 
domains (PTDs) in the United States, are able to facilitate the uptake of a large variety of 
conjugated substances (Langel, 2002). CPPs can be employed in order to generate cell-
permeable conjugates of peptides (Choi et al., 2003; Rohrbach et al., 2005), proteins (Fawell 
et al., 1994; Nagahara et al., 1998), peptide nucleic acids (PNAs) (Oehlke et al., 2004; 
Turner et al., 2005; Wolf et al., 2006), nanoparticles (Lewin et al., 2000), quantum dots 
(Santra et al., 2005a; Santra et al., 2005b), organometallic bioconjugates (Noor et al., 2009) 
and polymer-conjugated drugs (Nori et al., 2003). The cargo, even if it is a small molecule, 
can have a significant impact on the intracellular localization of the conjugate (Fischer et al., 
2002). Most studies dealing with CPPs have been conducted in mammalian cells. 
Nevertheless, it has been demonstrated that polyarginines can also enter protoplasts, thus, 
plant cells lacking cell walls via a comparable mechanism. (Unnamalai et al., 2004; Chang et 
al., 2005; Chugh and Eudes, 2007; Chugh and Eudes, 2008). Polyarginine peptides can 
even enter plant cells bearing a cell wall, although a considerable fraction of the cationic CPP 
is localized in the highly negatively charged cell wall (Mizuno et al., 2009). 
For the cellular attachment of cationic CPPs the heparan sulphate proteoglycans at the cell 
surface are considered an important structure (Fuchs and Raines, 2004). Structure-based 
studies show that peptides likely change their conformation upon interaction with 
phospholipid vesicles (Magzoub et al., 2001) and that the mode of membrane interaction is 
different for cationic and amphiphilic sequences (Zhang and Smith, 2005). Especially at 
lower concentrations clathrin-mediated endocytotic uptake plays a key role for cationic CPPs 
as was shown by means of the employment of variant specific endocytosis inhibitors (Fotin-
Mleczek et al., 2005a). But still, the endosomal escape mechanism required to mediate entry 
into the cytoplasm is not fully understood yet (Fischer et al., 2005). On the other hand, the 
employment of a splice correction assay (El-Andaloussi et al., 2006) could clearly 
demonstrate that CPP-cargo conjugates that are taken up by endocytosis are released from 
the endosomes effectively enough to allow the cargo to display its action in the cytosol 
(Lundin et al., 2008). In this context, it could be shown that the transmembrane pH gradient 
is required for efficient membrane permeation (Magzoub et al., 2005). 
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Endocytosis can lead to receptor internalization and as a consequence change the response 
of a cell to external stimuli. For instance, cationic CPPs can trigger the internalization of the 
tumor necrosis factor (TNF) receptor (Fotin-Mleczek et al., 2005b). In addition to 
endocytosis, CPPs can enter the cell via a second mechanism independent of endocytosis. 
This rapid uptake mechanism is found especially at higher concentrations (Duchardt et al., 
2007), whereas membrane integrity is entirely maintained. D-peptides show differing rates of 
rapid uptake (Tunnemann et al., 2008). Recently, it was demonstrated that certain peptides 
can also facilitate the cellular export of a cargo (Dupont et al., 2007). 
Independent of the uptake mechanism, proteolytic degradation of CPPs is one of the limiting 
factors of their application (Fischer et al., 2004). Additionally, in in vivo applications 
immunogetity is always a prominent concern. For that reason, peptides of human origin such 
as a human calcitonin-derived peptide (Schmidt et al., 1998) or peptides derived from human 
signal transduction proteins (Rojas et al., 1998) are of interest.  
 
 
 
Fig. 1.2. The CPP family. Adopted and updated from R. Fischer (Fischer et al., 2005). 
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1.1.6. Endocytotic uptake of small molecules 
 
Recent studies suggest that also small molecules are taken up by endocytotic processes to a 
larger extend than expected before. Reduction of the endocytotic rates in malignant cancer 
cells can lead to drug resistance (Chauhan et al., 2003). Recent studies indicate that 
polynuclear alkylamine platinum(II) complexes are beside other paths taken up by 
endocytosis (Chauhan et al., 2003). As a high rate of macropinocytosis is mostly related to 
changes in the intracellular signal transduction of the respective cells (Amyere et al., 2002) it 
can very likely function as an indicator for motile and metastatic cancer cells. The alkylamine 
platinum(II) complexes molecules show higher specificity to cancer cells than other platinum 
complexes (Kapp et al., 2006).  
 
 
1.1.7. The lactoferrin-derived cell-penetrating peptide 
 
One CPP of human origin is the human lactoferrin derived peptide. The 80 kDa human 
lactoferrin protein is an iron-binding glycoprotein of 703 amino acids (Metz-Boutigue et al., 
1984). It is found in considerable concentrations in human milk (15 % of the total protein 
content) and in lower concentrations in tears, nasal fluids, saliva, pancreatic, gastrointestinal 
and reproductive tissue secretions and in blood plasma (Levay and Viljoen, 1995). Here, it 
acts as an antimicrobial, antifungal and antiviral protein and, therefore, plays an important 
role in the innate immune defense (Legrand et al., 2008) by depletion of iron (Ward and 
Conneely, 2004) and through direct interaction with bacterial components (Valenti and 
Antonini, 2005). 
Oral uptake leads to a pepsin-mediated cleavage of the highly positively charged N-terminal 
domain off the rest of the protein, which is then degraded. The released peptide comprises 
49 amino acids, named lactoferricin (Bellamy et al., 1992), that carries potent antimicrobial 
activity (Gifford et al., 2005). In aqueous environment it comprises a “nascent helix” and a 
loop structure that is stabilized by two disulfide bonds. The helical structure is stable in the 
full-length protein and can be also stabilized by membrane-mimetic solvents (Hunter et al., 
2005). The structure of lactoferricin reveals hydrophobic and positively charged sections 
comparable to those found in numerous peptides that display antimicrobial activity (De and 
Contreras, 2005; Toke, 2005).  
It was demonstrated that antimicrobial peptides with these characteristics are taken up into 
mammalian cells (Takeshima et al., 2003) and that, the other way round, many CPPs show 
antimicrobial activities (Nekhotiaeva et al., 2004). It could be proven that a lactoferrin-derived 
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peptide can also act as a CPP (Brock et al., 2007). A cell-penetrating peptide was derived 
from the N-terminal domain of human lactoferrin, corresponding to amino acid residues 38-
59. 
 
 
 
Fig. 1.3. Structure of lactoferrin. The structure of full-length lactoferrin (Anderson et al., 1990) bears 
the lactoferrin-derived cell-penetrating peptide as a disulfide bond-stabilized loop on its surface (the 
CPP sequence is highlighted in yellow) (A). Whereas the 3D structure of lactoferricin is only partly 
helical in aqueous buffers (B), it is stabilized in a membrane-mimicking solvent (Hunter et al., 2005) 
(C) (the CPP sequence is highlighted in yellow). 
 
An analogous peptide sequence is found in all known lactoferrin sequences of different 
species. The sequences differ considerably, whereas the pontentially structure-determining 
residues are highly conserved. The sequence of all known species begins with lysine and 
cysteine, followed by a presumed -helical sequence of 8-11 residues which contains a 
methionine residue in all species except the pig and is able to bind lipopolysaccharides, a 
presumed turn region with at least one proline residue and a short presumed -sheet region 
with a second cysteine. 
1. INTRODUCTION 
 
 
14 
Tab. 1.3. Sequence comparison of lactoferrin peptides of different species. 
sequence origin (common name) origin (Latin name) amino 
acids 
position 
 
KCFQWQRNMR-KVRGPPVSCIKR 
 
Human 
 
Homo sapiens 
 
709 
 
38-59 
KCFRWQRNMR-RVRGPPVSCIKR Chimpanzee Pan trolodytes 711 38-59 
KCSQWQRNLR-RVRGPPVSCIKR Short-tailed Opossum Macaca cyclopis 710 37-58 
KCAQWQRRMK-KVRGPSVTCVKK Dromedary  Camelus dromedarius 708 37-57 
KCAKFQRNMK-KVRGPSVSCIKR Horse Equus caballus 698 37-56 
KCYQWQRRMR-KLGAPSITCVRR Goat Carpa hircus 708 37-58 
KCYQWQRRMR-KLGAPSITCVRR Sheep Ovis aries 708 37-58 
KCHRWQWRMK-KLGAPSITCVRR Water buffalo Babalus babalus 708 37-38 
KCRRWQWRMK-KLGAPSITCVRR Bovine Bos taurus 708 37-38 
KCRRWQWRMK-KLGAPSITCVRR Wild Yak Bos grunniens 708 37-58 
KCRQWQSKIR-RTN-P-IFCIRR Pig Sus scorfa 704 37-56 
KCLRWQNEMR-KVGGPPLSCVKK Mouse Mus musculus 707 36-56 
KCFMWQ-EMCNKAGVPKLRCARK Rat Rattus norvegicus 709 38-57 
     
KCXXWQXXM1-12X2P2-2C211 consensus sequence    
 
Highly conserved residues are displayed in blue, residues identical to those in the human 
peptide in red, residues similar to those in the human peptide regarding their 
physicochemical properties are bold. In the consensus sequence “1” represents a positively 
charged amino acid residue, “2” a hydrophobic one and “X” an arbitrary one. Between the 
two cysteine residues a disulfide bound in formed. According to Chou-Fasman calculations 
the conservation of the residues corresponds to a highly conserved secondary structure. 
 
 
 
Fig. 1.4. Structure comparison of different species. Although the sequences are considerably 
different in different species, the tertiary structures in the crystal structures of the full-length proteins 
are highly conserved for the structures corresponding to (A) the hLF peptide. The structure of (B) the 
bovine and (C) the equine lactoferrin are depicted.  
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1.1.8. Conjugation of therapeutic molecules to polymeric backbones 
 
Pharmacokinetic properties of therapeutic molecules can be altered by the conjugation to 
polymeric molecules (Duncan, 2003). For numerous drugs the conjugation to polymeric 
backbones has some explicit advantages such as improved and elongated blood circulation 
and therefore slower release kinetics (Seymour et al., 1990), decreased toxicity of many of 
the conjugated drugs such as doxorubicin (Duncan et al., 1998) and improved solubility of 
Class II and Class IV drugs such as doxorubicin and paclitaxel. In today‟s drug discovery 
many drugs are conjugated to polyethylene glycol (PEG) (Harris and Chess, 2003), 
especially orally delivered macromolecules often require polymer-conjugation (Goldberg and 
Gomez-Orellana, 2003). As tumour vessels bear a higher permeability for high-molecular 
weight molecules and many malignant tumour cells bear an increased macropinocytosis rate 
(Amyere et al., 2002) the polymer-conjugation of small molecule drugs accomplishes a 
certain selectivity for tumour tissues and cells by size-exclusion effects (Seymour et al., 
1995). The co-functionalization with different molecules, such as cell-penetrating peptides 
and small molecules (Nori et al., 2003) is possible and upon higher moiety loadings 
multivalency effects are observable (Mammen et al., 1998).  
Today, polymer-conjugated drugs are widely used in clinical trials, particularly in the field of 
anticancer drugs (Vicent and Duncan, 2006). SMANCS (Zinostatin stimalamer) represents 
the first protein-polymer conjugate that was brought to the market (Maeda, 2001). Proteins 
and peptides are regularly conjugated to polyethylene glycol (PEG) in order to prevent the 
molecules from degradation in the blood stream (Lee et al., 1999; Veronese, 2001; Esposito 
et al., 2003). One of the most common polymer backbone for small molecules represents 
HPMA (Poly[N-(2-hydroxypropyl)methacrylamide]) copolymers (Kopecek and Bazilova, 
1973). HPMA is widely used in numerous applications, mostly in cancer treatment (Kopecek 
et al., 2000) such as carriers for anti-angiogenesis drugs (Satchi-Fainaro et al., 2004). It 
could be demonstrated that polymeric backbones can be targeted to special cell types via 
antibodies (Kovar et al., 2002). In this thesis the advantages of the polymer-conjugation in 
cellular applications of peptides are combined with those of the CPPs. 
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1.2. Cellular pharmacodynamics 
 
1.2.1. The molecular binding - "CORPORA NON AGUNT NISI FIXATA" 
("Compounds do not act if they are not bound.", Paul Ehrlich) 
 
The first methodical pharmacodynamic studies were performed by the German scientist Paul 
Ehrlich and his co-workers in the end of the 19th century. On the basis of the previous 
findings that certain dyes were able to stain cellular structures selectively, his group 
developed the “magic bullet” concept. This theory explains that a toxic molecule, that 
binds selectively to its target structure(s), is able to eliminate harmful cells in order to cure 
patients. Today, this theory is still the basis of all chemotherapies. After a methodological 
lead identification and optimization process the outcome of his studies was the anti-syphilic 
agent Salvarsan (arsphenamine). Furthermore, Ehrlich conceived - contemporary with John 
Langley - the receptor theory stating that a therapeutic molecule, named ligand, has to bind 
to at least one certain target structure, named receptor, to show any activity. Consequently, 
the term for their interaction is ligand-receptor interaction. This is the case for 
chemotherapeutical as well as palliative drugs. Hence, the binding and its specificity is the 
molecular basis of all pharmacodynamic theories. 
A binding process can only occur if two molecules interact at their binding sites by means of 
physicochemical processes. First, they require a reasonable spatial compatibility. Here, small 
molecules offer infinit rotational degrees of freedom. High-molecular weight molecules, such 
as proteins, are often able to a adjust their binding site slightly by induced fit. Most ligand-
receptor interactions are non-covalent and are based on ionic, polar, hydrophobic and van 
der Waals interactions and interactions of aromatic -oritals. Additionally, the hydrogen bond 
has an outstanding importance in biological and biopharmaceutical systems. Most 
interactions are reversible, therefore, competable and dynamic (Gohlke and Klebe, 2002). 
The molecular binding can be described from different points of view. In total, it is classified 
thermodynamically. Here, the Gibbs free energy G must decrease in the total system while 
a binding occurs. The changes of G during the binding process are related to the changes in 
the enthalpy H and changes of the entropy S. 
 
STHG        (1.7) 
 
An interaction in an aqueous environment as it is observed in this thesis requires the 
dissolution of the hydrate sphere of the binding partners (with S > 0 and H < 0) and the 
non-covalent attachment of the ligand to the receptor (with S < 0 and H > 0). 
1. INTRODUCTION 
 
 
17 
1.2.2. Polyvalency effects influence the molecular binding 
 
In a polyvalent system the total change of the Gibbs free energy G is given by 
 
N
NmonoNtotal RTGG )ln(,      (1.8) 
 
Here,  is the enhancement factor for each single binding due to polyvalency effects 
(Mammen et al., 1998). Normally,  is rather positive which results in an exponentially 
increasing binding affinity of polyvalent systems. This is of particular interest in this thesis as 
polyarginines bear polyvalent guanidinium groups and multivalent peptide-polymer 
conjugates represent typical polyvalent systems.  
In contact with lipid bilayers, polyvalently positively charged polymers can change the local 
lipid composition by lateral lipid segregation (Yaroslavov et al., 2009). 
The theory of multivalency can also be adopted to other ligand-receptor models such as the 
binding of a small molecule drug to its receptor. Whereas few hydrogen and ionic bonds lead 
to a weak binding, a higher number can lead to extremely high affinities as it is observed for 
the methotrexate-dihydrofolate interaction that is used as a model system in this thesis. Then 
the changes in the Gibbs enthalpy of a single interaction Gn are summed up (Gohlke and 
Klebe, 2002). The same can be applied to protein-protein interactions (Reichmann et al., 
2007). 
 
n
ntotal GG
1
       (1.9) 
 
The effective valency of a polyvalent molecule is often determined by the steric properties of 
the molecule itself or the monomers it consists of. Some proteins have more than one 
binding site for a certain ligand. Streptavidin for instance bears four binding sites for biotin, 
many viruses have a well-defined topology resulting in a rather well-defined valency. The 
same is true for binding groups that are conjugated to a polymeric backbone in a site-specific 
manner. 
If, however, an artificial polymer is synthesized randomly by the polymerisation of a mixture 
of two or more different monomers of which only one can bind to the ligand or if ligand-
binding molecules are conjugated to a polymeric backbone in a non site-specific manner the 
average ratio of binding groups per molecule can be often determined experimentally. In the 
real situation there is a large statistic variety of ratios of both molecules. In this case the 
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distribution of molecules with different valencies can be assessed by means of a Poisson 
distribution 
 
e
k
P
k
!
        (1.10) 
 
Here, the valency distribution P and thus the fraction of a certain species of the polyvalent 
molecules with the valencies k is described by the average ratio of ligand-binding groups 
per molecule .  
 
 
 
Fig 1.5. The distribution of conjugates with different valencies in a mixture of statistically 
distributed polymers. The black bars represent a conjugate with the average loading ratio of 2, the 
white bars represent a conjugate with the average loading ratio of 4. 
 
The Poisson distribution obviously loses its validity if cooperative effects occur in the 
synthesis procedure. 
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1.2.3. The binding of small molecules to protein targets 
 
The structure of a small therapeutic molecule can be divided in subareas. Whereas the 
subarea named pharmacophore is required for the specific ligand-receptor interaction, 
additional binding groups facilitate improved binding activity and specificity to the target. 
Often, one or more sites of the molecule are freely modifiable, but affect its pharmacokinetic 
properties. In these positions the drug can be conjugated to other molecules such as 
fluorophores. Within this thesis this was the case for the attachment of a linker and the 
fluorophore Cy5 to methotrexate and Parke-Davis compound.  
The drug can compete with other molecules such as endogenous compounds for one 
particular binding site. Moreover, the drug molecule can also bind to other endogenous high-
molecular weight targets, therefore side targets, which often decreases its specificity. For 
these reasons, it is of utmost importance to classify the pharmacodynamic binding profile, 
thus, the endogenous binding partners of the pharmaceutical molecule and the affinity of the 
respective ligand-receptor interactions. 
Additionally, the range of efficacy of a drug can also be based on pharmacokinetics such as 
an explicitly high uptake rate in certain tissues or cells, as it is found for many polymeric 
drugs (Duncan, 2003), or it can be related to a differing metabolism in a certain cell type, that 
leads to variations in the molecular environment (Herman et al., 2005). 
Today, it is assumed that the human organism comprises between 5000 and 10000 potential 
drug targets (Drews, 2000) of which currently only approximately 500 are targeted by small 
molecule drugs (Drews and Ryser, 1997; Imming et al., 2006). Hence, there is still an unmet 
need for the exploitation of novel drugable targets. 
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Fig. 1.6. Structural requirements of the ligand-receptor interaction of dihydrofolate and its 
competitors with the dihydrofolate reductase binding site. (A) The molecule can be divided in 
subareas: the pharmacophore, additional binding groups and a freely modifiable subarea. (B) The 
dihydrofolate pharmacophore interacts in a highly specific manner and binds non-covalently in its 
binding pocket in the dihydrofolate reductase. (C) Methotrexate binds to the same site, but the 
molecule is thereby slightly rotated and binding strengthened due to an additional hydrogen bond. The 
images were adopted from published data (Kubinyi, 1994; Steinhilber/Schubert-Zsilavecz/Roth, 2005). 
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1.2.4. Cellular pharmacodynamic parameters 
 
The affinity of the interaction of a small molecule to a protein is typically described as the 
ratio between the concentrations of the unbound binding partners, therefore, the small 
molecule ligand [L]free and the unbound protein [P]free devided by the concentration of their 
complex [PL]complex. It is quantified as the equilibrium dissociation constant Kd. 
 
complexed
freefree
PL
PL
Kd
][
][][
       (1.11) 
 
The inverse of the Kd value is named the equilibrium association constant Ka. The Kd 
value can also be also described thermodynamically by: 
 
RT
G
eKd         (1.12) 
 
 
The parameter R is the gas constant, 8.31 JK-1mol-1. The third possibility to express the Kd is 
to describe it kinetically as a function of the rate constant of the association kon and of the 
rate constant of the dissociation koff. 
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Kinetics and thermodynamics are combined here. This is highly relevant as this relationship 
shows that a high affinity can also be based on kinetics if the association is particularly fast 
and/or the dissociation is particularly slow. The logarithm of the equilibrium constant KS, that 
describes the degree of proton dissociation and association to a substance S, respectively, is 
for acidic compounds given by the Henderson-Hasselbalch Equation 
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and for basic compounds as 
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By means of inductive, tautomeric and mesomeric effects the charge can be distributed over 
larger areas of the molecule.The above-mentioned relationships have a crucial impact on the 
binding properties, but also on pharmacokinetic parameters such as hydrophobicity, cell 
permeability and intracellular localization. For instance, a substance that is dissolved in blood 
or an respective buffer at pH 7.4 and is taken up via endocytosis may change its properties 
completely due to lysosomal acidification to approximately pH 5. In the cytosol, with a pH 
value of approximately 7.2, the proton concentration is therefore nearly 160-fold lower. There 
is evidence that this plays a key role in the endosomal escape of arginine-rich peptides 
(Fischer et al., 2004), but was not quantified for many drugs so far. 
At a given total target protein concentration and a total small molecule concentration and 
known Kd the fraction of the bound receptor molecules, the occupancy, can be easily 
calculated by 
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If a certain concentration of a competitive inhibitor [I] with an inhibitor constant Ki is added 
to the ligand-receptor equilibrium, the fraction of complex between the ligand and the protein 
diminishes. 
 
][
][
1
][%100
][
LK
K
I
L
PL
D
i
complexed      (1.17) 
 
In general, the concentration that is required in order to reach the half-maximal effect is given 
as EC50. For enzymatic inhibition the concentration of the half-maximal inhibition, the IC50, 
is given. The results of binding experiments are plotted as dose-response curves. Here, the 
respective EC50 can be directly quantified. The biological activity or effect at a certain ligand-
inhibitor-receptor equilibrium is named potency. If the receptor concentration is also known, 
the Kd can be easily calculated.  
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Fig. 1.7. Dose-response curves of a theoretical experiment. The calculations assume a ligand-
receptor interaction with an EC50 of 2 nM and are shown as (A) a linear and as (B) a logarithmic plot. 
The data without an inhibitor show the half-maximal binding at 2 nM, which exactly represents the 
EC50. If a competitive inhibitor is added (dashed lines), the curve is shifted to larger ligand 
concentrations, whereas an uncompetitive inhibitor (dotted lines) leads to lower levels of bound 
receptor. 
 
The above-mentioned dose-response curves can be fitted by the formula 
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     (1.18) 
 
Here, the hill slope reflects the steepness of the curve. According to the Cheng-Prusoff 
Equation the IC50 value is not only proportional to the inhibitor constant Ki of the compound, 
but also reciprocally proportional to the concentration of a second ligand [L] divided by the Km 
value of L (Cheng and Prusoff, 1973). This is of particular interest in experiments dealing 
with kinase inhibitors as in this particular case considerable impurities with other kinases and 
especially the competition with endogenous ATP plays a crucial role.  
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1.2.5. Special concerns regarding protein kinase inhibitors 
 
The formation of phosphate esters is naturally catalyzed by kinases and plays a key role in 
cellular homeostasis and intracellular signal transduction. Protein kinases control the cell 
cycle (Butt et al., 2008), intercellular attachment, interaction with extracellular matrices, 
angiogenesis (Roodhart et al., 2008), apoptosis (So et al., 2007; Strasser et al., 2009), 
inflammation (Wagner and Laufer, 2006) and other intracellular signalling cascades, they 
control the excretion of hormones, interleukines and other factors that allow intercellular 
communication. Great efforts were made to untangle the highly complex signal transduction 
networks of kinases (Stoevesandt and Taussig, 2007). A divergent balance of stimuli can 
lead to differing effects of the same signal transduction network and thus to different effects 
of certain small molecule inhibitors (Kohler et al., 2008). More than 500 putative protein 
kinase genes have been identified, constituting about 1.7 % of all human genes (Manning et 
al., 2002). Many of the phosphorylated sequences are recognized by phosphorylation-
dependend binding motifs such as Src homology 2 (SH2), phosphotyrosine binding (PTB), 
BRCA1 C-terminal (BRCT) and 14-3-3 domains. More than 175 kinases and their substrate 
specificities and over 100 phosphorylation-dependent binding domains of all kind were 
collected in an atlas in the data bank NetPhorest (http://netphorest.info) (Miller et al., 2008). 
Recently, the structure and function of numerous protein phosphotyrosine containing proteins 
and their binding partners was elucidated further (Barr et al., 2009). 
As protein kinases are involved in numerous serious diseases with a large market potential 
such as cancer, up to 30 % of all drug-discovery programs in the pharmaceutical industry 
deal with kinase inhibitors and numerous drug kinase inhibitors are in clinical trials or are on 
the market (Knight and Shokat, 2005). 
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Scheme. 1.8. Protein kinase inhibitors. Most commercial kinase inhibitors (I) compete reversibly for 
the ATP binding pocket.  
 
The vast majority of synthetic small molecule protein kinase inhibitors binds to the ATP 
binding pocket and competes with endogenous ATP. Here, the Michaelis-Menten constant 
KM for ATP in various kinases differs over three orders of magnitudes (Knight and Shokat, 
2005). Thus, the ATP concentration employed in an in vitro assay certainly is a critical issue 
as well as the concentrations of cofactors such as magnesium ions (Chrisman et al., 1984). 
Due to the similarity of the ATP binding sites in various kinases and other ATP-consuming 
enzymes many kinase inhibitors bear a rather promiscuous target profile (Capdeville et al., 
2002). Entirely specific effective kinase inhibitors were not developed yet. 
For this reason, inhibitors that facilitate the disruption of protein-protein interactions with a Kd 
in the nanomolar range would be of great interest (Berg, 2008). Although protein-protein 
interactions are examined by means of numerous approaches that combine bioinformatics 
and peptide-based experimental techniques such as protein epitope mimetic (Robinson et 
al., 2008), the physicochemical mechanisms of protein-protein interactions are still not 
entirely understood (Reichmann et al., 2007). 
In summary, the screening and in vitro testing of kinase inhibitors is still a delicate issue and 
is hampered by the imperfection of the implemented screening techniques. 
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1.2.6. Screening and lead optimization of kinase inhibitors 
 
In a first step, the modern drug discovery strategies require the identification of hit structures 
that are subsequently altered and optimized regarding their pharmacodynamic and 
pharmacokinetic properties and are finally pharmaceutically formulated and tested in 
preclinical and clinical phases. Lead structures can be of natural origins or be the outcome of 
high-throughput screening processes in which libraries of more or less randomly or rationally 
synthesized compounds are tested.  
The libraries used for primary screens regularly comprise more than 105 compounds, the 
ones utilized for secondary screens approximately 103 compounds. The compounds are 
tested in protein binding assays, kinetic studies and cell culture tests. Approximately 10 
promising candidate structures are selected as lead structures, optimized further and tested 
in preclinical studies. Only few compounds, if any, reach the phase I-IV clinical studies 
(Nolan, 2007). 
Traditionally, kinase inhibiting compounds are tested in protein activity assays by means of 
radioactivly labeled 32P-ATP (Witt and Roskoski, Jr., 1975; Casnellie, 1991). This test 
method is relatively slow, requires considerable care of the experimenters and is nowadays 
often displaced by other techniques (Lehel et al., 1997). Colorimetric assays have gained an 
increasing importance in high-throughput screening (Chapman and Wong, 2002). These 
assays and the 32P-ATP-based assays mentioned above are based on highly purified 
kinases that often tend to precipitate. 
One of the most important assays for the screening of drug-target interactions in today‟s drug 
discovery programs is the fluorescence depolarisation assay (van de Ven et al., 1984; 
Seethala and Menzel, 1997). Typically, a small molecule ligand is conjugated to spacers and 
fluorophores and is mixed with the purified high-molecular weight protein binding partner. 
The labelled small molecule ligand is competed with various amounts of different unlabeled 
compounds. Polarized light is irradiated into a sample and the excites molecules emit light. 
The rate-dependent loss of linear polarization is measured. As it is dependent on the rotation 
of the molecules and small molecules rotate faster and therefore show a higher rate of 
depolarization, the binding equilibria can be calculated. The advantages of the fluorescence 
depolarization assay are that the protein consumption is rather low and that the test is 
extremely fast and allows high-throughput screening of whole libraries of millions of 
substances in a respectively short period of time. The major drawback is that the technique is 
not very precise and that binding to side targets and unspecific binding is not distinguishable. 
Each fluorescently labeled molecule that binds to any high-molecular weight binding partner 
shows binding activity whether it binds to its specific binding site or just adsorbs 
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unspecifically. In order to perform accurate measurements the technique requires highly 
purified kinases. 
A relatively modern approach is the use of Kinobeads (Cellzome AG). Here, small molecule 
ligands were conjugated to microspheres and the kinase binding partners are fished out of a 
solution, that can represent or imitate the physiological environment. By means of 
competition experiments this assay allows the generation of quantitative data regarding the 
target profile of drugs (Bantscheff et al., 2007). This technique is useful for the description of 
target profiles of molecules by means of competition assays. 
For lead optimization procedures optical biosensors have an increasing importance (Cooper, 
2002). Especially the techniques that are based on surface plasmon resonance (SPR) are 
able to display the kinetics and dynamics of molecular binding processes (Flanagan and 
Pantell, 1984). Many commercially available SPR-based tools are on the market (e.g. Affinity 
sensors, Biacore, etc.). The technique is based on changes of the refractive index of a layer 
due to binding of one binding partner and allows the calculation of Kd values based on 
measurements of the on and off rates. A similar technique is represented by reflectrometric 
interference spectroscopy (RIfs) (Piehler et al., 1996). Here, the changes in the thickness of 
a layer are detected. Both techniques are highly dynamic, work with label-free ligands and 
receptors and give information about the ligand-receptor binding process and several 
samples can be read-out in parallel, but have the considerable drawback that the specificity 
of the binding is not displayed, purified receptor molecules are required and the receptor or 
the ligand have to be immobilized in a way that maintain activity. 
Furthermore, structure-related techniques such as the nuclear magnetic resonance (NMR) 
spectroscopy have an increasing importance concerning lead optimization processes 
(Pellecchia et al., 2002). 
In summary, it is obvious that there is still an unmet need for development of technologies 
that facilitate in vitro measurements of compound-target interactions in a physiological 
context and that do therefore not require purified enzymes and that are able to distinguish 
between specific on-target, off-target and unspecific binding. Next to others, this challenge is 
addressed in this thesis. 
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1.3. Techniques 
 
1.3.1. Confocal laser scanning microscopy 
 
Confocal laser scanning microscopy (LSM) represents an optical technique that allows the 
pixel-wise scanning of a precisely defined optical plane.  
Referring to the microscopic system used in this thesis, one or two laser beams are reflected 
by a semi-transparent filter (an acusto-optical beam splitter (AOBS)) and are focused into the 
specimen by an immersion objective with a high numerical aperture NA. The latter is required 
to achieve an efficient collection of the fluorescent light out of a small detection volume 
(Abbe, 1873). The parameter n describes the refractive index of the immersion medium 
between the lens and the specimen and sin  represents the half-angle of the light cone that 
can enter the lens. 
 
sinnNA         (1.20) 
 
The numerical aperture limits the maximal resolution d of all common light microscopes. The 
theoretically maximum of the resolution of a classical microscope is also limited by the 
wavelength of the used light. The shorter the wavelength, the higher is the achievable 
resolution. This drawback in resolution has recently been overcome by the Stimulated 
Emission Depletion (STED) technique (Westphal and Hell, 2005; Kastrup et al., 2005), but is 
not yet wide-spread, has no application in this thesis and is therefore not discussed further. 
The light that has entered the sample excites the fluorophores, which emit light that is partly 
collected by the objective, bundled and conducted back via the same optics. The 
bathochrome shifted emission light can now pass the AOBS and by means of a convex lens 
the detection volume is imaged into a pinhole. The pinhole allows the restriction of the size of 
the detection volume to a sub-femtoliter volume. The light that passes the pinhole is split 
spectrally by means of a prism. Then, the light of a certain wavelength interval is collected by 
independent photomultiplyer tubes (PMTs). The image is generated by a computer-assisted 
method via the scanning of several thousands of pixels. Additionally, the microscope also 
allows the generation of a quasi-three-dimensional image by scanning numerous optical 
slices in different heights. 
 
. 
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Fig. 1.9. Optical path of a laser scanning microscope based on Leica technique. 
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1.3.2. Fluorescence correlation spectroscopy 
 
“NAM CORPUS NULLUM NISI IN TEMPORE MOUERI AUDIO. [... ] CUM ENIM MOVETUR CORPUS 
TEMPORE METIOR QUAMDIU MOVEATUR EX QUO MOVERI INCIPIT DONEC DESINAT.” (“For I hear that 
no body is moved but in time. […] For when a body is moved, I by time measure how long it 
may be moving from the time in which it began to be moved till it left off.” (Augustinus, 398)) 
 
Fluorescence correlation spectroscopy (FCS) first presented by Elson and Webb in the 
1970s (Elson and Webb, 1975) was later developed further as a microscopy-based 
technique that allows the determination of the diffusion velocity of single molecules in 
solution and the exact quantification of fluorophore concentrations in a sub-nanomolar range 
(Rigler et al., 1993). Comparable to the confocal laser scanning microscope, a laser beam is 
focussed into the sample via a beam splitter, in the case of the mostly employed Leica SP5 
system an acusto-optical beam splitter (AOBS), and an immersion objective with a high 
numerical aperture. The light that is emitted by the excitated fluorophores is partly collected 
by the objective, bundled and conducted back via the same optics. Due to its bathochrome 
shift the light can now pass the AOBS and by means of a convex lens the detected sample 
volume is imaged into a pinhole. The latter allows the restriction of the size of the detection 
volume to a volume in the sub-femtoliter range. The light that passes the pinhole is detected 
by an avalanche photo diode (APD). Here, the photons per second are counted. A computer-
assisted process generates a time-resolved fluorescence fluctuation profile and calculates an 
autocorrelation function. By fitting the autocrorrelation function the number of molecules N 
that dwell averagely in the detection volume and their diffusion time D, thus the average 
residence time of the fluorophore in the detection volume, can be determined. From these 
values the fluorophore concentration can be calculated and the molecular weight can be 
assessed based on knowledge of the physical characteristics of the solvent, the influence of 
the measurement temperature and the shape and the density of the differing molecule. 
Additionally, FCS provides information about the photophysical properties of the observed 
molecule itself, such as its triplet time tr and its triplet amplitude Gtr, thus, the fraction of 
molecules that dwell in the triplet state. Therefore, FCS is a highly valuable tool in 
biochemistry and can also be applied on the cellular level (Brock et al., 1999; Kim et al., 
2007; Bacia et al., 2006). An extension of the technique is the use of two fluorophores 
enabling fluorescence cross-correlation spectroscopy (FCCS) (Schwille et al., 1997). The 
sample is hereby excited with the light of two laser lines, and the fluorescence is split 
spectrally by a beam splitter and detected by two independent APDs. This technique reveals 
all the information given by single-color FCS and, additionally, information on the fraction of 
1. INTRODUCTION 
 
 
31 
molecules that diffuse conjointly. It is regularly used to quantify degradation processes of 
dual-labeled molecules and to quantify ligand-target interactions (Weidemann et al., 2002). 
 
 
Fig. 1.10. Mode of the operation of an FCCS apparatus based on Leica technique.  
 
The size of the detection volume is defined by the confocal optics, by the pinhole and by the 
wavelength-dependent diffraction of the light. The larger the wavelength , the weaker is the 
diffraction of the laser light at a given diffractive index of the lens and the larger are the 
dimensions of the detection volume. Thus, a light beam with a short wavelength in the green 
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part of the spectrum g leads to a smaller detection volume than one in the red part of the 
spectrum r. The theoretical overlap of the two channels CC can be maximally 
 
3
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CC         (1.21) 
 
This value also represents the maximal fraction of cross-correlating particles, referred to the 
green channel. The spatial intensity profile of the excitation light is displayed by the point 
spread function (PSF( r )) divided by the excitation intensity I0, the emission profile is 
expressed by the collection efficiency function (CEF( r ). The spatial profile of the detection 
volume W( r ) is therefore given by 
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In a first approximation W( r ) can also be represented by a Gaussian Distribution 
(Weidemann et al., 2002) and is describable as an ellipsoid with the effective volume Veff. 
The three-dimensional extensions are defined by the spatial positions x, y and z the lateral 
radius xy and the axial radius z. 
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The structure parameter S is hereby defined as the ratio of z and xy and should be >1. 
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The fluorescence occurring from the detection volume Veff is detected over time and the 
generated fluctuation profile is analyzed by means of a computer-based method. Here, the 
fluorescence count rate F, which is recorded over the entire measurement period, is 
averaged out. 
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Then, the positive and negative deviation of the detected fluorescence count rate F from the 
respective average F  is recorded for multiple time points t and time intervals . These 
calculations lead to the autocorrelation function G( ) 
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The effective number of particles that on average dwell in the detection volume Neff is 
calculated by 
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The triplet state is described by the triplet time T and the triplet amplitude T 
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Thus, the entire curve can be fitted by the term 
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All models described here base on the assumption that all observed particles bear the same 
molecular brightness. This was also the case in this thesis. Otherwise, in multicomponent 
mixtures, the molecular brightness has to be corrected as the contribution of a certain 
species to the total autocorrelation function depents on its molecular brightness by the power 
of two (Weidemann et al., 2002).  
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Fig. 1.11. Generation of data from FCCS experiments. (A) The intensity profile of the detection 
volume determined by means of the confocal optics represents a three-dimensional Gaussian 
Distribution. (B) The time-resolved fluorescence fluctuations of both channels are detected. (C) Based 
on these data the curves are correlated with themselves (FCS) and with each other (FCCS), 
respectively, which leads to (D) autocorrelation and (E) cross-correlation curves. 
 
 
For dual-color FCCS the fluctuations of the detected fluorescence count rates of the green 
detection channel Fg and the red channel Fr from the respective averages <Fg> and <Fr> 
are correlated with each other and lead to the cross-correlation function GCC( ). 
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Potential effects such as quenching and cross-talk have to be carefully considered and, if 
necessary, be mathematically corrected (Weidemann et al., 2002; Földes-Papp, 2005). In 
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this thesis these obstacles were circumvented by the careful choice of spectrally and 
spatially well-separated fluorophores. 
In order to obtain an accurate quantification of the particle number N in the lower 
concentration ranges it is essential to take the fluorescence background as well as scattered 
light into consideration. Here, the signal-to-noise ratio can be relatively small and, hence, the 
measured particle number Nmeasured is typically overestimated whereas the fluorescence per 
molecule fpm is underestimated. Thus, the background intensity Ibackground, determined by the 
measurement of the sample buffer without the respective fluorophore, has to be subtracted 
from the total intensity Itotal, measured in each of the corresponding fluorophore-containing 
samples. For an autocorrelation function G(0) the corrected number of particles Ncorrected can 
be calculated according to the formula (Koppel, 1974) : 
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Additionally, the fluorescence per molecule fpm can be calculated, what represents an 
important control, as at a certain laser power the fpm should not be affected by the 
fluorophore concentration: 
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According to this technique the measurement of low intracellular concentrations in facilitated 
in the presence of background (Brock et al., 1998). 
In order to determine the precise concentration of the measured fluorophores the exact 
volume of the detection volume Veff has to be determined. The size of the detection volume 
can be determined in different ways. The first method is to measure a sample with a known 
concentration c and, subsequently, calculate the volume by (Buschmann et al., 2007) 
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NA represents the Avogadro number, therefore 6.022*10
23 mol-1. The major drawback is the 
fact that the exact adjustment of fluorophore concentrations in the lower nanomolar range is 
a highly critical issue.  
The second possibility is to measure the diffusion time D and the structure parameter S in 
order to calculate the lateral extension of the diffusion volume xy. This approach requires 
knowledge about the diffusion constant D of the respective fluorophore. 
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Assuming that the shape of the detection volume is elliptic and the intensity profile follows a 
Gaussian Distribution, the effective volume Veff is 
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The effective concentration ceff of fluorophores can be easily calculated by the effectively 
measured number of measured particles Neff by 
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Information of protein interactions can also be gained by a novel technique named cross 
correlation raster image spectroscopy method (Digman et al., 2009) which is based on the 
rapid generation of confocal images and displays the cross-correlation in each pixel of the 
microscopic image. 
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2. HPMA as a Scaffold for the Modular Assembly of 
Functional Peptide Polymers by Native Chemical 
Ligation 
 
This chapter is based on a publication in Bioconjugate Chemistry in 2008. The author of this 
thesis contributed Fig. 2.1-2.6 The caspase assay depicted in Fig. 2.7 was kindly provided by 
Dr. Falk Duchardt. 
 
 
2.1. Summary 
 
Synthetic peptides are valuable tools in fundamental and applied biomedical research. On 
one hand, these molecules provide highly efficient access to competitive inhibitors of 
molecular interactions and enzyme substrates by rational design. On the other hand, 
peptides may serve as powerful vectors to mediate cellular uptake of molecules that 
otherwise enter cells only poorly. The coupling of both such functionalities provides access to 
molecules interfering with molecular processes inside the cell. However, the combination of 
several functionalities on one synthetic peptide may be compromised by problems 
associated with the synthesis of long peptides. Native chemical ligation enables the 
chemoselective coupling of fully deprotected functional building blocks. However, peptide 
thioesters are still not accessible by standard solid phase peptide synthesis. Here, we 
demonstrate the cofunctionalization of a thioester-activated N-hydroxypropyl methacrylate 
(HPMA) copolymer (28,500 Da) with the cell-penetrating peptide (CPP) nonaarginine and a 
bioactive peptide as independent building blocks by native chemical ligation. Nonaarginine 
was employed as a cell-penetrating peptide (CPP), a fluorescein-labeled analog of a pro-
apoptotic peptide as a biofunctional cargo. Incorporation of the fluorescein label enabled the 
highly sensitive quantification of the coupling stoichiometry by fluorescence correlation 
spectroscopy (FCS) using 0.4 pmol/ 12 ng of labeled construct. A construct only bearing the 
functional cargo-peptide required cellular import by electroporation in order to show activity. 
In contrast, a construct combining all functionalities was active upon incubation of cells, 
validating the modular nature of the approach.  
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2.2. Introduction 
 
Peptides provide a rich source of bioactive molecules and numerous peptides and analogs 
are now used as drugs (Hruby and Balse, 2000; Bray, 2003; Leader et al., 2008). In 
fundamental biological and biomedical research, peptides have become a highly valuable 
tool for defining the principles of molecular recognition (Cooper and Waters, 2005).  
However, given the poor capacity of peptides to enter cells, most applications of bioactive 
peptides have focused either on extracellular targets, recombinant proteins or cell lysates. In 
order to mediate cellular entry, over the past years, conjugation with cell-penetrating peptides 
has received increasing attention. Cell-penetrating peptides are a diverse class of peptides of 
8 to 30 amino acids in length that promote the cellular uptake of the cargo molecules they 
are connected to (Fischer et al., 2005). In our hands, nonaarginine has proven to be a CPP 
of choice (Wender et al., 2000). This CPP is very well tolerated by cells, has high import 
efficiency and moreover, truncated sequences also show high activity as a CPP, rendering 
purification less problematic (Mitchell et al., 2000). 
For the cellular import of peptides, in most cases, the conjugation with the CPP occurs by N-
terminal elongation during solid-phase peptide synthesis. However, especially for longer 
peptides, purity and post synthesis work-up may become limiting factors. Moreover, in order 
to streamline the process from in vitro to intracellular testing, one may want to render a 
peptide, that has shown activity in an in vitro assay, competent for cell entry without the need 
for de novo synthesis of a cell-penetrating analog.  
Native chemical ligation (NCL) has proven to be a potent technique for the efficient and 
chemoselective coupling of fully deprotected peptides (Dawson et al., 1994; Tam et al., 
2001). In its original form, a peptide, bearing an N-terminal cysteine residue forms an amide 
bond with another peptide, carrying a C-terminal thioester-activated amino acid. In spites of 
its success in the synthesis of longer polypeptides the lack of protocols to generate the 
required C-terminal thioesters by standard solid-phase peptide chemistry is still a limiting 
factor for its broader application. 
As an alternative approach to overcome these limitations, we here describe the modular 
coupling of cysteine-bearing unprotected peptides to thioester-activated hydroxypropyl 
methacrylamide copolymer (HPMA). The HPMA serves as a linear scaffold to which the 
functional peptides are linked. HPMA has been demonstrated to be biocompatible and has 
therefore been used as a drug carrier in numerous applications (Duncan, 2003; Kopecek and 
Bazilova, 1973; Kopecek et al., 2000). Furthermore, conjugation with the Tat-derived CPP 
(Schwarze et al., 1999) has been shown to facilitate the uptake of HPMA-doxorubicin 
conjugates (Nori et al., 2003). 
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The pro-apoptotic peptide AVPIAQK (Fotin-Mleczek et al., 2005b; Fulda et al., 2002a) served 
as a bioactive cargo. This peptide corresponds to the seven N-terminal amino acids of the 
Smac (second mitochondria-derived activator of caspase) protein (Wu et al., 2000). Smac is 
a pro-apoptotic protein, that, following an apoptotic stimulus, is released from mitochondria 
and inhibits the anti-apoptotic action of IAPs (inhibitors of apoptosis proteins) (Du et al., 
2000). Introduction of this peptide into cells specifically enhances the controlled cell death, i. 
e. apoptosis, in cells exposed to ligands of death receptors such as the Tumor Necrosis 
Factor-receptor or Fas (Fulda et al., 2002a). This peptide exerts this activity only when 
introduced into the cytoplasm. We had shown for this peptide previously, that measurement 
of cell viability provides a reliable read-out for comparing import efficiencies of different 
delivery strategies (Fotin-Mleczek et al., 2005b).  
With respect to the quantification of coupled peptides per polymer, three options were 
considered. The first option had been the implementation into the synthesis protocol by 
photometric determination of a leaving group that is released upon coupling of a bioactive 
moiety (Searle et al., 2001). The second option is based on the degradation of an aliquot of 
the conjugate post synthesis and quantification of a suitable degradation product of the 
bioactive moiety (Ding et al., 2006). Finally, the third option is based on the spectroscopic 
quantification of a functional group per unit weight of polymer. Using a fluorescently labeled 
conjugate of the bioactive moiety we chose options two and three. Confocal fluorescence-
correlation spectroscopy (FCS) was employed as the analytical method to follow the release 
of a degradation product according to option two (Rigler et al., 1993). This technique 
provides information on the average number and size of fluorescently labeled molecules 
diffusing through a confocal detection volume. FCS works at concentrations of probe 
molecules in the lower nanomolar to subnanomolar range and in microliter volumes, 
therefore reducing sample consumption to a minimum.  
Our results show that the functionalization of HPMA via NCL occurs with uniform yields. By 
addressing the activity and cellular uptake of HMPA conjugated either to the AVPIAQK 
peptide or R9 alone or a combination of both peptides it is established that all three 
molecular entities act as functionally independent building blocks.  
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2.3. Experimental Procedures 
 
2.3.1. Reagents 
 
 The preactivated hydroxypropyl methacrylamide copolymer N-methacryloylglycylglycine p-
nitrophenyl ester (poly(HPMA-co-methacrylate-Gly-Gly-p-nitrophenyl ester)) was supplied by 
Polymer Laboratories (Shropshire, Great Britain). It has a linear structure, an average 
molecular weight (MW) of 28.5 kDa (MW/Mn: 1.32) and a total nitrophenol content of 8.28 
mol%. Based on the specifications provided by the manufacturer we estimated 12.5 reactive 
groups per molecule. Rink amide resin was from Rapp Polymers (Tübingen, Germany). 
Fmoc amino acids were purchased from Novabiochem (Läufelingen, Switzerland) and Senn 
Chemicals (Dielsdorf, Switzerland). The other chemicals for synthesis were supplied by 
Fluka (Deisenhofen, Germany), PD-10 columns by GE Healthcare (Uppsala, Sweden) and 
Sephacryl S-200 HR gel from Pharmacia Biotech (Uppsala, Sweden). Cell culture media 
were purchased from PAN biotech (Aidenbach, Germany). The agonistic anti-Fas-antibody 
was supplied by Biomol (Hamburg, Germany), cycloheximide by SIGMA (Steinheim, 
Germany) and Alexa647-labeled Annexin V by Invitrogen (Karlsruhe, Germany). 
 
 
2.3.2. Peptide synthesis  
 
Peptides were synthesized by automated solid-phase peptide synthesis using Fmoc/tBu 
chemistry. Fluorescein-labeled peptides were synthesized on Nα-carboxyfluorescein-labeled 
lysyl-Rink amide resin ((Fluo(Trt))-Lys-Rink), unlabeled peptides on Rink amide resin 
(Fischer et al., 2003). Purity was determined by analytical RP-HPLC (Nucleosil 100, 250 × 2 
mm, C18 column, 5 m particle diameter; Grom, Herrenberg, Germany), identity was 
validated via MALDI-TOF-mass spectrometry. For the R9-amide analog CYRRRRRRRRR 
the tyrosine residue was included to enable detection at 280 nm. Concentrations were 
determined by UV/Vis spectroscopy of peptides and conjugates diluted 1000fold in Tris/HCl 
buffer pH 8.8 assuming an extinction coefficient for fluorescein E492= 78,000 l/(mol×cm).  
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2.3.3. Synthesis of the peptide with a lysine-coupled cysteine residue 
 
Ala-Val-Pro-Ile-Ala-Gln(Trt)-Lys(Boc)-Lys(Dde)-Lys(Boc)-Leu-Lys(Boc)-εLys(Fluo) (15 mol) 
was synthesized on (Fluo(Trt))-Lys-Rink amide resin. The peptide was N-terminally protected 
by reaction with boc-anhydride (32.7 mg, 150 mol) in dimethylformamide (DMF)(1 mL) 
containing N,N-diisopropylethylamine (DIPEA) (29.8 L, 180 mol) for 24 h at 20 °C. After 
cleavage of the Dde-protecting group by hydrazine hydrate (2% v/v in DMF, 2 × 1 mL, 5 min, 
20 °C) the ε-amino group was conjugated with Fmoc-Cys(Trt)-OH (87.9 mg, 150 mol) using 
1-hydroxybenzotriazole (20.3 mg, 150 mol) and diisopropylcarbodiimide (23.5 L, 150 
mol) in DMF (1 mL, 24 h, 20 °C). Following removal of the Fmoc-protecting group by 
piperidine (20% v/v in DMF), the peptide was cleaved off the resin and side chains 
deprotected using a mixture of 92.5% TFA, 2.5% triisopropylsilane, 2.5% 1,2-ethanedithiol 
and 2.5% H2O (v/v/v), precipitated in cold diethylether (4 °C) and spun down (4000 rpm, 5 
min). The precipitate was washed with cold diethylether twice. Then the precipitate was 
dissolved in a mixture of acetonitrile/water (4 mL, 1:1, v/v) and lyophilized. 
 
Scheme. 2.1. Synthesis of the proapoptotic peptide with a cysteine residue coupled to a lysine side 
chain 
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2.3.4. Synthesis of HPMA-peptide conjugates  
 
Poly(HPMA-co-methacrylate-Gly-Gly-p-nitrophenylester) (4 mg) was dissolved in anhydrous 
DMSO (200 L), and benzylmercaptan (50 L) was added. After 15 min, peptide was 
dissolved in this solution (4.4 to 11.2 mM corresponding to an 8 to 20-fold excess over 
polymer and 0.64 to 1.60 excess over reactive groups, respectively) and incubated for 30 
min at 20 °C. After addition of thiophenol (50 L) and incubation for 16 h at 20 °C, phosphate 
buffer (100 mM), guanidiniumchloride (6 M), pH 7.5 (200 L), was added and the mixture 
incubated for 72 h at 20 °C. Finally, the reaction mixture was diluted with PBS (700 L) and 
purified twice with a PD-10 column followed by lyophilisation. The formation of a conjugate 
was validated using analytical gel filtration chromatography (ÄKTA-explorer Fast-Protein-
Liquid-Chromatography (FPLC)-station; flow: 0.25 mL/min, 4 °C; Sephacryl S-200 HR-
column, 150 × 10 mm). Absorption was detected at 215 nm (peptide bonds), 280 nm 
(aromatics) and 492 nm (fluorescein).  
 
Scheme 2.2. Coupling of the AVPIAQK analog to a preactivated HPMA (Poly(hydroxypropyl 
methacrylamide)-co-(methacryloyl-Gly-Gly-nitrophenyl ester)). (a) DMSO (anhydrous), 
benzylmercaptane; (b) DMSO (anhydrous), thiophenol; (c) DMSO, thiophenol, phosphate buffer (100 
mM), guanidiniumchloride (6 M, pH 7.5). Amino acids are printed as single letter code in italics. 
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2.3.5. Microscopy  
 
HeLa cells were incubated with HPMA(H2N-AVPIAQKK(C)KLKεK(Fluo)-NH2)n(CYR9-NH2)m 
denoted as AVPIAQK-HPMA-R9 and HPMA(H2N-AVPIAQKK(C)KLKεK(Fluo)-NH2)n denoted 
as AVPIAQK-HPMA (each 20 M with respect to the AVPIAQK peptide) in RPMI medium (45 
min, 37 °C) and afterwards analyzed by confocal laser scanning microscopy using an LSM 
510 confocal microscope (Carl Zeiss, Göttingen) equipped with a Plan-Apochromat 63x N.A. 
1.4 Oil DIC objective.  
 
 
2.3.6. Determination of stoichiometry by FCS 
 
Autocorrelation measurements were performed in a 384-well plate (175 m, low-base 
design, MMI, Eching, Germany) using a ConfoCor 2 fluorescence correlation spectroscope 
equipped with a C-Apochromat 40x N.A. 1.2 water immersion lens (Carl Zeiss, Jena, 
Germany) and a TCS SP5 fluorescence correlation spectroscope equipped with an HCX PL 
APO 63x N.A. 1.2 water immersion lens (Leica Microsystems, Mannheim, Germany). A 
solution of 25 nM peptide-HPMA was incubated in PBS-buffer containing 30 U/ml proteinase 
K for 1.5 h at RT. During this incubation autocorrelation measurements were performed in 
regular intervals until the diffusional autocorrelation time and the amplitude of the 
autocorrelation function had reached a minimum. After digestion the number of particles and 
the fpm of intact and completely digested samples were compared. The ratio of the number 
of particles after and before digestions represents the stoichiometry of peptides per polymer.  
 
 
2.3.7. Bioactivity of electroporated conjugates 
 
HeLa cells were detached by trypsination. Cells (4*105 cells in 200 L serum-containing 
medium) were electroporated with the indicated peptides or conjugates in a 4 mm-cuvette 
(peqlab Biotechnologie GmbH, Germany) using a 12.5 ms, 350 mV, 1700 F pulse (Fischer, 
Germany). After incubation for 10 min on ice the cells were washed by centrifugation, 
transferred to a 96-well microtiter plate (2*104 cells per well) and incubated in 200 L serum-
containing RPMI medium with anti-Fas antibody (100 ng/mL, human activating mouse IgM, 
clone CH11) and CHX (2 g/mL) for 20 h at 37 °C and 5% CO2. Dead cells were removed by 
washing twice with PBS, whereas the attached cells were stained with crystal violet (100 L, 
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0.5% w/v crystal violet, 20% methanol v/v, 80% PBS) (15 min, 20 °C). After removal of 
excess dye by washing with cold water, the intracellular dye was resolved in 100 L 
methanol and the absorption at 550 nm was determined. 
 
 
2.3.8. Caspase-3 activity assay 
 
HeLa cells were incubated with medium containing constructs for 30 min at 37 °C. After one 
washing step cells were treated as indicated with agonistic Fas antibody (100 ng/mL) and 
CHX (2 g/mL) for the induction of apoptosis followed by incubation for a further 3 h. Cells 
were harvested by scraping, washed with ice-cold PBS and lysed in lysis buffer (1% Triton, 
150 mM NaCl, pH 7.7, supplemented with protease inhibitor cocktail tablets (Roche 
Diagnostics, Mannheim, Germany) for 30 min on ice. The protein content in lysates was 
determined using a commercially available Bradford protein assay kit (Bio Rad Laboratories, 
München, Germany). Equivalents of 30 g protein for each sample were diluted in caspase 
activity buffer (20 mM HEPES, 10 mM dithiothreitrol, 10% glycerol, 100 mM NaCl, pH 7.5). 
Fluorogenic caspase-3 substrate (Ac-DEVD-AMC, Calbiochem, Bad Soden, Germany) was 
added to the samples to a final concentration of 2 M. The efficiency of the substrate 
cleavage by active caspase-3 was analyzed immediately after substrate addition and after 3 
h incubation at 37°C using a luminescence spectrometer LS50B (PerkinElmer, Norwalk, CT, 
USA). 
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2.4. Results 
 
2.4.1. Synthesis and analytical characterization of HPMA conjugates  
 
In order to ensure a broad applicability of a polymer-based approach, robust synthesis 
procedures as well as reliable analytical methods to determine coupling efficiencies are 
required. To validate our protocol, a series of coupling reactions with structurally different 
peptides was performed and, for selected peptides, also repeated several times. As a 
bioactive peptide, the pro-apoptotic AVPIAQK peptide was selected. This peptide requires a 
free N-terminus for biological activity. Therefore, in this case, the cysteine residue required 
for NCL was introduced via coupling to a lysine side chain (Scheme 2.1).  
 
A protease-releasable fluorescent reporter group was introduced by C-terminal elongation 
with the tripeptide Lys-Leu-Lys, followed by a fluorescein-labeled lysine residue (Fischer et 
al., 2003). The HPMA was obtained as a preactivated hydroxypropyl methacrylamide 
copolymer poly(HPMA-co-methacrylate-Gly-Gly-p-nitrophenyl ester) (linear structure, 
average MW 28.5 kDa, total nitrophenol content 8.28 mol%) with about 12.5 reactive groups 
per molecule. The active ester was first transesterified to a benzylmercaptyl-thiol ester in 
water-free DMSO, as we were concerned that due to its high reactivity the nitrophenylester 
moiety would engage in reactions with nucleophilic functional groups other than the 
sulfhydryl group of the N-terminal cysteine residue. Next, the polymer was incubated with 
peptide in water-free DMSO. After 16 h aqueous buffer was added. The products were 
purified by gel filtration chromatography (Fig. 2.1). The chemoselectivity of this modified one-
pot ligation protocol was validated in an independent experiment using control peptides with 
and without an N-terminal cysteine residue (Fig. 2.2). 
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Fig. 2.1. Analytical gel filtration chromatography of the HPMA(H2N-AVPIAQKK(C)KLKεK(Fluo)-NH2) 
conjugate: (A) crude reaction mixture, (B) after purification with a desalting column, (C) unbound 
peptide H2N-AVPIAQKK(C)KLKεK(Fluo)-NH2, and (D) free HPMA. Chromatograms were recorded at 
215 nm (dotted lines), 280 nm (solid lines) and 492 nm (dashed lines). 
 
 
Fig. 2.2. Chemoselectivity of the modified NCL protocol. (A,B) Analytical gel filtration chromatography 
of the HPMA thioester after reaction with the peptide H2N-CKLKεK(Fluo)-NH2 before (A) and after (B) 
removal of DMSO with a desalting column. (C, D) Analytical gel filtration chromatography after 
incubation of the HPMA thioester with the peptide H2N-AKLKεK(Fluo)-NH2 before (C) and after (D) 
purification with a desalting column (dotted line: absorption at 215 nm, solid line: absorption at 280 nm, 
dashed line: absorption at 492 nm). 
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Fig. 2.3. Characterization of photophysical shifts occurring upon HPMA conjugation of peptides. (A) 
Normalized absorbance and (B) fluorescence emission spectra of the free, fluorescein-labeled 
AVPIAQK analog (dashed line) and the HPMA-AVPIAQK conjugate (solid line). The conjugate and the 
free peptide were dissolved in Tris/HCl pH 8.8 to a concentration of 2.0 M with respect to the 
fluorescein moiety.  
 
 
For the determination of loading efficiency two independent approaches were evaluated. 
First, the absorption per weight was measured for a defined amount of polymer. Second, the 
number of fluorescent particles before and after digestion of peptide-coupled HPMA with 30 
U/ml proteinase K (Fig. 2.4) was determined by fluorescence correlation spectroscopy. Due 
to the nanomolar sensitivity and microliter measurement volumes of FCS only 0.4 pmol, 
corresponding to 12 ng of the labeled construct was required for one measurement. 
Digestion led to a decrease of the amplitude of the autocorrelation function (Fig. 2.4.A), 
corresponding to an increase in the number of fluorescent particles. The completeness of the 
reaction was confirmed by following the reaction over time. The stoichiometry of peptide 
loading was derived by calculating the number of particles before and after digestion (Table 
1). The release of the fluorescent reporter group from the scaffold was also reflected by the 
shift in the diffusional autocorrelation time from approximately 100 s to 35 s (Fig. 2.4.B). 
The results obtained by FCS corresponded very well to those obtained by the absorption-
per-weight-based methods. A slightly lower loading efficiency was obtained by the latter. This 
may be due to the presence of counterions in the polymer-preparation, leading to an 
overestimate of the amount of material. Due to the fact that the FCS-based method is not 
affected by salt that compromises a correct determination of weight and requires much 
smaller amounts, we judge this method superior. 
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Tab. 2.1. Summary of coupling reactions. For the bifunctional conjugates, information on coupling 
efficiency was obtained for the fluorescein-labeled analog only. 
conjugate fold 
excess 
excess 
over 
reactive 
group 
fluo-
analog 
per 
polymer 
reactive 
groups 
coupled to 
fluo-analog 
rfpm
1
 used in figure 
AVPIAQK(Fluo) -
HPMA-YR9
3
 
4:4:1 0.64 1.3 10% 1.1  
AVPIAQK(Fluo)
 
-
HPMA-R9
3
 
10:10:1 1.6 3.4 27% 1.0 2, 4B, 5 
AVPIAQK(Fluo)
 
-
HPMA
3
 
20:1 1.6 4.6
2
 33%  4C 
AVPIAQK(Fluo)
 
-
HPMA
3
 
10:1 0.8  3.3 26% 1.0 3, 5 
KQAIPVA(Fluo)
 
-
HPMA
4
 
20:1 1.6 4.4
2
 33%  3 
AVPIAQK(Fluo)
 
-
HPMA
3
 
20:1 1.6  4.1(3.4
2
) 33%  1.1 2 
HPMA-R9(Fluo)
 5
 10:1 0.8  2.7 22%  0.8 4A 
AVPIAQK(Fluo)
 
-
HPMA-R9(Fluo)
 3
 
10:10:1 1.6 3.5 28%  0.9  
Cys(Fluo)-HPMA-
R9 
10:10:1 1.6 2.3 18% 1.1  
 
1
the relative fluorescence per molecule (rfpm) was determined by dividing the fluorescence per 
molecule for the conjugate as determined by FCS through the one of the released peptide. 
2
loading efficiency determined by measuring the absorption per unit weight of peptide-coupled polymer  
3
AVPIAQK(Fluo) relates to Ala-Val-Pro-Ile-Ala-Gln-Lys-Lys(Cys)-Lys-Leu-Lys-εLys(Fluo) (see 
experimental procedures) 
4
KQAIPVA(Fluo) relates to Lys-Gln-Ala-Ile-Pro-Val-Ala-Lys(Cys)-Lys-Leu-Lys-εLys(Fluo) (see 
experimental procedures)  
5
R9(Fluo) relates to Cys-Arg-εLys(Fluo) 
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For the coupling efficiency, there was a positive correlation between the ratio of peptide in 
the coupling reaction over reactive groups (Fig. 2.4.C).  
Typically, with a molar excess of 10 with respect to the polymer, corresponding to 0.8 
peptides per reactive group, about 3 peptides were coupled per polymer. Interestingly, in the 
tested concentration ranges, addition of a non-fluorescent peptide did not affect the coupling 
efficiency of the fluorescently labeled peptide (Fig. 2.4.D). 
This observation indicates that at these concentrations, peptides did not compete for reactive 
groups. Also, for R9, the AVPIAQK peptide and a fluorescein-labeled cysteinyl- lysyl moiety, 
similar coupling yields were obtained. This result indicates the suitability of the coupling 
protocol for the testing of larger collections of structurally diverse peptides, without the need 
for the optimization of coupling conditions for each individual case. 
 
 
Fig. 2.4. Quantification of peptide loading per polymer by fluorescence correlation spectroscopy 
(FCS). One aliquot of the HPMA-peptide conjugate AVPIAQK-HPMA-R9 was digested by addition of 
proteinase K (30 U/mL) to the polymer conjugate solution (10 M). After incubation for 1.5 h at 37°C 
the solution was diluted in PBS (500-fold) and transferred to a 384-well plate. A reference aliquot was 
prepared in the same way in the absence of proteinase K. (A) Autocorrelation functions for the 
digested sample (open circles) and the undigested control (filled squares), (B) superposition of the 
autocorrelation functions normalized to an amplitude of 1 to better visualize the shift towards shorter 
diffusional autocorrelation times. (C) Positive correlation of peptides coupled per polymer and the 
excess of peptide over polymer in the coupling reaction. Values were taken from table 1. The excess 
relates to the excess of the fluorescently labeled analog. (D) The coupling efficiency was independent 
from the presence of a second peptide. The conjugates for which the coupling efficiency was only 
determined by absorption-per-weight are not included in this graph. 
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Moreover, by dividing the total fluorescence through the average number of molecules, 
information on the average fluorescence per molecule (fpm) was obtained. In principle, for 
polymers carrying several fluorescently labeled particles, the fpm should be a function of the 
stoichiometry of loading. However, due to self-quenching, the fpm can also be lower than 
expected (Chen and Knutson, 1988). The fpm for the HPMA conjugates relative to the one of 
the free peptide was around 1, independent of the coupling efficiency. This result confirms 
the presence of fluorescence quenching. The molecular brightness of the polymers therefore 
does not provide information on the coupling efficiency.  
We relate to quenching as a reduction of fluorescence per particle due to the spatial 
proximity of several fluorophores, not to the complete extinction of fluorescence for those 
polymers carrying more than one fluorophore. One could argue that for particles carrying 
several fluorophores, fluorescence is quenched completely and these conjugates could not 
be detected. Then, for the undigested sample, only those conjugates carrying one 
fluorophore could be detected. Upon digestion, fluorescent groups would be cleaved off 
polymers carrying several fluorophores, resulting in their dequenching. As a consequence, 
the number of particles per polymer would be overestimated.  
However, in our view, the very good agreement of the determination of coupling efficiency 
based on absorbance-per-weight and the FCS-based method argue against a total 
quenching of fluorescence for polymers carrying several fluorescein moieties. Assuming a 
Poissonian distribution of coupling efficiency, then at an average coupling ratio of 3 about 15 
% of the conjugates carry only 1 fluorophore. 80 % of the peptides would be coupled to 
polymers carrying two or more fluorophores. If all these moieties would only become visible 
after release from the polymer, then a coupling efficiency of 6-7 would be derived. 
 
 
2.4.2. Coupling to HPMA preserves the activity of the AVPIAQK peptide 
 
 Next, we intended to establish that conjugation of the peptide to the polymer does not 
compromise its biological activity. Previously, for the AVPIAQK-peptide we had employed 
electroporation as a means for CPP-independent cytoplasmic delivery (Fotin-Mleczek et al., 
2005b). The free and the HPMA-coupled peptide as well as their counterparts with the 
reverse sequence were loaded into HeLa cells by electroporation. The AVPIAQK-peptide 
does not induce apoptosis by itself. Instead it increases cell death in the presence of an 
apoptosis-inducing stimulus, as for example an agonistic anti-Fas antibody. Stimulation with 
anti-Fas alone, reduced cell viability by 64 % (Fig. 2.5). With the AVPIAQK peptide at a 
concentration of 20 M, cell viability was reduced by a further 8 %. In comparison, the 
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HPMA-conjugated AVPIAQK peptide at a concentration of 20 M (related to the fluorescein 
moiety, i. e. AVPIAQK peptide) reduced the viability by a further 29 %. This difference in 
activity indicates that conjugation to the HPMA strongly promotes the activity of the peptide, 
possibly by protection from proteolytic degradation. The reverse sequences had no effect on 
cell viability. For the HPMA constructs electroporated in the absence of an apoptotic stimulus 
viability was also fully maintained, demonstrating the biocompatibility of the HPMA scaffold. 
 
 
Fig. 2.5. Enhancement of apoptosis induction by electroporated HPMA-conjugates. The concentration 
was adjusted with respect to the fluorescent moiety. In this case, peptide loading was determined by 
absorption per weight (Tab. 2.1). Cell viability was determined by crystal violet staining. 
AVPIAQK(Fluo) relates to Ala-Val-Pro-Ile-Ala-Gln-Lys-Lys(Cys)-Lys-Leu-Lys-εLys(Fluo) (see 
experimental procedures); KQAIPVA(Fluo) relates to Lys-Gln-Ala-Ile-Pro-Val-Ala-Lys(Cys)-Lys-Leu-
Lys-εLys(Fluo) (see experimental procedures). The statistical significance was determined by a two-
tailed unpaired Student‟s T-test.  
 
 
2.4.3. Cellular uptake and bioactivity of bifunctional conjugates 
 
Having established, that the HPMA is inert with respect to cell entry and that the HPMA-
conjugated AVPIAQK-peptide fully maintains activity, we next co-functionalized the HPMA 
with the AVPIAQK-peptide and nonaarginine to obtain conjugates competent for cell entry. 
Both, the HPMA conjugate functionalized with R9 only as well as the one cofunctionalized 
with R9 and the AVPIAQK peptide efficiently entered cells (Fig. 2.6). 
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In contrast to what we typically observe for free R9, a large part of the fluorescence was 
localized close to the plasma membrane. In addition, there was homogenous intracellular 
fluorescence. Inside the nucleus, the nucleoli were visible; an observation that we and others 
have made for cell-penetrating conjugates before (Duchardt et al., 2007). For the bifunctional 
HPMA construct only the AVPIAQK-moiety was fluorescently labeled. The intracellular 
fluorescence therefore provided direct evidence for the cofunctionalization of the HPMA 
scaffold with the nonaarginine. 
 
 
Fig. 2.6. Cellular uptake and subcellular distribution of HPMA-peptide-conjugates. Confocal 
microscopy of cells incubated (A) with HPMA-R9, (B) the bifunctional AVPIAQK-HPMA-R9 conjugate 
and (C) a conjugate bearing the functional peptide only (AVPIAQK-HPMA)(20 M). One confocal slice 
as well as orthogonal sections along the indicated lines are shown. Cells were incubated with the 
respective conjugate at a concentration of 20 M with respect to the fluorescent moiety for 45 min at 
37 °C. The bar denotes 20 m.  
 
 
Finally, we assessed, whether the bifunctional HPMA-conjugate would also combine both 
biological functions, namely, cell entry and apoptosis enhancement. To fully establish that 
the conjugates acted by enhancement of apoptosis and to exclude that a reduction of cell 
viability was due to general cell toxic effects, we determined the activity of the executioner 
caspase 3 in cell lysates as an apoptosis-specific read-out.  
Neither of the constructs led to an increase of caspase 3 activity beyond the about 2-fold 
increase in activity observed for control cells incubated in the absence of stimulus and 
conjugate (Fig. 2.7).  
The apoptotic stimulus increased the caspase 3 activity 3.5 fold. For the conjugate bearing 
the AVPIAQK moiety alone, no further increase was observed, consistent with the inability of 
this molecule to enter the cells. In contrast, the bifunctional conjugate increased the caspase 
3 activity by up to 8-fold in a concentration-dependent manner. Some increase in activity to 
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5.3-fold was also observed for the conjugate bearing the nonaarginine moiety, only. This 
activity may be due to a higher sensitivity of the apoptosis-induced cells to the import of a 
polycation (Law et al., 2006). In the absence of the proapoptotic stimulus there was no 
cytotoxic activity for neither of the constructs. This result, in conjunction with the absence of 
activity for the electroporated reverse KQAIPVA(Fluo)-HPMA conjugate validate the 
biocompatibility of the conjugates. 
 
 
 
Fig. 2.7. Bioactivity of HPMA-conjugates. HeLa-cells were incubated with different concentrations of 
the counjugates for 30 min at 37°C. Afterwards the cells were washed and apoptosis was induced by 
stimulation with an agonistic anti-Fas antibody (100 ng/mL) and cycloheximide (CHX, 2 g/mL).For 
measurements of the caspase-3 activity cells were harvested after 3 h after induction of apoptosis. 
The figure shows averages and standard deviations of two independent cell stimulations, that were 
analyzed twice/three times by a colorimetric caspase assay. The biological activity is expressed as 
fold-induction of caspase 3 activity in relation to lysates of untreated cells obtained at t=0. The results 
of the individual assays were normalized based on the accumulated absorbance of all samples. The 
pointed line indicates the increase of caspase 3 activity during the 3 h incubation period of the assay 
in the absence of an apoptotic stimulus. The dashed line indicates the Fas stimulus-dependent 
increase in caspase activity, ++ the presence of the apoptotic stimulus. Concentrations were derived 
from the absorption of fluorescein. The statistical significance was determined by a two-tailed unpaired 
Student‟s T-test.  
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At present the molecular basis for the different subcellular localization of the HPMA 
conjugates in comparison to free CPPs is not understood. To this point, we have not 
resolved, whether this distribution is a consequence of a poor induction of endocytosis and 
therefore increased association with the plasma membrane or of differential vesicular 
trafficking of HPMA-loaded vesicles. For free cell-penetrating peptides, sequestration within 
the endolysosomal compartment is also a major limitation for bioactivity (Fotin-Mleczek et al., 
2005b). Typically, these vesicles are distributed throughout the cell (Duchardt et al., 2007). 
More importantly with respect to their application, the localization close to the plasma 
membrane is not associated with the induction of membrane damage as validated by the 
biocompatibility of the conjugates in the absence of an apoptotic stimulus. 
 
 
2.5. Conclusions 
 
In summary, our results show that the HPMA-based strategy provides a convenient access 
to cell-penetrating bioactive peptides. Peptides mediating cell entry and bioactivity are 
coupled as fully unprotected building blocks to the preactivated HPMA polymers by native 
chemical ligation. Due to the modular nature of the approach, shorter peptides may be 
employed which facilitates the synthesis of cell-penetrating conjugates especially for longer 
bioactive peptides. Therefore, the modular nature of the approach represents a considerable 
short-cut for testing the activity of peptides inside a cell. The assessment of bioactivity and 
uptake for the individual conjugates confirmed that the functionality of the three molecular 
elements, i. e. scaffold, bioactive peptide and CPP, combine independently in a modular 
fashion.  
The coupling reaction proceeded with little day-to-day variation. Our results indicate that the 
coupling efficiency correlates positively with the excess of peptide over functional groups. In 
further studies it will therefore be highly interesting to systematically assess the effect of 
variations of either the number of bioactive peptides or the CPP with respect to bioactivity, 
uptake and trafficking. Also the incorporation of peptides known to promote endosomal 
release as a further element will be a promising option to explore for increasing bioactivity 
(Wadia et al., 2004). These advancements will strongly promote the development and 
application of functional peptides in fundamental and applied biomedical research (Vicent 
and Duncan, 2006). 
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3. Coupling to polymeric scaffolds stabilizes 
biofunctional peptides for intracellular applications 
 
The author of this thesis synthesized the HPMA conjugates used in this study and 
contributed the Fig.3.2-3.6 The caspase assay depicted in Fig. 3.1. was kindly conducted by 
Dr. Falk Duchardt. Moreover, Dr. Falk Duchardt contributed the apoptosis assay depicted in 
Fig. 3.7. 
 
 
3.1. Summary 
 
Peptides and proteins are rapidly gaining significance as drugs and as bioactive molecules in 
biomedical research. However, nearly all of these peptide-based approaches relate to 
extracellular applications. In contrast, the intracellular applicability is still seriously limited by 
the poor intracellular half-life of peptides. Stabilization by incorporation of modified amino 
acid residues or backbone modifications requires extensive revalidation of structure-activity 
relationships. Therefore, stabilization of an unmodified peptide would be highly 
advantageous. For extracellular applications, conjugation to polymers is a strategy for 
increasing stability and decreasing elimination. We have shown recently, that conjugation of 
peptides to a thioester-activated N-hydroxypropyl methacrylamide (HPMA) copolymer (28.5 
kDa) via native chemical ligation provides polymer-coupled peptides in a simple one-pot 
synthesis. Here we demonstrate for an apoptosis-inducing peptide, introduced into Jurkat T 
cell leukemia cells by electroporation, that coupling to the polymer greatly increases the 
intracellular biological activity per peptide moiety. The molecular basis of this finding was 
elucidated in detail. Electroporation efficiency was lower for HPMA-conjugates, while the 
cellular residence time of fluorescence was the same. However, HPMA conjugation strongly 
increased the half life of the peptides in crude cell lysates, revealing proteolytic protection as 
the basis for higher activity. A bifunctional conjugate containing the cell-penetrating peptide 
nonaarginine for mediating cellular entry, induced apoptosis in a concentration-dependent 
manner. In summary, these results do not only present a generalization of the potential of the 
HPMA-based conjugation strategy, they also provide a mechanism for the increase in 
activity. 
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3.2. Introduction 
 
The chemical nature of peptides provides a nearly infinite diversity in structure, accessible by 
highly robust and parallel synthesis protocols (Rademann and Jung G, 2000). Therefore 
peptides provide a highly valuable repertoire of molecular interactors, both in basic and 
applied biomedical research (Cooper and Waters, 2005). In the past years, numerous 
peptides have been admitted as drugs (Hruby and Balse, 2000; Bray, 2003; Leader et al., 
2008). Nevertheless, the intracellular applicability of peptides is still limited. One major 
drawback of short peptides is their short cytoplasmatic half-life. Major efforts have been 
invested into increasing the stability of peptides. The incorporation of non-native amino acids 
such as D-amino acids (Chorev et al., 1979) beta-amino acids (Frackenpohl et al., 2001; 
Griffith, 1986) in the peptide sequence or backbone modifications such as N-methylation 
(Gordon et al., 2001) have been presented as possible solutions. However, these 
approaches do not only render the synthesis more time consuming and expensive, they also 
require a careful revalidation of the structure-activity relationship of the molecule 
(Ruijtenbeek et al., 2001). 
An alternative approach that is well established in order to extend the plasma half-life of 
small molecule drugs in the blood stream and to prevent liver accumulation is the conjugation 
of the drugs to high-molecular weight polymers (Duncan, 2003; Vicent and Duncan, 2006). In 
this context the hydroxypropyl methacrylamide copolymer (HPMA) is widely used (Kopecek 
and Bazilova, 1973; Kopecek et al., 2000; Malugin et al., 2004; Satchi-Fainaro et al., 2004). 
In a previous study, we have shown that coupling of peptides containing an N-terminal 
cysteine residue to thioester-preactivated HPMA polymers provides a convenient and robust 
access to polymer-coupled peptides via native chemical ligation (Dawson et al., 1994; 
Ruttekolk et al., 2008; Tam et al., 2001). Conjugates containing an apoptosis-enhancing 
peptide, loaded into cells by electroporation had a greatly increased biological activity in 
comparison to the free peptide. Correspondingly, bifunctional conjugates containing the 
apoptosis-enhancing peptide and nonaarginine as a cell-penetrating peptide (CPP) (Mitchell 
et al., 2000; Wender et al., 2000) showed a higher biological activity than the bioactive 
peptide extended by the CPP. 
Differences in import efficiency, retention time inside the cell and stabilization from proteolytic 
break-down were considered as the basis for this observation. However, the structure of the 
bioactive peptide compromised a determination of the molecular basis of this observation. 
The peptide required free and unmodified seven N-terminal amino acids for bioactivity and 
could therefore only be linked to the polymer via a cysteine residue coupled to a C-terminal 
lysine side chain. Therefore, it was impossible to assess proteolytic cleavage of the polymer-
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coupled peptide. Ideally, a peptide used for the analysis of proteolytic stability should be 
coupled to the polymer via its N-terminus and carry a fluorescent reporter group at its C-
terminus. 
Here, we therefore selected a Bid-derived BID-BH3 peptide as a model peptide (Cory et al., 
2003; Kuwana et al., 2002; Willis and Adams, 2005). This peptide has a length of 22 amino 
acids and does not require a free amino terminus for biological stability. Coupling to the 
polymer occurred straight-forward via an N-terminal cysteine residue. A fluorescein label was 
attached to a C-terminal lysine residue. Therefore, in contrast to our previous choice, this 
peptide was ideally suited to detect proteolytic cleavage off the polymer and release of C-
terminal low molecular weight fluorescein-labeled fragments. The BID-BH3 peptide can 
directly induce apoptosis by interacting with the multidomain proapoptotic BCL-1 family 
protein BAX. BAX forms homo-oligomers at the mitochondrial membrane and triggers the 
release of cytochrome c and other proapoptotic factors (Kuwana et al., 2002; Walensky et 
al., 2006). The free peptide was N-terminally capped by labeling with fluorescein and C-
terminally blocked by amidation.  
In order to eliminate the complex CPP-mediated import kinetics, involving endosomal release 
(Fotin-Mleczek et al., 2005a), the free peptides and the conjugates were introduced into the 
cell via electroporation and the bioactivity of both was investigated. Again the polymer-
coupled peptide exhibited a greatly increased activity.  
The import efficiency and intracellular distribution were analyzed by confocal laser scanning 
microscopy and flow cytometry. The intracellular retention was addressed by time-lapse 
microscopy in combination with quantitative image analysis. Finally, the proteolytic stability 
was compared by incubation of conjugate and peptide with crude cell lysate. The latter 
measurement was performed by fluorescence correlation spectroscopy (FCS)(Rigler et al., 
1993). This fluorescence-based analytical technique provides information about the average 
number and size of fluorescently labeled molecules that diffuse through a sub-femtoliter 
confocal detection volume. Less than one pmol referring to few ng of the labeled construct 
were required per measurement. For the HPMA conjugate the import efficiency was reduced 
while the intracellular retention of fluorescence was the same as for the free peptide. In 
contrast, the stability against cytosolic proteases was tremendously increased. Finally, we 
demonstrated that a bifunctional HPMA conjugate, containing nonaarginine as a cell-
penetrating peptide next to the functional BID-BH3 peptide induced apoptosis in a 
concentration dependent manner. Together, the results demonstrate a generalization of our 
HPMA-based approach and provide a mechanistic basis for the capacity of this approach. 
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3.3. Experimental Procedures 
 
3.3.1. Reagents 
 
Preactivated hydroxypropyl methacrylamide copolymer N-methacrylateglycylglycine p-
nitrophenyl ester (poly-(HPMA-co-methacrylate-Gly-Gly-p-nitrophenyl ester)) with an average 
molecular weight (MW) of 28.5 kDa (Mw/Mn: 1.32) and a total nitrophenol content of 8.28 
mol % was purchased from Polymer Laboratories (Shropshire, Great Britain). On the basis of 
the specifications provided by the manufacturer, 12.5 reactive groups were estimated per 
molecule. Peptides were purchased from EMC microcollections (Tübingen, Germany). The 
other chemicals for synthesis were supplied by Fluka (Deisenhofen, Germany), PD-10 
columns by GE Healthcare (Uppsala, Sweden). Cell culture media were purchased from 
PAN biotech (Aidenbach, Germany). The electroporation kit Cell Line Nucleofector Kit V was 
provided by AMAXA (Cologne, Germany). Alexa647-labeled annexin-V was supplied by 
Invitrogen (Karlsruhe, Germany). 
 
 
3.3.2. Peptide synthesis 
 
Peptides were synthesized by automated solid-phase peptide synthesis using Fmoc/tBu 
chemistry. Fluorescein-labeled peptides with a C-terminal fluorophore were synthesized on 
preloaded carboxyfluorescein-labeled lysyl-Rink amide resin ((Fluo(Trt))-Lys-Rink) (Fischer 
et al., 2003), unlabeled peptides on Rink amide resin. N-terminal labeling proceeded as 
described previously (Fischer et al., 2003). The peptides were purified by preparative RP-
HPLC (Grom-SIL 120 ODS-4 HE, 125× 20 mm, C18 column, 5 μm particle diameter; Grom, 
Herrenberg, Germany). Purity was determined by analytical RP-HPLC (Grom-SIL 120 ODS-4 
HE, 100 × 2 mm, C18 column, 5 μm particle diameter; Grom), identity was validated via 
electrospray mass spectrometry with a LCQ Advantage Max mass spectrometer (Thermo 
Fisher Scientific, Waltham, USA). Concentrations were determined by UV/Vis spectroscopy 
of peptides and conjugates diluted 1000-fold in Tris/HCl buffer pH 8.8 assuming an extinction 
coefficient for fluorescein E492 = 78 000 L/(mol × cm).  
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3.3.3. Synthesis of HPMA-peptide conjugates 
 
Poly(HPMA-comethacrylate-Gly-Gly-p-nitrophenylester) (4 mg) was dissolved in anhydrous 
benzylmercaptan (50 μL) and anhydrous DMSO (200 μL). After 15 min, peptide was 
dissolved in this solution (5.6 mM corresponding to a 10-fold excess over polymer and 0.8 
excess over reactive groups, respectively) and incubated for 30 min at 20 °C. After addition 
of thiophenol (50 μL) and incubation for 16 h at 20 °C, phosphate buffer (100 mM) and 
guanidinium chloride (6 M), pH 7.5 (200 μL), were added and the mixture was incubated for 
72 h at 20 °C. Finally, the reaction mixture was diluted with PBS (700 μL) and purified twice 
with a PD-10 column followed by lyophilization. Absorption was detected at 215 nm (peptide 
bonds), 280 nm (aromatics), and 492 nm (fluorescein). For the bifunctional conjugates either 
BID-BH3, or mutBID-BH3, or and C- K(Fluo)-NH2 and nonaarginine were conjugated to the 
HPMA polymer in a ratio of 10:10:1 (cargo:nonaarginine:HPMA). 
 
 
 
Scheme 3.1. Synthesis of a HPMA-BID-BH3 conjugate. (a) DMSO (anhydrous), benzylmercaptane; 
(b) DMSO (anhydrous), thiophenol; (c) DMSO, thiophenol, phosphate buffer (100 mM), 
guanidiniumchloride (6 M, pH 7.5). Amino acids are represented in single letter code and printed in 
italics. 
 
 
3.3.4. Determination of stoichiometry by FCS 
 
The determination of stoichiometry proceeded as described previously (Ruttekolk et al., 
2008) using fluorescence correlation spectrosopy (FCS). FCS measurements were 
performed in 384-well plates (175 μm, low-base design, MMI, Eching, Germany). A solution 
of 25 nM peptide-HPMA was incubated in PBS-buffer containing 40 U/mL proteinase K for 
1.5 h at RT. During this incubation, autocorrelation measurements using a TCS SP5 
fluorescence correlation spectroscope equipped with an HCX PL APO 63× N.A. 1.2 water 
immersion lens (Leica Microsystems, Mannheim, Germany) were performed in regular 
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intervals until the diffusional autocorrelation time and the amplitude of the autocorrelation 
function had reached a minimum. After digestion, the number of particles and the 
fluorescence per molecule (fpm), calculated by dividing the total background-corrected 
fluorescence by the number of molecules, of intact and completely digested samples were 
compared. The ratio of the number of particles after and before digestions represents the 
stoichiometry of peptides per polymer. 
 
Tab. 3.1. Summary of Peptides and HPMA Conjugates. 
name conjugate fold 
excess 
fluo-
analog 
per 
polymer
1
 
reactive 
groups 
coupled 
to fluo-
analog 
Rfpm
2
 
BID-BH3 Fluo-EDIIRNIARHLAQVGDSMDRSI / / / / 
mBID-BH3 Fluo-EDIIRNIARHAAQVGASADRSI
3
 / / / / 
HPMA-
BID-BH3 
HPMA-
CEDIIRNIARHLAQVGDSMDRSI(Fluo) 
10:1 1.8 14% 1.2 
HPMA-
mBID-BH3
 
 
HPMA-
CEDIIRNIARHAAQVGASADRSI(Fluo)
3
 
10:1 2.1 17% 1.0 
R9-HPMA-
BID-BH3 
R9-HPMA-
CEDIIRNIARHLAQVGDSMDRSI(Fluo) 
10:10:1 2.4 19% 1.2 
R9-HPMA-
mBID-BH3
 
 
R9-HPMA-
CEDIIRNIARHAAQVGASADRSI(Fluo)
3
 
10:10:1 2.8 22% 1.1 
R9-HPMA-
C 
R9-HPMA-C(Fluo)
2
 10:10:1 2.3 18% 0.9 
 
1
The loading refers to the fluorescein moieties per polymer. 
2
the relative fluorescence per molecule (rfpm) was determined by dividing the fluorescence per 
molecule for the conjugate as determined by FCS through the one of the released peptide. 
3
The mutated amino acid residues are underlined. 
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3.3.5. Electroporation 
 
106 Jurkat E6.1 cells were resuspended in 100 L Nucleofector Solution V (Lonza Cologne, 
Cologne, Germany) and the respective peptide or HPMA conjugate was added into the 
electroporation cuvette (Lonza Cologne) in the desired concentration. Electroporation was 
performed in a Nucleofector (Lonza Cologne) using the electroporation method X-001 
according to the recommendations of the manufacturer. Subsequently, 900 L RPMI medium 
were added carefully and the cells were incubated for 5 min at RT. Subsequently, the cell 
suspension was washed in medium by centrifugation. 
 
 
3.3.6. Bioactivity of conjugates 
 
For the testing of the activity of electroporated conjugates, the electroporated cells were 
washed, transferred to a 24-well tissue culture plate with flat bottom (Sarstedt, Nümbrecht, 
Germany) and incubated for 20 h in RPMI medium. Subsequently, the cells were washed in 
cold PBS and incubated in 100 L annexin-binding buffer (10 mM HEPES, 140 mM NaCl and 
2.5 mM CaCl2, pH 7.4) containing 5 L annexin-V Alexa Fluor 647 for 15 min on ice. 400 L 
annexin-binding buffer were added and the samples were analyzed by flow cytometry with a 
FACSCalibur System (BD Biosciences, San Jose, USA). 
For determination of apoptosis induction by cell-penetrating conjugates Jurkat cells were 
incubated either with BID-BH3-HPMA-R9, mutBID-BH3-HPMA-R9 or Lys(Fluo)-HPMA-R9. 
Concentrations were adjusted based on the fluorescein absorption of the cargo moieties. 
Following incubation with the conjugates for 10 h at 37 °C the cells were washed with PBS 
by centrifugation and stained with Alexa647-labeled annexin V. Dead cells were quantified by 
flow cytometry. An aliquot of the annexin-labeled cells was resuspended in DMEM-medium 
containing 10 % FCS and examined by confocal laser scanning microscopy. For microscopy, 
here an LSM510 confocal microscope (Carl Zeiss, Jena, Germany) was used. For the double 
detection of fluorescein-labeled peptide conjugates and Alexa647-labeled annexin V the 488 
nm line of an argon ion laser and the light of a 633 nm helium-neon laser were directed into 
the sample with an HFT UV/488/633 beam splitter and fluorescence was detected using an 
HFT 545 beam splitter in combination with a BP 505-530 band pass filter for fluorescein 
detection and an LP 650 long pass filter for Alexa647 detection. 
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3.3.7. Analysis of peptide release 
 
5 x 105 electroporated Jurkat E6.1 cells were incubated in 200 L phenol red-free RPMI 
medium for 10 min at 37 °C until they had settled on the bottom of a 8-well chambered 
coverglass (Nunc, Rochester, USA). Subsequently, the cells were analyzed by confocal laser 
scanning microscopy using a Leica SP5 confocal microscope equipped with an HCX PL APO 
63× N.A. 1.2 water immersion lens (Leica Microsystems, Mannheim, Germany). The cells 
were incubated at 37°C and 5 % CO2 in an cell culture incubator and in certain time intervals 
confocal images were taken by laser scanning microscopy. The microscopy stage was 
housed in an incubator box maintained at 37°C. 
 
 
3.3.8. Image analysis 
 
For intracellular quantification of fluorescence, the confocal microscopy images were 
imported into the program ImageJ 1.41. The images were smoothed with a low pass filter 
and converted into a black and white mask with a threshold that was adjusted to include all 
cells. Adjacent cells were separated with a watershed operation. This binary mask was used 
for segmentation of the original image. The program automatically quantified the mean 
fluorescence intensity of the cells. 
 
 
3.3.9. Proteolytic stability in cell lysate 
 
For preparation of cell lysate 4 x 106 HeLa cells were harvested by treatment with trypsin and 
EDTA and washed with medium and PBS. The cells were resuspended in 1 mL PBS 
containing 1 % (v/v) Triton-X-100 and lysed for 45 min on ice. Subsequently, the cell 
membranes were removed by centrifugation (20,000 g for 20 min at 4°C). The supernatant 
was split into two aliquots of 500 L, each, into which either 2 M HPMA-BID-BH3 conjugate 
or BID-BH3 peptide were added. The concentration of the cell suspension was adjusted so 
that the degradation of the peptide and conjugate could be followed over several hours. The 
samples were incubated at 37°C. At the indicated times samples of 5 L were taken, mixed 
with 95 L protease inhibitor cocktail (Complete, Roche Diagnostics, Mannheim, Germany) 
and frozen. Finally, the frozen samples were thawn, 1000 L Tris buffer (100 mM Tris-HCl, 
pH 8.8) were added and aliquots of 50 L were transferred into a 384-well plate (175 μm, 
low-base design, MMI). Autocorrelation measurements were performed using a TCS SP5 
3. COUPLING TO POLYMERIC SCAFFOLDS STABILIZES BIOFUNCTIONAL PEPTIDES FOR INTRACELLULAR APPLICATIONS 
 
63 
fluorescence correlation spectroscope equipped with an HCX PL APO 63× N.A. 1.2 water 
immersion lens. The fractions of intact and degraded polymer or peptide were derived from 
two-component fits to the autocorrelation function. The diffusional autocorrelation times for 
the high molecular weight component were fixed to values determined for the intact 
conjugate or peptide. The diffusional autocorrelation time for the low molecular weight 
component was fixed to the one of a fully degraded sample. After 24 h a high concentration 
of 40 U/mL proteinase K (2 U in 50 L) was added in order to validate the general sensitivity 
of the conjugates to protease degradation. 
 
 
3.4. Results 
 
3.4.1. Synthesis and analytical characterization of HPMA conjugates  
 
Following our previously published procedure (Ruttekolk et al., 2008), the BID-BH3 peptide, 
containing an uncapped N-terminal cysteine residue was coupled to an active ester-
preactivated HPMA polymer by native chemical ligation. For the determination of loading 
efficiency the number of fluorescent particles before and after digestion of the HPMA-peptide 
conjugate with 40 U/mL proteinase K (2 U in 50 L) was determined by fluorescence 
correlation spectroscopy. Digestion led to a decrease of the amplitude of the autocorrelation 
function, corresponding to an increase in the number of fluorescent particles. The release of 
the fluorescent reporter group from the scaffold was also reflected by the shift in the 
diffusional autocorrelation. The completeness of the reaction was confirmed by observing the 
reaction over time. The stoichiometry of peptide loading was derived from calculating the 
number of particles before and after digestion. On average each polymer carried two 
peptides (Tab. 3.1.). Assuming a Poissonian distribution of coupling efficiency, at an average 
coupling ratio of 2 about 27 % of the conjugates carried only 1 peptide, 59 % of the polymers 
carried two or more peptides and 14 % of the polymers had remained unfunctionalized. 
Fluorescence correlation spectroscopy also revealed the molecular brightness per molecule 
(fpm – fluorescence per molecule), calculated by dividing the total background-corrected 
fluorescence of a sample by the number of molecules. As before, even though the polymer 
on average carried two fluorophores per molecules, the molecular brightness was the same 
for the polymers and for the free peptide (Tab. 3.1.). This observation is very likely due to 
quenching of fluorescence. 
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3.4.2. Bioactivity of electroporated conjugates 
 
Cellular import of functional conjugates lacking a cell-penetrating moiety was chosen to 
elucidate whether coupling to the polymer affected the activity per peptide. For the cellular 
import, electroporation was chosen. In electroporation cells are briefly exposed to a strong 
electric field that transiently introduces pores into the plasma membrane (Gehl, 2003). 
Electroporation is a powerful method to introduce molecules directly into the cytoplasm of 
cells. For our analyses of intracellular activity, electroporation therefore circumvented the 
complications of endosomal uptake, breakdown and release associated with CPP-mediated 
cellular import (Fischer et al., 2005; Fotin-Mleczek et al., 2005a). After washing by 
centrifugation the cells were incubated for 20 h to allow the induction of apoptosis. 
Quantification of apoptotic cells occurred by incubation with annexin-V Alexa Fluor 647 using 
flow cytometry. Annexin-V binds to the phospholipid phosphatidylserine on the cell surface, 
which is externalized to the outer leaflet of the plasma membrane during apoptosis. Only the 
HPMA-BID-BH3 conjugate showed activity in a concentration dependent manner (Fig. 3.1). 
As the indicated concentrations represent peptide concentrations, this result demonstrates 
that the specific activity of the peptides was increased considerably due to the conjugation of 
the peptides to polymers. 
We therefore aimed to resolve the molecular basis of the different activities. Next to a mere 
difference in electroporation efficiency of the polymer and the free peptide, differences in 
intracellular residence time or stabilization from proteolytic breakdown were considered. 
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Fig. 3.1. Apoptosis induction by HPMA conjugates and free peptides. Jurkat cells were electroporated 
with the free apoptosis-inducing BID-BH3 peptide, the mutated mBID-BH3 peptide or the respective 
polymer-conjugated peptides HPMA-BID-BH3 and HPMA-mBID-BH3 in the indicated concentrations. 
(A-C) The cells were washed and incubated in FCS-containing medium for 20 h. Subsequently, cells 
were stained with Alexa 647-labeled annexin-V. (A) Microscopy image of annexin-V-stained cells, 
electroporated with 40 M HPMA-BID-BH3, 20 h after incubation. (B) Flow cytometry histograms of 
Jurkat cells electroporated with various concentrations of HPMA-BID-BH3 and stained for 
phosphatidylserine exposure with Alexa 647-labeled annexin-V. (C) Fraction of annexin-V-positive 
Jurkat cells upon electroporation of peptides and HPMA conjugates. (D) Jurkat cells were 
electroporated with peptides and HPMA conjugates and after incubation for 6 h in FCS-containing 
medium the caspase-3 activity was determined. The figures show the results of representative 
experiments. The concentrations relate to the number of bioactive peptides. 
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3.4.3. Quantification of electroporation efficiency  
 
In a first step, we compared the electroporation efficiency of the conjugates and the free 
peptides. To this end, 30 M of the BID-BH3 peptide and the HPMA-BID-BH3 conjugate 
were electroporated into Jurkat E6.1 cells. The intracellular fluorescence was quantified by 
flow cytometry and observed by confocal laser scanning microscopy 1 h after 
electroporation. All electroporated cells were positive for fluorescence. The cellular 
fluorescence of the peptide was approximately 4-fold higher than that of the HPMA conjugate 
(Fig. 3.2). Considering that (i) both the peptide and the conjugate had the same molecular 
brightness and (ii) that the polymer carried on average two peptides per polymer, this finding 
indicated that in case of the free peptide about twice as many peptides were inside the cells 
than in the case of the polymer-coupled peptides. 
 
 
Fig. 3.2. Electroporation efficiency of peptides and conjugates. Jurkat E6.1 cells were electroporated 
with (A) medium 30 M of (B) BID-BH3 peptide or (C) HPMA-BID-BH3. The concentration of 
conjugate related to the number of peptide moieties. Subsequently, the living cells were washed with 
medium and observed by (A-C) confocal laser scanning microscopy 1 h after electroporation. The 
scale bar in the microscopy images represents 50 m; (D-E) corresponding flow cytometry histograms 
and (G) medians of intracellular fluorescein intensities. 
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3.4.4. Determination of intracellular retention 
 
The induction of apoptosis was determined 20 h after electroporation. We therefore reasoned 
that the higher biological activity could be explained by a longer residence time of the higher 
molecular weight conjugates. For a comparison of residence times, Jurkat E6.1 cells were 
electroporated with 30 M solutions of the peptides and conjugates. The cells were washed 
and observed by confocal laser scanning microscopy over time in a chase experiment (Fig. 
3.3). Subsequently, the images were analyzed by digital image analysis and the average 
brightness of the cells was calculated (Fig. 3.4). The fluorescence residence time of the 
unbound BID-BH3 peptide had a half life of 5.8 ± 1.8 h, the one for the free mBID-BH3 
peptide 5.0 ± 1.1 h, the HPMA-BID-BH3 conjugate 10.6 ± 7.4 h and the HPMA-mBID-BH3 
conjugate 4.4 ± 1.7 h. In contrast, the free fluorescein molecules had an intracellular half-life 
of less than 0.5 h. For the HPMA-conjugates larger errors were found repeatedly due to the 
lower intensity of cellular fluorescence that also precluded an observation over longer times. 
The intracellular distribution did not change significantly over time (Fig. 3.5). In all cases, 
fluorescence remained homogenuously distributed inside the cytoplasm demonstrating that 
no sequestration into intracellular structures occurred. These results clearly indicate that the 
intracellular residence time is not a relevant factor to explain the increased activity of HPMA-
conjugated peptides. 
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Fig. 3.3. Release of cellular fluorescence after electroporation of peptides and HPMA conjugates. 
Jurkat E6.1 cells were electroporated with 30 M of peptides and HPMA conjugates or fluorescein. 
The concentration of conjugate related to the number of peptide moieties. Subsequently, the cells 
were washed twice with medium, seeded into an 8-well chambered coverglass and incubated at 37°C. 
In certain time intervals confocal images were taken by laser scanning microscopy. The scale bar 
represents 50 m. 
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Fig. 3.4. Analysis of release kinetics. The confocal images generated by laser scanning microscopy 
(Fig. 3.3) were analyzed by quantitative image analysis via ImageJ. (A) Superposition of all curves (the 
intensity at the beginning of the experiment was set to 100 %), (B) BID-BH3 peptide, (C) mBID-BH3 
peptide, (D) HPMA-BID-BH3 conjugate, (E) HPMA-mBID-BH3 conjugate and (F) fluorescein. The data 
were fitted with a first order exponential decay. 
 
 
Fig. 3.5. Intracellular distribution of fluorescence at different time points after electroporation. Jurkat 
E6.1 cells electroporated with (A) the BID-BH3 peptide, (B) the HPMA-BID-BH3 conjugate, (C) the 
mBID-BH3 peptide, (D) the HPMA-mBID-BH3 conjugate and (F) fluorescein were observed (A-E) 30 
min after electroporation and (F-J) 6h after electroporation. The scale bar represents 20 m. 
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3.4.5. Peptide stability 
 
Having excluded differences in loading and retention as the source for the increased 
biological activity, we therefore addressed the sensitivity to proteolytic breakdown of the free 
peptide and the HPMA-conjugated peptide. It has been shown that terminal capping 
(Brinckerhoff et al., 1999) as well as linking of peptides to dendrimers (Bracci et al., 2003) 
increases the resistance towards serum proteases. HPMA-BID-BH3 conjugate and BID-BH3 
peptide were incubated with crude HeLa cell lysate as a source of proteolytic activity. The 
concentration of the lysate was adjusted so that the degradation of peptide and conjugate 
could be followed over several hours. The samples were incubated at 37 °C for 24 h. At 
certain times aliquots were extracted. Degradation was detected by fluorescence correlation 
spectroscopy. In a representative experiment the autocorrelation time D for the intact HPMA-
BID-BH3 conjugate was 80.9 s, for the undigested BID-BH3 peptide 50.4 s and for the 
digested samples 30.6 s. By fixing these values, the fractions of intact and degraded 
polymer/peptide were derived from two component fits to the autocorrelation functions. With 
the selected concentration of cell lysate, the HPMA-BID-BH3 conjugate showed a half-life of 
51.7 ± 12.6 h whereas the unbound BID-BH3 peptide showed a half-life of only 1.8 ± 0.2 h 
(Fig. 3.6). The complete degradation of both, peptide and conjugate upon conjugation with 
proteinase K confirmed that both molecules could be in principle digested by proteases. The 
results revealed that the HPMA conjugate stabilizes the peptide from being proteolytically 
digested in cell lysate. Given the very similar loading efficiencies and comparable 
intracellular retention times, protection from proteolytic breakdown should therefore be the 
explanation for the higher biological activity.  
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Fig. 3.6. Proteolytic stability of HPMA-BID-BH3 and the free BID-BH3 peptide in crude HeLa cell 
lysate. Cell lysate was generated by lysis of HeLa cells in Triton-X-100. The cell lysate was mixed with 
2 M HPMA-BID-BH3 conjugate and BID-BH3 peptide and the samples were incubated at 37°C. The 
concentration is related to the number of peptide moieties. After certain time points samples were 
extracted and frozen. After 24 h proteinase K was added to the samples in order to confirm the 
general sensitivity to proteases. The fractions of intact peptide (blank circles) and conjugate (filled 
squares) were determined by fluorescence correlation spectrosopy and derived from two-component 
fits of the autocorrelation functions. Half-lifes were derived from first-order exponential fits. The figure 
shows the results of a representative experiment. 
 
 
3.4.6. Biological activity of a bifunctional cell-penetrating conjugate 
 
Finally, we addressed whether for the BID-BH3 peptide as well, cofunctionalization of the 
HPMA polymer with a cell-penetrating moiety would yield a bioactive conjugate that would 
induce apoptosis by CPP-mediated cell entry.  
The bifunctional BID-BH3-HPMA-R9 conjugate was also conveniently obtained following the 
standard synthesis protocol. The conjugate effectively induced apoptosis in Jurkat cells in a 
concentration-dependent manner, while the mutated peptide or a cell-penetrating conjugate 
cofunctionalized with a cell-penetrating moiety only did not (Fig. 3.7). 
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Fig. 3.7. Apoptosis induction by BID-BH3-HPMA-R9. (A-C) Confocal microscopy of Jurkat cells 
incubated with (A) BID-BH3-HPMA-R9 (20 M), (B) mutBID-BH3-HPMA-R9 (20 M), and (C) 
Lys(Fluo)-HPMA-R9 (20 M) for 10 h at 37 °C. The exposure of phosphatidylserine on the cell surface 
was detected by Alexa 647-labeled annexin V (red). Fluorescein-labeled conjugates are represented 
in green. The bar denotes 20 m. (D-G) Determination of cell death by flow cytometry for cells 
incubated with HPMA conjugates. (D-F) Flow cytometry scatter diagrams of forward versus sideward 
scatter for (D) BID-BH3-HPMA-R9 (20 M), (E) mutBID-BH3-HPMA-R9 (20 M), and (F) Lys(Fluo)-
HPMA-R9 (20 M). Jurkat cells were incubated with conjugates for 10 h at 37 °C. (G) Titration of cells 
with HPMA conjugates and quantification of cell death. Cell populations were gated based on forward 
and sideward scatter (D-F), and the fraction of dead cells determined from the ratio of events in both 
gates (red). Signals of dead cells are located in the left gate. Concentrations of the polymer conjugates 
in the medium were adjusted to the same concentration with respect to the functional peptide. 
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3.5. Conclusions 
 
Our previous analyses had shown that coupling of peptides to an HPMA polymer by native 
chemical ligation yielded bioactive conjugates by a modular design (Ruttekolk et al., 2008). 
These initial analyses had already indicated that the polymer-coupled peptides had a higher 
activity per peptide moiety. Differences in cellular loading efficiency, in retention inside the 
cell as well as in peptide stability were considered as the molecular basis for this 
observation. However, the bioactive peptide, derived from the proapoptotic protein Smac 
(Fulda et al., 2002b), that we had selected was not accessible to an elucidation of these 
questions. For this peptide a free amino terminus was required for activity. Therefore, 
coupling to the polymer occurred via a cysteine residue coupled to a lysine side chain at the 
C-terminus of the peptide. Here, we selected an apoptosis-inducing peptide derived from the 
proapoptotic Bid protein that could be coupled to the polymer via the N-terminus in a straight-
forward manner. Using this peptide we demonstrate an increase in the activity per peptide 
moiety that is very likely due to a protection from proteolytic degradation. Given the faster 
degradation of the free peptide one could also expect a faster release of degradation 
products from the cells. However, cellular retention times were the same for free peptides 
and for conjugates. We explain this observation by the generation of fragments that are still 
efficiently retained within the cells.  
For a bifunctional conjugate that also carried a cell-penetrating moiety, we could also further 
demonstrate the general applicability of the modular approach. The synthesis was carried out 
by a modified native chemical ligation protocol as described before. Coupling efficiencies for 
this longer peptide were in the same range as those reported before, confirming the general 
usefulness and robustness of this synthesis procedure. 
For the HPMA-conjugated peptide the activity was increased considerably per peptide 
moiety. In fact the free peptide did not show any activity. Previously, a conjugate of this 
peptide to the CPP d-octaarginine had shown apoptosis inducing activity in a number of 
cancer cells (Goldsmith et al., 2006). However, the activity of a particular peptide inside the 
cell as well as sensitivity to apoptosis induction may vary largely between cell lines. The 
conjugate bearing the mutated peptide in which three of the residues required for activity 
where exchanged against alanine residues did also not show any activity. This finding 
confirmed that phosphatidylserine exposure was not due to electroporation or to a toxic effect 
by the polymer itself.  
Finally, the HPMA-based strategy also prooved its potential as a modular synthesis approach 
for the combination of different functionalities. Synthesis of a single 29 amino acid peptide 
containing the BID-BH3 domain and the nonaarginine CPP is a major challenge and we 
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repeatedly obtained this peptide only with low purities and yields. Fusion of peptide 
fragments by native chemical ligation requires synthesis of a C-terminal thioester, which is 
also not straight forward in Fmoc peptide chemistry. Separate synthesis of the functional 
BID-BH3 peptide and the CPP and incorporation into the polymer therefore constitutes a 
major synthetic advantage.  
In summary, our results show that the HPMA-based strategy provides a suitable way to 
increase the functionality of peptides with respect to intracellular applications in fundamental 
and applied biomedical research.  
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4. Short intracellular residence times limit the 
applicability of bioactive peptides in cells 
 
The author of this thesis contributed all figures except Fig. 1 which was contributed by Heike 
Glauner. 
 
 
4.1. Summary 
 
Protein-protein interactions mediated by peptide motifs and protein binding domains play a 
crucial role in intracellular signal transduction (Pawson and Nash, 2003; Liu et al., 2006; 
Miller et al., 2008). It was previously demonstrated in cell-free systems that these interactions 
can be easily and highly selectively inhibited by inhibitory peptides (Pawson and Nash, 2003; 
Stoevesandt et al., 2005b). On the other hand, the action of inhibitory peptides in living cells 
is highly complicate. Whereas the poor cellular uptake of peptides was extensively 
investigated and this drawback was finally overcome by electroporation (Knight and Scrutton, 
1986), cell-penetrating peptides (Langel, 2002) and other strategies, the intracellular 
behavior of peptides is still not fully understood. Especially the intracellular residence time is 
important to achieve an adequate duration of bioactivity. In this study, we focus on the fate of 
fluorescently labeled peptides electroporated into living Jurkat E6.1 T cell leukemia cells. The 
cells were observed by confocal microscopy over time and the total intracellular fluorescence 
and the peptide localization was determined by digital image processing. It could be shown 
that the electroporation efficiency is not dependent on the physicochemical properties of the 
peptides. Nevertheless, the peptides had significantly different intracellular residence times 
with half-lifes between approximately 1 h up to more than 10 h. Interestingly, negatively 
charged phosphotyrosine-containing peptides showed a longer intracellular residence time 
than neutral or positively charged proline-rich peptides. In order to answer the question if 
these findings are related to the physicochemical properties only or to the proteolytic stability, 
we employed retro-inverso D-peptides (Chorev et al., 1979), thus peptides with identical 
physicochemical characteristics and high proteolytic stability. These peptides were retained 
in cells with a much lower half life. The degradation kinetics were determined in lysate of the 
T cell lymphoma cells and determined by autocorrelation measurements by fluorescence 
correlation spectroscopy (FCS). Indeed, the cellular residence time is highly dependent on 
the proteolytic stability of the peptides. 
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4.2. Introduction 
 
Signal transduction processes play a crucial role in every cell (Pawson and Nash, 2003). 
Especially cell types specialized on intercellular communication such as T cells have highly 
complicated intracellular signal transduction networks which could, to this day, not entirely 
disentangled due to a considerable lack of highly specific inhibitors for protein-protein 
interactions (Kroczek et al., 2004; Turner and Billadeau, 2002; Horejsi et al., 2004). T cell 
signal transduction represents a good example for a network in which a major part of 
interactions are mediated by the interplay of linear peptide motifs such as phosphotyrosine 
containing or proline-rich peptides with SH2 and SH3 domains (Li, 2005; Yaffe, 2002). 
Indeed, several protein-protein interactions could be effectively interrupted by addition of an 
excess of competing phosphotyrosine and proline-rich peptides (Stoevesandt et al., 2005a; 
Stoevesandt et al., 2005b; Pawson and Nash, 2003). Nevertheless, the applicability of 
peptides in living cells is still hampered by their poor plasma membrane permeability and 
inadequate intracellular stability. 
In recent years several strategies have been developed in order to overcome the cell 
membrane barrier: Microinjection (Celis, 1984; Brandner et al., 1974; Stephens and 
Pepperkok, 2001; Zhang and Yu, 2008) and irradiation by near-infrared lasers (Tirlapur and 
Konig, 2002) enable the direct transfer of impermeable molecules into single cells. But, 
obviously, these two techniques are restricted to a limited number of cells. The loading of 
molecules into cell populations can be facilitated by ultrasound (Postema and Gilja, 2007) 
and by the attachment of cationic lipids (Rao and Alving, 2000; Drummond et al., 1999). 
Additionally, cell-penetrating peptides (CPPs) represent a promising approach which was 
shown to facilitate the uptake of a large variety of cargo molecules (Langel, 2002; Choi et al., 
2003; Rohrbach et al., 2005; Fawell et al., 1994; Nagahara et al., 1998; Oehlke et al., 2004; 
Turner et al., 2005; Lewin et al., 2000; Santra et al., 2005b; Noor et al., 2009; Nori et al., 
2003; Foerg and Merkle, 2008). In fact, some peptide-CPP conjugates show considerable 
activity within cells such as the proapoptotic Smac peptide (Fulda et al., 2002a; Fotin-
Mleczek et al., 2005b). Nevertheless, CPPs can have a non-negligible influence on the cells. 
It has been reported that arginine-rich CPPs decreased the concentration of the tumor 
necrosis factor (TNF) receptor on the cellular surface by co-endocytosis (Fotin-Mleczek et 
al., 2005b). As a consequence, the cells were less sensitive to TNF stimuli. Furthermore, 
especially at lower concentrations CPPs are mainly taken up via endocytosis (Fischer et al., 
2004) and only minor fractions reach the cytosol. Information on the intracellular 
concentrations cannot be obtained and CPP-based uptake itself is a time-dependent 
process. An alternative approach to overcome the plasma membrane is the employment of 
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electroporation (Knight and Scrutton, 1986; Gehl, 2003). Electroporation is based on a single 
short high-voltage pulse or on a series of pulses that cause short-term pore formation in the 
plasma membrane and hereby enable the cellular entry of the molecules of interest. Thus, 
the cytosol can be addressed directly and moreover the technique provides a well-defined 
temporal starting point what is of high importance for bioactivity studies. From the 1980s 
onward electroporation facilitated the efficient import of DNA (Neumann et al., 1982), small 
molecules (Melvik et al., 1986) and proteins (Mir et al., 1988).  
The second obstacle, the poor proteolytic stability of peptides, can be overcome by the 
employment of retro-inverso D-peptides (Chorev et al., 1979), - peptides (Frackenpohl et 
al., 2001) and dendrimers (Haag and Vogtle, 2004). Furthermore, peptides, proteins and 
other molecules of therapeutic value are regularly stabilized by conjugation to for example 
polyethylene glycol (PEG) (Harris and Chess, 2003). Especially orally delivered 
macromolecules often require covalent polymer-conjugation (Goldberg and Gomez-Orellana, 
2003) or non-covalent polymer attachment (Sandanaraj et al., 2005). Although in recent 
years notable progress in the development of strategies to overcome the plasma membrane 
barrier and the the poor proteolytic stability have been made, still little is known about the 
intracellular fate of peptides. In fact, the question how long a peptide is present in the cell of 
interest may clearly be highly relevant for the duration of its bioactivity. 
In this study, the intracellular behaviour of ten different fluorescently labeled peptides with 
different physicochemical properties was observed in Jurkat E6.1 T cell leukemia cells. First, 
it was demonstrated that the electroporation efficiency was independent of the 
physicochemical properties of the peptides. For this purpose a relatively mild electroporation 
method based on a multi-pulse protocol was employed. Subsequently, the cells were 
observed by confocal microscopy over a time period of 6 h. The intracellular localization 
could be determined and digital image processing provided quantitative results regarding the 
cellular residence times of the fluorescently labeled peptide moieties. As the time of the half-
maximal fluorescence signal significantly varied between the different peptides, it was 
addressed whether proteolytic stability was the molecular basis for this observation. For this 
purpose, retro-inverso D-peptides (Chorev et al., 1979) were synthesized, which means that 
these peptides contain only D-amino acids and the amino acid sequence is reversed. On the 
one hand they are nearly completely protease resistant due to the changed peptide 
backbone, on the other hand the spatial positions of the side chain moieties are comparable 
with the ones of the respective L-peptide. Thus, the employment of retro-inverso D-peptides 
provides a strategy to compare peptides of identical physicochemical properties and 
comparable binding patterns. 
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4.3. Experimental procedures 
 
4.3.1. Reagents 
 
The peptides were purchased from EMC microcollections (Tübingen, Germany). Peptides 
were N-terminally conjugated to an aminohexanoic acid spacer (Ahx) and carboxyfluorescein 
to enable detection of fluorescence and prevent them from N-terminal degradation. 
Additionally, the peptides were protected against C-terminal degradation by means of 
amidation. Chemicals were obtained from Fluka (Deisenhofen, Germany). Cell culture media 
were purchased from PAN biotech (Aidenbach, Germany). Protease inhibitor cocktail 
Complete was obtained from Roche Diagnostics (Mannheim, Germany). Cell Line 
Nucleofector Kits V were provided by Lonza (Cologne, Germany). 
 
 
4.3.2. Peptide Synthesis 
 
The peptides were purified by preparative RP-HPLC (Grom-SIL 120 ODS-4 HE, 125 × 20 
mm, C18 column, 5 μm particle diameter; Grom, Herrenberg, Germany). Purity was 
determined by analytical RP-HPLC (Grom-SIL 120 ODS-4 HE, 100 × 2 mm, C18 column, 5 
μm particle diameter; Grom, Herrenberg, Germany). Identity was validated via electrospray 
mass spectrometry with an LCQ Advantage Max mass spectrometer (Thermo Fisher 
Scientific Inc., Waltham, USA). Concentrations were determined by UV/Vis spectroscopy. 
The peptides were diluted 1000-fold in Tris/HCl buffer pH 8.8, assuming an extinction 
coefficient for fluorescein E492 = 75,000 L/(mol × cm). 
 
 
4.3.3. Electroporation 
 
Jurkat E6.1 were cultivated in RPMI medium supplemented with 10 % fetal calf serum. In 
order to achieve optimal electroporation 106 Jurkat E6.1 cells were resuspended in 100 L 
Nucleofector Solution V and the respective peptide was added. Electroporation was 
performed in a Nucleofector device (Lonza, Cologne, Germany). Here, the preinstalled 
electroporation method “X-001” was employed. Subsequently, 900 L RPMI medium were 
added carefully and the cells were incubated for 5 min at RT. Finally, the cell suspension was 
washed in medium by centrifugation. 
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4.3.4. Flow cytometry 
 
5 x 105 electroporated Jurkat E6.1 cells were washed in PBS buffer and the median 
fluorescein fluorescence for the viable cell fraction, determined by gating in the forward 
versus sideward scatter plot, was analyzed by flow cytometry with a FACSCalibur System 
(BD Biosciences, San Jose, USA). 
 
 
4.3.5. Microscopy 
 
5 x 105 electroporated Jurkat E6.1 cells were incubated in 200 l phenol red-free RPMI 
medium for 10 min at 37 °C to allow them to settle on the bottom of a 8-well chambered 
coverglass microscopy slide (nunc, Rochester, USA). Subsequently, the cells were analyzed 
by confocal laser scanning microscopy over time using a Leica SP5 confocal microscope 
equipped with an HCX PL APO 63 × N.A. 1.2 water immersion lens (Leica Microsystems, 
Mannheim, Germany). 
 
 
4.3.6. Loss of intracellular fluorscence  
 
Solutions containing 30 M of peptide were electroporated into Jurkat E6.1 cells. Next, cells 
were washed. Over an incubation period of 6 h at 37°C in a humidified atmosphere 
containing 5 % CO2 the cells were periodically observed by confocal microscopy. 
Subsequently, the acquired images were analyzed by digital image processing. 
 
 
4.3.7. Image analysis 
 
The generated confocal microscopy images were analyzed by digital image processing using 
ImageJ 1.41 (freeware, National Institute of Health (NIH), USA) and ImagePro Plus 
(MediaCybernetics, Bethesda, USA). The images were low pass filtered and converted into a 
black and white mask using a fluorescence intensity and a size threshold. A watershed 
operation allowed the separation of adjacent cells. Finally, a mask of the cellular cross-
sections was generated and applied on the original images. The program automatically 
quantified the mean fluorescence intensity in the optical planes of the cells. 
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4.3.8. Investigation of the proteolytic stability of L- and D-peptides 
 
Jurkat E6.1 cells were resuspended to a density of 107 cells/ml in PBS lysis buffer containing 
1 % v/v Triton-X-100 and incubated for 1 h on ice. Subsequently, the membrane debris was 
removed by centrifugation at 20,000 x g for 20 min at 4°C. 2 M of the L-peptides SLP179 
and LATpY132 and the respective retro-inverso peptides ri-slp179 and ri-latY132 were added 
to aliquots of the cell lysate. The samples were incubated at 37°C. Periodically aliquots of 5 
L were withdrawn, mixed with 95 L protease inhibitor cocktail and frozen. After an 
incubation period of 2h 40 U/mL proteinase K (2 U in 50 L) was added in order to determine 
the accessability to proteolysis. Subsequently, the samples were incubated at 37°C for 
another 32 h. Frozen samples were thawed, 900 L Tris buffer (100 mM Tris-HCl, pH 8.8) 
were added and aliquots of 50 L were transferred into a 384-well plate (175 μm, low-base 
design, MMI). Fluorescence autocorrelation measurements were conducted employing a 
Leica TCS SP5 fluorescence correlation spectroscopy unit equipped with an HCX PL APO 
63 × N.A. 1.2 water immersion lens. The autocorrelation functions were analyzed by the 
computer program ISS Vista (ISS facilities, Champaign, USA) with two-component fits 
assuming a triplet fraction. The autocorrelational diffusion time D for the low-molecular 
weight component was fixed to the one determined for the fully degraded sample and the D 
for the high-molecular weight to values determined for the intact peptides.  
4. SHORT INTRACELLULAR RESIDENCE TIMES LIMIT THE APPLICABILITY OF BIOACTIVE PEPTIDES IN CELLS 
 
 
81 
4.4. Results 
 
4.4.1. Electroporation of peptides with different physicochemical 
properties 
 
Jurkat E6.1 cells were electroporated with 30 M peptide solutions. The peptides had 
comparable lengths but variant physicochemical properties. The cell viability and the median 
fluorescein fluorescence of the cells was determined by flow cytometry. For all peptides, the 
cell viability decreased by approximately 20 %. All peptides were imported efficiently and to a 
comparable degree. In contrast, the free fluorescein dye could be imported more efficiently. 
In general, the physicochemical properties did not influence the uptake notably. 
 
 
Fig. 4.1. Electroporation of peptides having comparable length and different physicochemical 
properties. Jurkat E6.1 cells were electroporated with 30 M solutions of each peptide (table 1, A-J) or 
fluorescein. Subsequently, the cells were washed with medium and observed by (A) flow cytometry. 
The (B) fraction of fluorescein-positive cells, the (C) cell viability and (D) the median fluorescence per 
cell was determined. 
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4.4.2. Loss of intracellular fluorescence 
 
Jurkat E6.1 cells were electroporated with 30 M solutions of the peptides, washed and 
observed by confocal microscopy over 6 h at 37°C. Digital image analysis revealed that the 
negatively charged phosphotyrosine-containing peptides had a considerably longer cellular 
residence time than the rather positively charged proline-rich peptides. Overall, the cellular 
fluorescence half-lifes varied from approximately 1 h to more than 10 h. In contrast, the free 
fluorescein dye had a short residence time of less than 1 h, which was significantly shorter 
than the one for all peptides observed in this study. This indicates that the fluorescein moiety 
released from a fully degraded peptide would be exported efficiently. In general, the 
negatively charged peptides showed significantly longer cellular residence times. 
 
 
Fig. 4.2. Loss of fluorescence after electroporation of peptides of different physicochemical properties. 
Jurkat E6.1 cells were electroporated with 30 M solutions of peptides or fluorescein. Subsequently, 
the cells were washed twice with medium, transferred into 8-well chambered coverglass microscopy 
slides and incubated at 37°C. Periodically confocal images were generated by laser scanning 
microscopy. The scale bar denotes 50 m. 
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Fig. 4.3. Loss of cellular fluorescence for the various peptides. The peptides (table 1, A-J) (A) 
LATpY226, (B) LATpY132, (C) CD3 pY72/83, (D) LATpY191, (E) GAB2pY614, (F) control peptide, 
(G) GAB2_509, (H) PAK1_6, (I) SLP179, (J) SLP228 and (K) fluorescein were electroporated into 
Jurkat E6.1 cells and the cells were incubated over time. The confocal images generated by laser 
scanning microscopy were analyzed by digital image analysis. The resulting values were fitted with an 
exponential decay of the first order depicting the fluorescence loss of the cells. 
 
 
 
Fig. 4.4. Peptide residence times in dependence on the peptide net charge. 
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Tab. 4.1. Peptides and their residence times. 
name sequence
1
 Mw 
[Da] 
net 
charge 
residence 
time [h] 
     
LATpY226 Fluo-Ahx-EVEEEGAPD(pY)ENLQELN-NH2 2528 - 9 5.8 ± 0.9 
LATpY132 Fluo-Ahx-EDEDDYHNPG(pY)LVVLPDSTP-NH2 2825 - 7 > 10 
CD3 pY72/83 Fluo-Ahx-NQL(pY)NELNLGRREE(pY)DV-NH2 2868 - 6 2.8 ± 0.5 
LATpY191 Fluo-Ahx-EASLDGSRE(pY)VNVSQEL-NH2 2446 - 5 5.1 ± 1.2 
GAB2pY614 Fluo-Ahx-KSTGSVD(pY)LALDFQPS-NH2 2278 - 3 1.9 ± 0.4 
control peptide Fluo-Ahx-VKPLNEPDLPPAKIPTKPDQN-NH2 2842 ± 0 1.1 ± 0.2 
PAK1_6 Fluo-Ahx-LDIQDKPPAPPMRNT-NH2 2164 ± 0 1.3 ± 0.1 
SLP179 Fluo-Ahx-SGKTPQQPPVPPQRPMAAL-NH2 2471 + 2 1.7 ± 0.6 
SLP228 Fluo-Ahx-AKLPAPSIDRSTKPPLDRS-NH2 2520 + 2 1.4 ± 0.1 
GAB2_509 Fluo-Ahx-QPPPVNRNLKPDRKAKPTPLD-NH2 2853 + 3 2.1 ± 0.3 
     
ri- latY132 Fluo-Ahx-ptsdplvvlygpnhyddede-NH2 2745 - 5 > 10 
ri- slp179 Fluo-Ahx-laamprqppvppqqptkgs-NH2 2471 + 2 > 10 
     
fluorescein  332 ± 0 < 1.0 
5(6)-carboxy-
fluorescein 
 376 - 1 < 1.0 
 
1
Ahx: aminohexanoic acid, Fluo: 5(6)-carboxyfluorescein, -NH2: C-terminal amidation. 
 
 
 
4.4.3. Intracellular localization of peptides with different physicochemical 
properties 
 
The question whether the differences in the loss of fluorescence were caused by different 
subcellular localization patterns was addressed by high-resolution confocal microscopy. It 
turned out that the peptides that possessed a shorter cellular residence time tended to be 
localized less homogeneously after an incubation time of 6 h at 37°C than the peptides 
possessing a long residence time. Nevertheless, the differences in subcellular localization 
cannot explain the differences in cellular residence times as no enrichment in certain 
compartments could be observed. 
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Fig. 4.5. Time dependence of the intracellular localization of peptides. Electroporated Jurkat E6.1 cells 
were observed by confocal microscopy before and after incubation for 6 h at 37°C. The brightness and 
contrast parameters of the images generated after 6 h were adjusted for all peptides in the same 
degree in order to improve the visualization of the intracellular distribution. After the incubation the 
peptides possessing a shorter cellular residence time were localized less homogeneously than the 
peptides possessing a longer residence time. The scale bar represents 20 m. 
 
 
4.4.4. Cellular peptide release of L- and retro-inverso D-peptides  
 
Next, the question was, if the differences in the cellular residence time were either due to 
differences in the physicochemical properties of the peptides or due to differences in their 
proteolytic stability. In order to investigate the influence of the proteolytic stability we 
synthesized retro-inverso D-peptides showing extensive proteolytic stability, but the same 
physicochemical and binding properties as the L-peptides. In a first experiment the cellular 
release kinetics of L- and retro-inverso D-peptides were compared. For LatpY132 the retro-
inverso peptide contained a tyrosine instead of a phosphotyrosine residue. 
For this purpose 30 M solutions of the L-amino acid peptides of LATpY132 and SLP179 and 
the respective retro-inverso peptides ri-latY132 and ri-slp179 were electroporated into Jurkat 
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E6.1 cells, the cells were washed and incubated at 37°C. Confocal images were generated 
over time and analyzed subsequently for cellular fluorescence.  
Both retro-inverso D-peptides ri-latY132 and ri-slp179 showed very long and comparable 
cellular residence times >10 h. In contrast, the L-peptides showed significant differences. 
Whereas LATpY132 had a half maximal cellular residence time longer than 10 h, SLP179 
was exported rapidly with a half-life of 1.7 ± 0.6 h. Carboxyfluorescein had a half maximal 
residence time < 1 h. These findings indicated that the kinetics of the cellular fluorescence 
loss might correlate with the proteolytic breakdown. 
 
Fig. 4.6. Loss of fluorescence after electroporation of L- and retro-inverso D-peptides. Jurkat E6.1 
cells were electroporated with peptides or 5(6)-carboxyfluorescein. The cells were washed twice with 
medium, seeded into 8-well chambered coverglass microscopy slides, incubated at 37°C and 
observed by laser scanning microscopy. The scale bar represents 50 m. 
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Fig. 4.7. Digital image analysis of the loss of fluorescence of L- and retro-inverso D-peptides. 30 M 
solutions of the (A) LATp132 peptide, (B) ri-latY132 peptide, (C) 5(6)-carboxyfluorescein, (D) SLP179 
peptide and (E) ri-slp179 peptide were electroporated into Jurkat E6.1 cells and the living cells were 
observed by confocal microscopy. Subsequently, the images were analyzed by quantitative image 
analysis via ImageJ. The results were fitted with an exponential decay of the first order to determine 
half-lifes of intracellular fluorescence. 
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4.4.5. Intracellular localization of peptides comprising L-amino acids and 
retro-inverso D-peptides 
 
Next, we were interested to learn whether the increased proteolytic stability also effected the 
subcellular localization of retro-inverso D-peptides. Thus, the localization was investigated by 
high-resolution confocal microscopy. Consistent with the previous finding, it turned out that 
the L-amino acid peptide SLP179 that possessed the shortest cellular residence time was 
localized less homogeneously after an incubation time of 6 h at 37°C than the other peptides 
that possessed a long residence time. 
 
 
 
Fig. 4.8. The intracellular localization of L- and retro-inverso D-peptides in dependence on incubation 
time. Jurkat E6.1 cells were electroporated with 30 M solutions of the peptides (A,F) LATpY132, 
(B,G) ri-latY132, (C,H) SLP179, (D,I) ri-slp179 and (E,J) 5(6)-carboxyfluorescein and observed by 
confocal microscopy (A-E) before and (F-J) after incubation of 6 h at 37°C. The brightness and 
contrast parameters of the images generated after 6 h were adjusted for all peptides in order to 
improve the visualization of the intracellular distribution. The scale bar represents 20 m. 
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4.4.6. Long residence times correlate with high proteolytic stability 
 
The cellular fluorescence loss was likely due to proteolytic breakdown and release of 
fragments. The proteolytic sensitivity was therefore determined by an incubation of the L-
peptides LATpY132 and SLP179 and the retro-inverso D-peptides ri-latY132 and ri-slp179 at 
a concentration of 2 M in Jurkat cell lysate. The integrity of the peptides was analyzed by 
fluorescence correlation spectroscopy (FCS). Whereas SLP179 had a proteolytic half-life of 
0.3 ± 0.0 h, LATpY132 had longer half-life of 1.7 ± 0.4 h. In contrast, the retro-inverso 
peptides were not even degraded upon the addition of 40 U/ml proteinase K and subsequent 
incubation for another 32 h. 
 
 
Fig. 4.9. Proteolytic stability of L- and retro-inverso D-peptides. Whereas the L-peptides SLP179 and 
LATpY132 were completely degraded in Jurkat cell lysate within a few hours, the respective retro-
inverso peptides maintained integrity and could not even been degraded by 40 U/ml proteinase K 
(time of addition indicated by arrows) for 48 h at 37°C. Notably, the LATpY132 peptide was more 
stable than the SLP179 peptide. 
 
 
Whereas the retro-inverso D-peptides both showed a very high and comparable proteolytic 
stability, the L-peptide LATpY132 showed a considerably longer half-life than SLP179. This 
findings correspond very well with the determined cellular residence times. These results 
therefore strongly indicate that higher proteolytic stability leads to extended cellular residence 
times. 
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4.4.7. Swelling of cells upon electroporation 
 
In the microscopy experiments it could be observed that the cell volume increased upon 
electroporation. This effect was quantified with digital image processing using ImageJ. The 
analysis revealed that the area of the cross-section decreased by 24 % in the first 2 h after 
electroporation. Assuming spherical cells the cellular volume therefore decreased by 
approximately 50 %. 
 
 
Fig. 4.10. Loss of cell size over time. Upon incubation the area of the cross-sections decreased by 24 
% which corresponds to a volume decrease by 50 %. 
 
This had an notable impact on the quantification of the intracellular residence time. The 
detected fluorescence signal occurring from the fluorescence labeled peptides detected in 
the first measurement after 30 min was lower than expected due to swelling and the resulting 
dilution effect. In fact, this effect was indeed observable. Consequently, for most peptides the 
cellular fluorescence intensity increased from 30 min to 2 h. Especially for molecules that 
have a long intracellular residence time this effect should be taken into consideration as 
intracellular concentrations can be easily underestimated directly after electroporation due to 
swollen cells that shrink over time. 
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4.5. Conclusions 
 
Peptides are regularly used in cellular bioactivity studies and their bioactivity has been 
extensively elucidated. For this purpose peptides are regularly imported by means of 
electroporation. Nevertheless, the intracellular fate of the electroporated peptides is not fully 
understood yet. 
In this study, fluorescently labeled peptides were electroporated into JurkatE6.1 T cell 
lymphoma cells and the intracellular fate of the fluorescein moiety was observed by confocal 
microscopy. It could be demonstrated that the electroporation efficiency was independent of 
the physicochemical properties of the peptides. In contrast, the observation of the cells over 
a time period of 6 h revealed that the cellular residence times were clearly different for the 
different peptides and the fluorescence half-lifes varied from approximately 1 h for a 
uncharged control peptide up to more than 10 h for a 7-fold negatively charged LATpY132 
peptide. Interestingly, it turned out that the negatively charged phosphotyrosine peptides in 
general had longer residence times than the neutral or positively charged proline-rich 
peptides. The low-molecular weight dyes fluorescein and 5(6)-carboxyfluorescein were 
exported notably faster than all fluorescent peptide moieties released from the peptides 
employed in this study. Furthermore, we considered whether the differences in fluorescence 
loss were due to peptide export or due to intracellular degradation and release of fragments. 
In order to investigate this further, we synthesized two retro-inverso D-peptides (Chorev et 
al., 1979). Retro-inverso D-peptides represent peptides with an reversed sequence 
composed of D-amino acids. Hence, they show identical physicochemical and binding 
properties but are proteolytically inert. As peptide sequences we chose one peptide that had 
a long cellular residence time, LATpY132, and SLP179 with a short residence time. Whereas 
the residence time of the L-peptides was in the range of few hours, both retro-inverso D-
peptides ri-latY132 and ri-slp179 had a very long and comparable intracellular half-life larger 
than 10 h. Thus, it was very likely that proteolytic stability plays a key role in the loss in 
fluorescence. In order to determine the proteolytic stability of the peptides against cytosolic 
proteases, we generated cell lysate from the JurkatE6.1 T cell lymphoma cells in an isotonic 
buffer of neutral pH. The degradation was determined by fluorescence correlation 
spectroscopy (FCS). Rapid release strongly correlated with rapid breakdown. 
In summary, we could demonstrate that the intracellular residence time is clearly dependent 
on the proteolytic stability and is highly sequence-specific. In cellular studies the differences 
in cellular residence times are an underestimated but severe challenge. 
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5. A cell-penetrating peptide derived from human 
lactoferrin with conformation-dependent uptake 
efficiency 
 
The author of this thesis purified the peptides, contributed Fig 5.1, Fig. 5.5.A-B and 
conjugated hLF peptide to streptavidin (Fig. 5.8). Dr. Falk Duchardt performed the cellular 
experiments shown in Fig. 5.2, 5.3, 5.7.B-C and 5.8. Wouter P.R. Verdurmen performed the 
heparinise experiment (Fig. 5.7.A) and the comparison of hLF and rLF (Fig. 5.4). The NMR 
experiments were performed by Prof. Dr. Geerten W. Vuister (Fig. 5.5.C-E). the CD 
measurements by Dr. Jochen Bürck (Fig. 5.5.F-I) and the SPR measurements by Hugues 
Lortat-Jacob (Fig. 5.6). 
 
 
5.1. Summary 
 
The molecular events that contribute to the cellular uptake of cell-penetrating peptides (CPP) 
are still a matter of intense research. Here, we report on the identification and 
characterization of a 22 amino acid CPP derived from the human milk protein lactoferrin. The 
peptide exhibits a conformation-dependent uptake efficiency that is correlated with efficient 
binding to heparan sulfate (HS) and lipid-induced conformational changes. The peptide 
contains a disulfide bridge formed by terminal cysteine residues. At concentrations 
exceeding 10 M, this peptide undergoes the same rapid entry into the cytoplasm that was 
previously described for the arginine-rich CPPs nonaarginine and the Tat peptide. 
Cytoplasmic entry strictly depends on the presence of the disulfide bridge. In order to better 
understand this conformation dependence, NMR spectroscopy was performed for the free 
peptide, and circular dichroism (CD) measurements were performed for the free and for the 
lipid-bound peptide. In solution, the peptide showed only slight differences in secondary 
structure, with a predominantly disordered structure both in the presence and absence of the 
disulfide bridge. In contrast, in complex with large unilamellar vesicles, the conformation of 
the oxidized and reduced forms of the peptide clearly differed. Moreover, surface plasmon 
resonance (SPR) experiments showed that the oxidized form binds to heparan sulfates with 
a considerably higher affinity compared to the reduced form. The requirement of the disulfide 
bond for heparan sulfate binding was further confirmed by heparin-column-based liquid 
chromatography. Consistently, membrane binding and cellular uptake of the peptide were 
reduced when heparan sulfate chains were removed. 
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5.1. Introduction 
 
Cell-penetrating peptides (CPPs1) such as the antennapedia-derived penetratin (Derossi et 
al., 1994) and the Tat peptide (Vives et al., 1997) are widely used tools for the delivery of 
peptides, proteins and oligonucleotides into cells (Fischer et al., 2001). Areas of application 
range from cell biology (Jarver et al., 2007) to biomedical research (Langel, 2002). Most 
CPPs used to date are of non-human origin but the immunological relevance of these 
molecules is particularly important to biomedical research. Especially when conjugated to 
proteins and nanoparticles these molecules may give rise to an adaptive immune response. 
Therefore, CPPs like the human calcitonin-derived peptide (Schmidt et al., 1998) and 
peptides corresponding to signal sequences of human proteins (Rojas et al., 1998) are being 
considered as highly attractive import vehicles.  
Human lactoferrin (hLF) is an 80 kDa iron-binding glycoprotein of 703 amino acids (Metz-
Boutigue et al., 1984). It constitutes about 15% of human milk protein and can also be found 
in low concentrations in blood plasma, tears, nasal fluids, saliva, pancreatic, gastrointestinal 
and reproductive tissue secretions (Levay and Viljoen, 1995). With antifungal, antimicrobial 
and antiviral activities, the protein plays an important role in the innate immune defense 
(Legrand et al., 2008). In addition to iron depletion (Ward and Conneely, 2004), the protein 
exerts its activity through direct interaction with bacterial components (Valenti and Antonini, 
2005).  
The hLF N-terminal domain in particular carries potent activity against pathogens (Gifford et 
al., 2005). In the gastrointestinal tract this domain can be cleaved through pepsin digestion 
resulting in the release of an antimicrobial peptide called lactoferricin (Bellamy et al., 1992). 
Human lactoferricin comprises 49 amino acids (20 to 68 of the parent sequence) that form a 
loop, stabilized by two disulfide-bonds. The peptide contains sections of hydrophobic and 
positively charged amino acids comparable to those found in numerous peptides that display 
antimicrobial activity.  
It has been demonstrated that antimicrobial peptides and CPPs possess concordant 
functional characteristics. On one hand, antimicrobial peptides are taken up into mammalian 
cells (Takeshima et al., 2003) and on the other hand CPPs show antimicrobial activity 
(Nekhotiaeva et al., 2004). Therefore, we considered whether a lactoferricin-derived peptide 
may also have the ability to act as a CPP by entering into mammalian cells. 
Here, we report the characterization of a new cell-penetrating peptide derived from the N-
terminal domain of human lactoferrin, corresponding to amino acid residues 38-59 (19-40 of 
human lactoferricin). The peptide overlaps with the lipopolysaccharide-binding region of 
lactoferricin (Elass-Rochard et al., 1995). The peptide shows a well-defined structure-activity 
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relationship and enters cells efficiently. The uptake mechanism of the peptide is 
concentration-dependent. Above a threshold concentration rapid delivery into the cytoplasm 
and nucleus is observed, which has previously been described for the arginine-rich CPPs 
nonaarginine and the Tat-derived peptide (Duchardt et al., 2007; Tunnemann et al., 2006). 
Very remarkably, the hLF-derived peptide (hLF-peptide) contains only four arginine and two 
lysine residues. Instead, an intramolecular disulfide bridge is required for the efficient uptake, 
demonstrating that a high number of arginine residues in the peptide sequence is not a 
prerequisite for triggering the rapid import. Instead, for the hLF peptide efficient import is 
strictly conformation dependent.  
A combination of surface plasmon resonance (SPR), NMR and circular dichroism 
experiments revealed a conformation dependence of interactions with heparan sulfate 
proteoglycans and demonstrated that only the cyclic form of the peptide undergoes a 
conformational transition when interacting with large unilamellar vesicles. Heparinase 
treatment of cells reduced membrane binding and uptake of the peptide, demonstrating the 
relevance of heparan sulfate binding for the function of the peptide as a CPP. By using a 
biotinylated analog of the peptide, we validated the capacity of the peptide to mediate cellular 
import of a protein cargo. These results illustrate that the hLF-peptide is a promising new 
candidate for a human CPP with a structure-activity relationship that should stimulate further 
research on the molecular principles that govern CPP interaction with cell membranes.  
 
 
5.3. Experimental Procedures 
 
5.3.1. Cells and Reagents 
 
The human cervical carcinoma cell line HeLa was obtained from the American Type Culture 
Collection (Manassas, VA, USA). 1,4-Dithiothreitol (DTT) was from Merck (Darmstadt, 
Germany). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), heparinases 
I-III, BSA and glucose were obtained from Sigma (Steinheim, Germany). Rottlerin was from 
Calbiochem (Bad Soden, Germany). The Zenon mouse IgG1 AlexaFluor647 labeling kit 
(specific for the Fc part of IgG1 antibodies) was purchased from Invitrogen (Karlsruhe, 
Germany). The anti-heparan sulfate (HS) VSV-tagged single chain antibody HS4C3 (van 
Kuppevelt et al., 1998) and the mouse anti-VSV (clone P5D4) antibody were a kind gift of Dr. 
Toin van Kuppevelt (Dept. of Biochemistry, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP∙HCl) was 
obtained from Thermo Fisher Scientific (Bonn, Germany). The phospholipids DPC 
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(dodecylphosphocholine), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DMPG 
(1,2-dimyristoyl-sn-glycero-3-phosphoglycerol) used for vesicle preparation were purchased 
from Avanti Polar Lipids (Alabaster, AL, USA). Biotin-LC-hydrazide was from Pierce 
(Rockford, USA). The HBS-P buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005 % 
surfactant P20, pH 7.4) was from Biacore AB (Uppsala, Sweden). 
 
 
5.3.2. Peptide synthesis 
 
Unlabeled hLF peptide was supplied by Thermo Fisher Scientific. The other peptides were 
purchased from EMC microcollections (Tübingen, Germany) and fluorescently labeled by N-
terminal conjugation of 5(6)-carboxyfluorescein. The purity of all peptides was determined by 
analytical HPLC. The identity of the peptides was confirmed by MALDI-TOF mass 
spectrometry. Peptides with a purity of less than 90% were purified by preparative HPLC.  
 
 
Tab. 5.1. Primary structures of the peptides used in this study. All peptides were synthesized as C-
terminal peptide amides (-CONH2). Fluo represents 5(6)-carboxyfluorescein and Ahx aminohexanoic 
acid. 
Peptide Sequence 
R9 Fluo-RRRRRRRRR-CONH2 
penetratin Fluo-RQIKIWFQNRRMKWKK-CONH2 
hLF peptide Fluo-KCFQWQRNMRKVRGPPVSCIKR-CONH2 
M1 Fluo-KCFQWQRNMRKVRGPPVSC       -CONH2 
M2 Fluo-KSFQWQRNMRKVRGPPVSSIKR -CONH2 
M3 Fluo-KCFQWQRNMRKVR                      -CONH2 
M4 Fluo-      FQWQRNMRKVRGPPVS         -CONH2 
M5 Fluo-               QRNMRKVRGPPVSCIKR-CONH2 
M6 Fluo-               QRNMRKVR                      -CONH2 
biotinylated 
hLF peptide 
Biotin-Ahx-KCFQWQRNMRKVRGPPVSCIKR-CONH2 
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5.3.3. Peptide modification 
 
For intramolecular disulfide bond formation, peptides were oxidized by introducing pure 
oxygen into the peptide solution followed by an incubation at 37°C for 2 h. For reduction of 
the disulfide bond 10 mM DTT was added and the peptide solution was then incubated for 2 
h at 37°C. Biotinylated hLF peptides (200 M) were bound to Streptavidin-AlexaFluor488 
conjugates (50 M) (Invitrogen) by incubation at 4°C for 12 h in PBS. For the analysis of 
cellular uptake the solution was diluted 1:10 with medium.  
 
 
5.3.4. Flow cytometry 
 
HeLa cells were incubated with medium containing peptides at the indicated concentrations 
for 45 min at 37°C. After incubation, cells were washed with medium, detached by 
trypsinization for 5 min, suspended in PBS and measured immediately by flow cytometry (BD 
FACSCalibur System, Becton Dickinson, Heidelberg, Germany). In each case, the 
fluorescence of 10,000 viable cells was acquired. Viable cells were gated based on sideward 
and forward scatter.  
 
 
5.3.5. Confocal laser scanning microscopy 
 
Confocal laser scanning microscopy was performed on an inverted LSM510 laser scanning 
microscope (Carl Zeiss, Göttingen, Germany) using a Plan-Apochromat 63 x 1.4 N.A. Oil DIC 
lens and a TCS SP5 confocal laser scanning microscope (Leica Microsystems, Mannheim, 
Germany) equipped with an HCX PL APO 63 x N.A. 1.2 water immersion lens. All 
measurements of peptide uptake were performed with living cells.  
 
 
5.3.6. Incubation with inhibitor 
 
Cells were treated with rottlerin (20 M) for 30 min at 37°C. Then, the medium was removed 
and medium containing peptide as well as the inhibitor was added. After 30 min incubation at 
37°C cells were washed twice with medium and analyzed by confocal laser scanning 
microscopy or flow cytometry.  
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5.3.7. Immunofluorescence 
 
HeLa cells were seeded at a density of 1.5 x 104/well in 8-well chambered covered glasses 
and cultivated to 75 % confluency, after which they were incubated with medium containing 
33 mIU/ml of heparinases I, 8 mIU/ml of heparinase II and 5 mIU/ml of heparinase III for 1 h 
at 37°C. Then the cells were washed with ice-cold HBS/BSA/glucose (10 mM HEPES, 135 
mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4 containing 0.1 % (w/v) BSA and 5 
mM glucose) and incubated with the anti-HS antibody HS4C3 on ice. After 1.5 h of 
incubation cells were washed with ice-cold HBS/BSA/glucose. To visualize bound antibodies 
the cells were incubated for 1 h with an anti-VSV antibody (P5D4)/Zenon Alexa Fluor 647 
conjugate on ice. The antibody staining was analyzed by confocal laser scanning 
microscopy. 
 
 
5.3.8. MTT assay 
 
HeLa cells were seeded in 96-well microtiter plates (1.5 x 104/well) and cultivated over night. 
The next day, cells were incubated with peptides for 6 h or 24 h at 37°C. Cell viability was 
measured using the colorimetric MTT dye. Cells were incubated with MTT at a concentration 
of 1 mg/ml for 4 h. The formazan product was solubilized with SDS (10% (w/v) in 10 mM 
HCl). Cell viability was determined by measuring the absorbance of each sample relative to a 
control not treated with peptide at 570 nm using a microplate reader (Molecular Devices 
SpectraMax 340, GMI, USA). 
 
 
5.3.9. Preparation of CD samples 
 
The hLF peptide was dissolved in phosphate buffer to a concentration of 0.1 mM. Reduction 
of the disulfide bonds was obtained by the addition of a 30-fold molar excess of TCEP and a 
subsequent incubation for 2 h at 37°C. Oxidation of the hLF-peptide was obtained by purging 
of pure oxygen for 15 min and a subsequent incubation for 2 h at 37°C. The DMPC and 
DMPG lipids were dissolved in 50 % chloroform / 50 % methanol (v/v) in order to prepare 
lipid stock solutions. Aliquots of these stock solutions were mixed to obtain the DMPC:DMPG 
mixture (molar ratio 3:1). Subsequently, the organic solvents were removed under a gentle 
stream of nitrogen followed by overnight vacuum evaporation to remove the residual solvent 
from the respective DMPC or DMPC/DMPG lipid films that had been formed in the vial. The 
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lipid layers were dispersed by the addition of phosphate buffer, vigorous vortexing (10 x 1 
min) and homogenization by ten freeze-thaw cycles. Finally, large unilamellar vesicles 
(LUVs) were prepared by means of 11 extrusion cycles using an Avanti mini extruder 
equipped with a 100 nm polycarbonate filter. Here, the temperature was maintained above 
40°C by thermostatting the extruder block at 50°C.  
For preparation of the final CD samples aliquots of the oxidized and reduced hLF peptide 
solutions were added to aliquots of the respective buffers, micellar solutions or lipid 
dispersions. The final peptide concentration in all samples was 17.5 µM, the SDS and DPC 
concentration in the micellar solutions 10 mM (peptide-to-detergent ratio 1:570) and the lipid 
concentration in the vesicle dispersions 1.45 mM (peptide-to-lipid ratio 1:80). 
 
 
5.3.10. CD and UV spectroscopy 
 
CD spectra of the reduced and oxidized hLF peptide in phosphate buffer and in membrane-
mimicking environments such as 50 % TFE / 50 % phosphate buffer solution, SDS and DPC 
micellar solution and in DMPC or DMPG/DMPC vesicle dispersions were recorded on a J-
815 spectropolarimeter (JASCO, Groß-Umstadt, Germany) equipped with 1 mm-Suprasil 
quartz glass cells (Hellma, Müllheim, Germany). The samples were measured at a scan-rate 
of 10 nm x min-1 and a 1 nm bandwidth in 0.1 nm intervals between 260 and 185 nm at 20°C 
for the buffer and micellar solutions and at 30°C for the vesicle suspensions, i.e. above the 
phase transition temperature of the lipids contained in the vesicle suspensions. Three repeat 
scans were averaged for each sample. CD spectra were smoothened by the adaptive 
smoothing of the Jasco Spectra Analysis software and the secondary structure was analyzed 
by the CONTINLL program with the implemented ridge regression algorithm (Provencher and 
Glockner, 1981; van, I et al., 1990) that is provided by the DICHROWEB server (Lobley et 
al., 2002; Whitmore and Wallace, 2004). The quality of the fit between experimental and 
back-calculated spectrum corresponding to the derived secondary structure element 
fractions was assessed from the normalized root mean square deviation (NRMSD), with a 
value < 0.1 considered as a good fit (Whitmore and Wallace, 2004). For calculation of the 
mean residue ellipticities used for the secondary structure estimation, the results were 
normalized to the UV absorbance at 280 nm assuming a molar extinction coefficient of 5625 l 
x mol-1 x cm-1 for the protein with oxidized Cys residues and 5500 l x mol-1 x cm-1 for reduced 
Cys residues (Pace et al., 1995). The absorption spectrum in the range of the aromatic 
bands due to tryptophan (and cystine for the oxidized peptide) was recorded in the range 
from 240–340 nm using a quartz glass half-micro-cuvette with 1 cm optical path length 
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(Hellma, Müllheim, Germany). For correction of the scattering, the baseline of a log 
absorbance against log wavelength from the non-absorbing region between 310 and 340 nm 
was extrapolated towards lower wavelengths and subtracted from the measured spectrum to 
get the final spectrum (Kelly et al., 2005). 
 
 
5.3.11. NMR 
 
All NMR samples were prepared using a Shigemi NMR tube dissolving 0.83 mg of hLF in 
300 L 95:5 (v:v) H2O buffer/D2O. Two-dimensional ROESY and NOESY experiments 
employing a WATERGATE solvent suppression scheme were performed at 10°C or 20°C on 
a Varian Inova 600 MHz spectrometer equipped with a 5 mm triple-resonance three-axis 
gradient probe using a 200 ms ROE or NOE mixing period. The spectra were recorded as 
2048 x 512 hypercomplex points with 9009.1 x 8000 Hz spectral widths for the F2 and F1 
dimensions, respectively. Spectra were transformed using the nmrPipe processing package. 
 
 
5.3.12. Surface plasmon resonance binding experiments 
 
The surface plasmon resonance experiments were conducted as described previously (Ram 
et al., 2008). The reducing ends of 6 kDa HS were biotinylated by preactivated biotin-LC-
hydrazide (Pierce). The biotinylation procedure was verified by streptavidin-peroxidase 
labeling after blotting of the material onto zetaprobe membrane. CM4 flow cell Biacore 
sensorchips were activated with 50 L of 0.2 M N-ethyl-N‟-(diethylaminopropyl)-carbodiimide 
and 0.05 M N-hydroxysuccinimide before injection of 50 L of streptavidin (0.2 mg/ml in 10 
mM acetate buffer, pH 4.2). The remaining activated groups were blocked with 50 L 
ethanolamine 1 M, pH 8.5. Typically, this procedure permitted the coupling of approximately 
3.000–3.500 resonance units (RU) of streptavidin. Subsequently, the biotinylated HS (10 
g/ml) molecules were immobilized by injection over a one-surface flow cell leading to an 
immobilization level of approximately 50 RU. The flow cells were then conditioned with 
several injections of 2 M NaCl. Untreated one-flow cells served as negative control. Binding 
assays were conducted with different concentrations of oxidized and reduced hLF in HBS-P 
and at 25°C and a flow rate of 20 L/min. Regeneration of the sensorchip surface was 
achieved by a 5 min pulse of 2 M NaCl in HBS-P buffer. 
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5.4. Results 
 
5.4.1. Cellular uptake of the human lactoferrin-derived peptide 
 
For the use of peptides in biomedicine there are grave concerns of potential immunogenicity. 
This is especially the case, when peptides are conjugated to larger molecular weight 
proteins. Given recent observations that certain antimicrobial peptides may act as cell-
penetrating peptides, we selected a peptide corresponding to amino acids 38 to 59 from 
human lactoferrin as a potential candidate for a new CPP derived from a human protein. This 
peptide was shown previously to possess antimicrobial activity (Groenink et al., 1999). The 
peptide comprises an exposed loop of the lactoferrin protein that is terminally flanked by 
cysteine residues. These cysteine residues form a disulfide bridge, both in the protein and in 
lactoferricin, a naturally occurring degradation product of lactoferrin. In our peptide, at the N-
terminal side of the first cysteine residue, a lysine residue of the lactoferrin sequence was 
preserved. Similarly, a lysine and an arginine residue from the lactoferrin sequence were 
included at the C-terminus of the second cysteine residue. Given the requirement for positive 
charge to promote cellular uptake, we reasoned that these three residues should promote 
the function of the peptide as a CPP. 
The peptide was synthesized as a peptide amide labeled with carboxyfluorescein at its N-
terminus. In order to apply stringent criteria for classifying this peptide as a potential new 
CPP, uptake was compared with the uptake of fluorescein-labeled analogs of the well-
established CPPs penetratin and R9. Hela cells were incubated with these peptides at 
concentrations ranging from 5 to 20 M and uptake quantified in living cells by flow 
cytometry. Trypsinization of cells, required to detach the cells from the tissue culture plate 
prior to flow cytometry, was used to remove peptides merely adsorbed to the outer plasma 
membrane.  
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Fig. 5.1. Concentration dependence of uptake. HeLa-cells were incubated with increasing 
concentrations of the indicated peptides for 45 min. Afterwards the cells were washed with cold PBS 
and harvested with trypsin/EDTA. Uptake into cells was analyzed by flow cytometry. Independent 
experiments were normalized to the median fluorescence for 20 M hLF. 
 
 
Fig. 5.2. Concentration-dependent phenotypes for the cellular uptake of the hLF peptide and toxicity. 
(A) HeLa cells were incubated for 30 min with different concentrations of the peptide. After two 
washing steps the cellular peptide uptake was analyzed by confocal laser scanning microscopy. The 
scale bar indicates 20 m. (B) HeLa cells were incubated with increasing concentrations of the hLF 
peptide for 6 h (squares) or 24 h (circles) and subsequently cell viability was determined using the 
MTT assay. 
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All three peptides were taken up in a concentration-dependent manner and no saturation of 
uptake was observed (Fig. 5.1). For penetratin, the cellular import was proportional to the 
concentration of peptide present in the medium. R9 uptake increased strongly at 20 M 
which very likely reflects the efficient cytoplasmic uptake via localized areas of the plasma 
membrane that we have called nucleation zones (NZ) (Duchardt et al., 2007). Uptake of the 
hLF peptide also showed a clear concentration dependence. From 10 to 20 M, the relative 
increase in uptake was notably stronger than from 5 to 10 M. 
 
 
5.4.2. Intracellular distribution of the hLF peptide 
 
Given our recent observation of a rapid cytoplasmic delivery of certain CPPs at higher 
concentrations, we were particularly interested to investigate the concentration dependence 
of the intracellular distribution of the hLF-peptide. The intracellular localization of the peptide 
in living cells was investigated by confocal microscopy. For concentrations up to 10 M the 
peptide was predominantly localized in vesicles (Fig. 5.2.A). In contrast, at a concentration of 
20 M, next to a vesicular staining, nearly all cells showed a homogeneous cytoplasmic and 
nuclear peptide distribution. This concentration dependence of the intracellular distribution 
very much ressembled our former observation for the R9 and Tat peptides (Duchardt et al., 
2007) of a cytoplasmic entry via NZ. In order to further establish that entry of the hLF-peptide 
occurred via the same process, we followed the uptake by time-lapse confocal fluorescence 
microscopy. This experiment confirmed the induction of NZ as the basis for rapid entry (not 
shown). We previously showed that for arginine-rich peptides this rapid entry is neither 
associated with membrane damage nor with cytotoxicity. To exclude also for the hLF-peptide 
that the cytoplasmic delivery results in cell death HeLa cells were incubated with peptide for 
6 h and 24 h and cell viability was assessed by the MTT assay. After 6 h of incubation the 
cells were viable at peptide concentrations up to 40 M, whereas viability was reduced by 25 
% for cells incubated for 24 h at a peptide concentration of 10 M.  
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5.4.3. Structure-activity relationship of the hLF-peptide for efficient uptake 
 
After testing the uptake properties and intracellular distribution, we were interested in 
defining the structure-activity-relationship of the hLF peptide for efficient cellular uptake. With 
22 amino acids, the hLF peptide is a CPP of intermediate length. Four of the seven cationic 
amino acids and the aromatic amino acids are localized in the sequence nested between the 
cysteine residues. Positively charged and aromatic residues are typically associated with 
CPP activity. In the full-length protein, the cysteine residues form a disulfide bridge that 
constrains the domain into a loop conformation (Peterson et al., 2000).  
First, we wondered whether a shorter peptide would also show efficient import (Table 1). 
Removal of the three C-terminal residues following the cysteine residue was tolerated 
(5.3.A). In contrast, as soon as a cysteine residue was omitted, import efficiency was 
reduced dramatically. This result suggested a structural requirement for the formation of the 
disulfide bridge for obtaining efficient import. We therefore also tested a peptide, in which the 
cysteine residues were exchanged for serine residues. Again import of the resulting analog 
was reduced drastically. This finding further demonstrates that efficient uptake can be 
attributed to the capacity of the cysteines to form a disulfide bridge. Formation of the disulfide 
bridge was analytically confirmed by mass spectrometry (see below). We validated the result 
by confocal microscopy comparing the uptake of hLF and the C/S hLF mutant (M2) (Fig. 
5.3.B). For the mutant peptide the intracellular distribution was strictly vesicular. Also at 
higher concentrations, the cytoplasmic import could not be observed, demonstrating that this 
import is a function of the disulfide bridge. To test whether the number of positive charges of 
the side chains was involved or whether additional sequence-specific elements were 
involved in the uptake, the uptake of hLF was compared with a rat-derived lactoferrin peptide 
containing 6 positively charged amino acids, versus 7 for the hLF peptide. The rLF also 
contains a disulfide bridge. The uptake efficiency was greatly reduced for rLF compared to 
hLF (Fig. 5.4), suggesting that the specific sequence of hLF is important for uptake. 
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Fig. 5.3. Structure-activity relationship of hLF. (A) HeLa-cells were incubated with increasing 
concentrations of the indicated peptides for 30 min. Afterwards the cells were washed and harvested 
with trypsin/EDTA. Uptake into cells was quantitated by flow cytometry. (B) HeLa-cells were incubated 
with increasing concentrations of the indicated peptides for 30 min, washed and analyzed by confocal 
laser scanning microscopy. The scale bars indicate 20 m. 
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Fig. 5.4. Comparison of the uptake of human (h) and rat (r)-derived LF peptides. HeLa cells were 
incubated with 5 and 20 M hLF or rLF for 60 min at 37°C in RPMI supplemented with 10% fetal calf 
serum. Cells were washed twice and imaged immediately using confocal microscopy. The scale bar 
indicates 20 m. 
 
 
5.4.4. Structural analyses 
 
The cellular uptake experiments provided strong functional evidence for the requirement of 
cyclization for the efficient cellular import of the hLF-peptide. Therefore, we next addressed 
explicitly the structure of the peptide and how this structure depended on the presence of the 
disulfide bridge. The hLF-peptide comprises the loop and one disulfide bridge of human 
lactoferricin which at pH 4 forms a nascent helix (Hunter et al., 2005). Formation of the 
disulfide bridge upon oxidation was confirmed by mass spectrometry (Fig. 5.5.A-B).  
First, we addressed conformational differences of the reduced and oxidized, cyclic form of 
the peptide using NMR. The spectra showed relatively broad and ill-defined peaks and only 
limited ROE cross peak patterns. In particular, no amide-amide ROE or NOE cross-peaks 
indicative of helix formation were observed and amide-H  cross-peaks in the fingerprint 
region did not identify significantly down-field shifted H  resonances indicative of extended 
conformation, expected for the N-terminal residues of the peptide (Fig. 5.5.C). The absence 
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or presence of the disulfide bridge did not result in major changes in the NMR spectral 
appearance. Lowering the temperature to 10°C did also not result in a substantial 
improvement of the spectrum. In contrast to the NOE spectra recorded previously for the 
longer lactoferricin peptide (Hunter et al., 2005), the ROESY spectra recorded on the hLF 
discriminate cross-peaks resulting from the ROE with those originating from chemical 
exchange on the basis of their sign. Interestingly, clear exchange cross-peaks were 
observed in the aromatic/amide region as well as in the aliphatic region of the spectrum (Fig. 
5.5.D-E). Dissolving the peptide in the solvent mixture H2O:CD3OD:CDCl3 (1:4:4, w/w/w) as 
previously employed (Hunter et al., 2005), did not radically change the spectral appearance, 
although an increase in spectral dispersion was observed and weak, upfield shifted H  
resonances as well as downfield shifted methyl resonances suggested the formation of an 
extended structure (not shown). However, relatively broad lines were again observed in 
conjunction with a lack of cross-peaks in the fingerprint region and amide region. It is 
noteworthy that under all conditions the single, easily identifiable Trp42 (peptide: Trp5) 
sidechain N1-proton shows as much as four different resonances of varying intensities. 
Overall, the NMR data suggest a potentially oligomeric, (partially) folded state, subject to 
conformational exchange. 
Having failed to observe an oxidation-dependent conformational difference in an aqueous 
buffer, we next employed CD spectroscopy for obtaining information about the secondary 
structure in membrane mimicking environments and in buffers containing micelles or 
vesicles. Consistent with the NMR analysis, in aqueous buffer, reduction of the disulfide 
bridge by incubation with DTT had no effect on the shape of the CD spectrum in a 
temperature range of 5°C to 20°C (not shown). The CD spectra could not be described by a 
linear combination of CD spectra for classical secondary structure elements, i.e. -helix, -
sheet and random coil. However, the spectrum was also distinct from the one to be expected 
for purely random coil. Addition of 50 % TFE led to the formation of an -helix in the reduced 
and oxidized states of the peptide. 
In contrast, both forms showed different spectra in solutions containing detergent or lipid. 
SDS increased the -sheet content in the reduced form, only, DPC increased the content in 
the reduced and in the oxidized form. In contrast, for DMPC and DMPC/DMPG, the -sheet 
content increased only for the oxidized form, with DMPC/DMPG inducing the most 
pronounced changes (Fig. 5.5.F-I). The latter results demonstrate that oxidation affects the 
capacity of the peptide to undergo conformational changes. 
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Fig. 5.5. Structural analyses at micellar membranes. (A, B) Electro spray mass spectrometry spectra 
depict the multiple-charged species of the reduced (A) and oxidized (B) form of the hLF peptide 
identifying a m/z shift of +2 Da upon reduction of the peptide. (C) NOESY spectrum of 1 mM hLF in 
H2O solution. Up-field (D) and aliphatic (E) regions of the ROESY spectrum of hLF in H2O solution. 
Cross-peaks with negative intensity (corresponding to ROE peaks) are shown as single contours, 
whereas cross peaks with positive sign (corresponding to the diagonal and exchange peaks) are 
shown with multiple, exponentially spaced contours. (F, G) CD spectroscopy in an aqueous phosphate 
buffer (F) and phosphate buffer containing DMPC/DMPG 3:1 vesicles (G). (H,I) Data analysis via the 
CONTINLL algorithm of the reduced peptide (H) and the oxidized hLF peptide (I). Especially at the 
surface of DMPC/DMPG 3:1 vesicles (highlighted by the arrows) -strand formation was induced for 
the oxidized form of the peptide.  
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5.4.5. Binding of the hLF peptide and hLF C/S to heparan sulfate 
proteoglycans 
 
Heparan sulfate proteoglycans (HSPGs) have been reported to contribute to the uptake of 
several CPPs (Poon and Gariepy, 2007; Tyagi et al., 2001). Therefore, these sugars could 
also contribute to the dependence of uptake on the presence of the disulfide bridge. The 
difference between the oxidized and reduced hLF was observed using a SPR based binding 
assay, a more physiologically relevant system in which low amount of HS is coupled through 
its reducing end to a sensorchip, thus better representing HSPG presentation at the cell 
surface. Injection of reduced hLF over this surface, in the 250 – 3000 nM range, gave binding 
curves plateauing at 25 to 75 resonance units (RU), while the oxidized form of the peptide 
gave binding curves plateauing at 48 to 156 RU (Fig. 5.6). From the binding curves of the 
oxidized peptide a Kd value of 2 M was obtained. In a similar set of experiments in which 
binding of the fluorescein-labeled hLF was compared to binding of the fluorescein-labeled 
C/S mutant, a Kd value of 10 M was obtained for the wild-type hLF while no binding could 
be detected for the mutant peptide (not shown). These results validate the specificity of 
binding of the hLF peptide for HS. The residual binding obtained for the reduced peptide may 
be due to incomplete reduction. 
 
 
Fig. 5.6. Affinity measurements of (A) oxidized and (B) reduced hLF for HS-coated surfaces using 
SPR. 
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5.4.6. HSPG-dependence and rottlerin sensitivity of the uptake 
 
Having observed a strong conformational dependence of the binding of the hLF-peptide to 
HS using biochemical assays, we next addressed the relevance of this interaction for the 
binding to cells. Removal of HS chains after a one-hour treatment with heparinases I-III 
nearly abolished the binding of the hLF peptide to the cell surface and reduced the number 
and intensity of vesicles (Fig. 5.7.A). 
Furthermore we tested the effect of rottlerin on the cytoplasmic uptake of the oxidized hLF-
peptide. Rottlerin has been described originally as a PKC inhibitor with strongest activity 
towards the PKC-  isoform (Gschwendt et al., 1994). However, the specificity was 
questioned later (Davies et al., 2000). Previously, we showed that this drug acts as an 
effective inhibitor of cellular peptide uptake via nucleation zones (Duchardt et al., 2007). 
Cells were preincubated with rottlerin and peptide uptake was analyzed by flow-cytometry 
and fluorescence microscopy (Fig. 5.7.B-C). At low peptide concentrations, at which only 
vesicular uptake occurred, rottlerin reduced uptake only weakly. At peptide concentrations at 
which uptake via NZ occurred, peptide uptake was inhibited by up to 50 %. Confocal 
microscopy confirmed that rottlerin only inhibits the efficient cytoplasmic peptide uptake. The 
concentration-dependent increase in cell-associated fluorescence observed in the presence 
of rottlerin (Fig. 5.7.B) may therefore be attributed to the vesicular peptide uptake which is 
not affected by rottlerin. 
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Fig. 5.7. Cytoplasmic import of hLF is HS proteoglycan-dependent and negatively affected by rottlerin. 
(A) HeLa cells were treated for 1 h with heparinases I, II and III (33, 8 and 5 mIU/ml, respectively) or 
remained untreated. Subsequently, the cells were washed and incubated with different concentrations 
of the hLF peptide. Images were taken after 30 min of peptide incubation. Removal of HS chains from 
the cell surface was confirmed by immunofluorescence staining of treated and untreated cells. (B, C) 
HeLa cells were treated with 20 M rottlerin for 30 min or remained untreated. After one washing step 
the cells were incubated with different concentrations of hLF in the presence (white bars) or absence 
of rottlerin (black bars). After 30 min of incubation the cells were analyzed by flow cytometry or 
confocal laser scanning microscopy. The scale bars indicates 20 m. 
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5.4.7. hLF-mediated import of protein cargos 
 
The ability to mediate cellular uptake of a diverse set of cargos is an important characteristic 
for a CPP to be valuable for applications in biological and biomedical research. As such, the 
fluorophore could already be considered a cargo since it may affect the cellular trafficking of 
a CPP (Dupont et al., 2007). Therefore, our data suggest that lactoferrin is well suited for the 
efficient cellular import of small molecules that otherwise cross the plasma membrane only 
poorly. In addition, we tested whether the hLF peptide was able to mediate import of a large 
molecular weight protein cargo. For these complexes, potential immunogenicity of the CPP is 
an important concern. Therefore, using a human protein-derived peptide is of particular 
importance. To this end, a biotinylated hLF was synthesized and coupled to Alexa488-
labeled streptavidin in a molar ratio of 4:1 (peptide:streptavidin). Import of these conjugates 
into HeLa cells was visualized by confocal fluorescence microscopy (Fig. 5.8). Streptavidin-
Alexa488 was internalized into vesicular compartments, in accordance with observations for 
high molecular weight complexes of other CPPs (Tunnemann et al., 2006). This uptake 
occurred only when the protein was conjugated to biotinylated hLF peptide. Neither the 
protein alone nor the protein in the presence of non-biotinylated hLF peptide was taken up. 
 
Fig. 5.8. Biotinylated hLF peptide efficiently transports streptavidin-Alexa488 into cells. HeLa cells 
were incubated for 30 min with 5 M of the biotinylated hLF-streptavidin-Alexa488 complex. After two 
washing steps the cellular uptake was analyzed by confocal laser scanning microscopy. Coincubation 
of streptavidin with PBS and non-biotinylated hLF peptide served as controls. The scale bar indicates 
20 m. 
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5.5. Conclusions 
 
The results shown in this chapter present a new cell-penetrating peptide corresponding to 
amino acids 38 to 59 of human lactoferrin (amino acids 19-40 of human lactoferricin). With 
22 amino acids, the hLF peptide is a CPP of intermediate length. Nevertheless, repeated 
batches of peptide obtained by solid-phase peptide synthesis following standard procedures 
showed typical purities of the N-terminally labeled peptide of about 80 %. 
In contrast to shorter ones, oligoarginine peptides of more than eight amino acids in length, 
enter cells more efficiently and show a concentration-dependent uptake mechanism into the 
cytoplasm (Kosuge et al., 2008). Even though the hLF peptide contains less arginine 
residues compared to the Tat peptide or R9, a concentration-dependent uptake mechanism 
was also observed. At concentrations above 10 M, the peptide rapidly enters the cytoplasm. 
The sensitivity of this uptake to rottlerin treatment of cells suggests that this mechanism is 
the same that was observed for R9 and the Tat-peptide. Thus far, the rottlerin-sensitive 
uptake mechanism was only observed for arginine-rich CPPs. Our observations on the 
conformation-dependent uptake of the hLF-peptide suggest that the particular structure of 
this peptide may functionally replace a high arginine content for this mechanism of cell entry. 
The sequence nested within the two cysteine residues is reminiscent of cationic amphipathic 
CPPs such as penetratin. However, removal of the disulfide bridge, either by reduction of 
cysteine residues (not shown) or by replacement by serine residues strongly reduced the 
capacity of the peptide to enter cells. To our knowledge, this is the first report of a cell-
penetrating peptide that requires a cyclic structure for its activity. However, numerous 
antimicrobial peptides have been investigated to this aim, though with differing results, such 
as gramicidin S (Wadhwani et al., 2006), (protegrin-1 (Buffy et al., 2003), (RTD-1 (Selsted, 
2004), renatuerin-1 (Sonnevend et al., 2004), bactenecin (Wu and Hancock, 1999) and 
tachyplesin-1 (Matsuzaki et al., 1997; Ramamoorthy et al., 2006; Doherty et al., 2008). In the 
latter case, aggregation was found to be the de-activating factor, which is being prevented by 
proper cyclization. 
The dependence of the efficient import on a disulfide bridge is not predicted by our current 
knowledge on CPPs. A prediction identified the central QWQRNMRKVR motif as essential 
for the CPP activity (Hällbrink et al., 2005). The terminal residues in the cysteine-containing 
wild-type peptide as well as the serine-containing mutant analog were not predicted to 
influence the uptake significantly (M. Hällbrink, personal communication). This consideration 
indicates that for the hLF peptide, a simple examination of the primary structure fails to 
predict the structural determinants required for efficient cell entry of the peptide.  
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In the crystal structure of human lactoferrin (Sun et al., 1999), the residues corresponding to 
hLF are part of an  motif that is stabilized by the formation of a disulfide bridge 
between Cys39 and Cys56 (positions 2 and 19 in the peptide) and hydrophobic interactions 
that involve Trp42 andVal54 (positions 5 and 17 in the peptide) and Met46 and Pro52 (positions 
9 and 15 in the peptide). For the human lactoferricin peptide NMR data indicate that the 
amino acid residues corresponding to the hLF peptide adopt a „nascent‟ helical structure in 
aqueous solutions and a conformation resembling the crystal structure in membrane-
mimicking solvent. Our data clearly show the necessity of the presence of the Cys39-Cys56 
(peptide: 2, 19) disulfide bridge for efficient import. However, in solution, neither CD nor NMR 
spectra were significantly affected by disulfide formation. Whereas the CD data indicate a 
non-random coil conformation of hLF, the NMR data also point to conformational exchange. 
It is tempting to speculate that Trp42 (position 5 in the peptide) is a crucial factor affecting the 
NMR spectra because of its essential structural role and the putative large changes in 
shielding effects it could exert. Other dynamic effects such as dimer formation could similarly 
affect the NMR spectra and such a phenomenon was postulated for the longer human 
lactoferricin peptide in aqueous solvent (Hunter et al., 2005).  
Therefore, CD spectra were also recorded in the presence of phospholipid micelles in order 
to get further insights into the structural impact of lipid surfaces on the peptide. Here, the 
oxidized peptide showed a clear preference for -strand formation, whereas the reduced 
peptide presented no defined secondary structure. Interestingly, the differences in secondary 
structure formation of the oxidized and reduced hLF peptide were most pronounced in the 
presence of DMPC/DMPG vesicles, which ensure strong electrostatic attraction of the 
peptide and are also a good mimick of the cellular membrane environment. 
Additionally, the interaction with heparan sulfate chains was investigated by means of fast 
protein liquid chromatography, surface plasmon resonance and in cellular assays. SPR 
experiments showed that the interaction with HS is enhanced significantly upon oxidation of 
the peptide. Cellular assays show the physiological relevance of the different HS-peptide 
interactions. In cell experiments we made an interesting additional observation concerning 
the involvement of HSPG in NZ-dependent cytoplasmic uptake. Consistent with our previous 
results, heparinase treatment over 6 h abolished the rapid cytoplasmic uptake of hLF (not 
shown). In contrast, short-term treatment over only 1 h had no significant effect on NZ-
dependent import. However, membrane binding of hLF at lower peptide concentrations was 
strongly reduced. We therefore conclude that the previously observed effect of long-term 
heparinase treatment on NZ-dependent uptake is due to perturbations of membrane protein 
organization or molecular events involved in this cytoplasmic uptake. 
Given that the cell uptake experiments did not show any concentration dependent saturation, 
the lactoferrin-derived CPP exhibited one of the most prominent characteristics for the 
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uptake of CPPs. For the full length lactoferrin protein, cellular uptake has been described for 
various cellular systems. While it has been observed that the polycationic nature of the N-
terminus confers by itself an interaction with sugars on the cell surface, cellular uptake and 
the biological effects of lactoferrin have been attributed to the binding to one of the several 
receptors identified for this protein (Suzuki et al., 2005). In contrast to our peptide, binding to 
these receptors was therefore saturable. Very remarkably, for binding to the lymphocyte 
lactoferrin receptor and the platelet lactoferrin receptor, evidence for an involvement of the 
loop domain corresponding to the lactoferrin-derived CPP was obtained (Legrand et al., 
1992; Leveugle et al., 1993). Competition experiments with our peptide for binding of 
lactoferrin may thus help to better define ligand binding domains for other types of lactoferrin 
receptors.  
In summary, the results show that the hLF peptide is a new CPP with highly interesting 
structural and functional characteristics. With respect to the mechanism of import, we expect 
that further analyses of the structure-activity relationship will yield new insights into the 
molecular determinants of the cell surface that mediate the molecular interaction and induce 
the efficient cellular import via nucleation zones. Furthermore, it will be interesting to 
compare analogous peptides derived from lactoferrin of different species. In the past, the 
antimicrobial characteristics of bovine lactoferrin-derived peptides have been compared in 
detail to the ones of their human counterparts (Gifford et al., 2005). Due to its human origin 
the hLF peptide is expected to be non-immunogenic. For this reason, this molecule is a 
candidate as a vector for biomedical applications, especially for the import of high molecular 
weight complexes. 
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6. Analysis of the intracellular pharmacokinetics and 
pharmacodynamics of small molecule anti-cancer drugs 
 
The FCS measurements described in this chapter were performed by Heike Glauner and 
Ben Steemers. The author of this thesis performed the analysis of the data, developed,  
synthesized and tested the doubly-labeled FCCS standard (Fig. 6.1.B) and labeled the 
compound MTX-Cy5. Dr. Frank Becker, Dr. Stefan Hannus and Kerrin Hansen provided the 
transfected Hek293 cells, the DNA vectors and the labeled compounds PD-Cy5 and Pur-
Cy5. Heike Glauner established a HeLa-TRex cell line expressing DHFR-GFP. Yi-Da Chung 
determined the size of the exact detection volume by microbeads and performed the gel 
electrophoresis depicted in Fig. 6.1.A. 
 
 
6.1. Summary 
 
In drug development there is great awareness that in vitro assays that determine activities of 
drug candidates with isolated targets, have only limited predictive value for activities in 
cellular assays. Poor membrane permeability and off-target binding are major reasons for 
lack of activity. However, possibilities to directly analyze these processes on a subcellular 
level are still very limited. To this end, the well-established dihydrofolate reductase inhibitor 
methotrexate and the kinase inhibitors Parke-Davis compound PD173956 and purvanolol B 
were conjugated via polyethyleneglycol linkers with the indocyanine fluorophore Cy5. 
Labeling did not affect the activity of these drugs towards their targets. The cellular uptake 
and subcellular distribution of these compounds in single human cancer cells was 
investigated by confocal laser scanning microscopy. In addition, molecular interactions inside 
the cell with the respective target proteins were investigated in the nanomolar range by 
fluorescence cross-correlation spectroscopy (FCCS) using cells stably transfected with 
green-fluorescent protein fusion proteins of the dihydrofolate reductase (DHFR-GFP) and 
Abelson kinase 1 (ABL1-GFP). Large differences in the interaction patterns were found for 
the investigated drugs. For methotrexate-Cy5 drug target interactions could be detected and 
dissociation constants determined. In contrast, PD-Cy5 strongly interacted with intracellular 
high-molecular weight structures. In summary, FCCS provides a powerful means to assess 
subcellular pharmacokinetics and -dynamics of drug candidates at nanomolar 
concentrations.  
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6.2.Introduction 
 
In drug development, assays that determine the activity of a drug in intact cells are gaining 
significance (Perlman et al., 2004; Korn and Krausz, 2007; Lang et al., 2006). While 
providing less detailed information on the interaction of a drug candidate towards a specific 
molecular target, the results of such assays intrinsically provide information on off-target 
effects and cytotoxicity. In addition, many compounds fail to show any biological effect, even 
if biological activity was detected towards an isolated target molecule in an in vitro screen. 
For compounds that exert their activity inside the cell such failure is typically attributed to 
poor cellular uptake. However, this assumption rather reflects a lack of knowledge of the 
intracellular pharmacology of a drug, rather than being based on direct evidence. This deficit 
is due to an absence of methods describing the interaction patterns of compounds on the 
subcellular level. Next to the failure to cross the plasma membrane, absence of activity may 
also be due to interactions with membranes, sequestration in vesicular compartments, 
binding to DNA in the cell nucleus and binding to cytoskeletal structures and other proteins. 
For example, numerous cationic amphiphilic drugs are enriched in the lysosomal 
compartment (Bareford and Swaan, 2007; Almela et al., 2009). Great efforts have been 
invested to optimize the route of cellular uptake of small molecule drugs. On the one hand 
prodrug strategies are widely employed (Rautio et al., 2008) to improve the uptake efficiency, 
on the other hand small molecule drugs can be conjugated to peptidic vectors (Fischer et al., 
2001) or high-molecular weight structures (Omelyanenko et al., 1998; Duncan, 2003) in order 
to modify the uptake kinetics. Moreover, the subcellular localization of a drug can vary for 
different cell types and differences in the applied dose (Stumpf et al., 2008).  
In the past decades, numerous techniques have been developed to investigate the 
subcellular localization of small molecule drugs. Generally, high-resolution fluorescence 
microsocopy has become the method-of-choice for studying molecular dynamics on a 
subcellular level in living cells. However, only few small molecule drugs possess intrinsic 
fluorescence compatible with live cell microscopy. One such example is doxorubicin (de 
Lange et al., 1992; Lankelma et al., 1999). In contrast, the majority of small molecule drugs 
lacks such characteristics therefore requiring conjugation to fluorophores for visualization. 
Alternatively, the molecular localization of unlabeled proteins, peptides and small molecules 
in tissues can be determined by mass spectrometry imaging (Chaurand et al., 2005; 
Goodwin et al., 2008; Signor et al., 2007). The major drawback of this technique is the 
comparably low spatial resolution. Nevertheless, with novel ion optics systems a resolution 
down to approximately 4 m is reached (Luxembourg et al., 2006). IR microscopy and 
Raman scanning techniques provide information about the localization and molecular nature 
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of macromolecular assemblies, but the detection is rather unspecific for particular molecules 
and the spatial resolution (> 1 m) is limited as well in comparison to high-resolution 
microscopy (Boskey et al., 1992; Lasch and Naumann, 2006; Gotter et al., 2008). 
Microscopic autoradiography enables high spatial resolution in the subcellular localization of 
drugs, but requires the fixation of cells and the synthesis and manipulation of radioactively 
labeled drug molecules (Kawamoto, 1990; Stumpf, 2005). 
The dihydrofolate reductase inhibitor methotrexate is a prominent example, that illustrates 
the potential of fluorescent labeling for an analysis of cellular transport and the subcellular 
localization of a drug molecule (Gapski et al., 1975; Remy and Michnick, 2001; Kaufman et 
al., 1978; Miller and Cornish, 2005; Miller et al., 2004; Powell et al., 2006). Fluorescein and 
TexasRed were used as fluorophores in these previous applications. However, due to 
spectral characteristics that overlap with the majority of fluorescent proteins used for the 
tagging of proteins, fluorescein- and TexasRed-labeled compounds have only limited 
suitability for a highly sensitive simultaneous detection of the drug and its target. For this 
purpose, red-fluorescent fluorophores such as Cy5 are preferable. This fluorophore has an 
excitation maximum around 670 nm and is spectrally well separated from green fluorophores 
with excitation maxima below 550 nm, enabling the simultaneous detection with proteins 
fused to green fluorescent protein (GFP). Especially for the highly sensitive detection of 
molecular interactions by fluorescence cross-correlation spectroscopy (FCCS), avoidance of 
fluorescence resonance energy transfer (FRET) (Clegg, 1995) is highly preferable 
(Weidemann et al., 2002; Földes-Papp, 2005).  
FCCS is an extension of fluorescence correlation spectroscopy (FCS) (Schwille et al., 1997). 
In FCS, information on the mobility and concentration of molecules is obtained from an 
analysis of fluorescence fluctuations, caused by diffusion of molecules through a 
subfemtoliter confocal detection volume (Rigler et al., 1993). With a sensitivity in the 
subnanomolar range, FCS has become a highly powerful tool to address molecular dynamics 
in cells and subcellular compartments (Brock et al., 1999; Sorscher et al., 1980; Brock and 
Jovin, 1998; Schwille et al., 1999; Hink et al., 2000; Wachsmuth et al., 2000; Koopman et al., 
2007). Binding of a low-molecular weight drug candidate to a target protein slows down 
diffusion. Binding equilibria can be derived from the contributions of a slow and fast moving 
fraction to the total autocorrelation function (Meseth et al., 1999). In recent years, FCS-based 
high-throughput methods have gained singificant importance in drug discovery (Hintersteiner 
and Auer, 2008). 
In FCCS, concerted fluorescence fluctuations, caused by codiffusion of two spectrally well 
separated fluorophores are detected. For the detection of drug-target interactions two main 
characteristics set this method apart from FRET: First, there is no dependence of the signal 
on the distance of the fluorophores. Therefore, there are no constraints on the use of linker 
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molecules between drug and fluorophore. Second, especially for interacting molecules that 
are homogeneously distributed throughout a cell and at low concentrations, FCCS has a 
much higher sensitivity for the detection of interactions. Also for FCCS intracellular 
applications have been presented (Schwille et al., 1999) (Schwille et al., 1999; Bacia et al., 
2006), including the determination of binding constants of fluorescent proteins (Shi et al., 
2009).  
Given these powerful characteristics for the detection of molecular interactions, we here 
employed a combination of confocal laser scanning microscopy, FCS and FCCS to 
investigate the subcellular pharmacokinetics and -dynamics of Cy5-labeled anti-cancer 
drugs. Methotrexate (MTX), purvalanol B (Pur) and Parke-Davis compound PD173956 (PD) 
were selected for this purpose. Previous studies had shown that these compounds show 
bioactivity in the lower nanomolar range (Washtien, 1982; Gray et al., 1998; Kraker et al., 
2000). Hydrophobicity is a major determinant for the pharmacological properties of a drug 
(Lipinski et al., 2001). Therefore, the drugs were selected to cover a broad range of 
hydrophobicity. Whereas the antimetabolite methotrexate is hydrophilic, having a logarithmic 
octanol/water partition coefficient (logP) of -1.8, the kinase inhibitor purvalanol has a logP of 
3.8 and the kinase inhibitor Parke-Davis compound PD173956 a logP of approximately 5, 
according to the PubChem data base (National Center for Biotechnology Information (NCBI), 
Bethesda, USA). 
The intracellular localization of MTX-Cy5, Pur-Cy5 and PD-Cy5 was determined in living 
human cervical cancer HeLa cells and the human embryonic kidney cell line Hek293. The 
hydrophobic kinase inhibitors both accumulated in the plasma membrane and vesicular 
structures. For assessing molecular interactions in the cytosol, this accumulation could be 
overcome by import of molecules via electroporation (Knight and Scrutton, 1986; Gehl, 2003; 
Melvik et al., 1986). For cells expressing GFP-tagged target proteins of MTX and PD, FCS 
and FCCS were employed for detecting interactions of these two molecules inside the cell. 
Whereas FCCS specifically detected interactions with GFP-tagged target proteins, FCS 
yielded information on the total fraction of bound molecules. PD-Cy5 showed a much 
stronger off-target binding to intracellular structures than MTX-Cy5. The different 
characteristics of these drugs also confirmed that the Cy5 label did not impart the analysis of 
subcellular pharmacology. In summary, our results reveal major differences in intracellular 
off-target binding for different drug molecules and demonstrate that a combination of FCS, 
FCCS and confocal microscopy is a powerful combination to address such differences. 
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Scheme 6.1. Determination of the intracellular pharmacological properties of small molecule drugs by 
a combination of FCS and FCCS measurements in living cells. (A) The drug molecules were 
conjugated to the fluorescent dye Cy5 via a PEG linker. (B) Cells expressing GFP-tagged target 
proteins were loaded with the Cy5-labeled compounds and observed by confocal laser scanning 
microscopy. Subsequently, the laser beam was displaced vertically in order to identify a measurement 
position of the detection volume inside the cytoplasm along the optical axis (z-position). Alternatively, 
the z-position was identified from a confocal section in x-z-position. Measurements of interactions 
inside the cell (C) resulted in (D) a fluorescent count trace over time from which (E) autocorrelation 
functions G( ) for both channels (red and green) and a cross-correlation function G( ) (black) were 
calculated. (F) From the auto- and cross-correlation functions, concentrations of the various 
fluorescent species could be derived such as free GFP-tagged target protein, unbound compound-
Cy5, compound-Cy5:target protein-GFP complexes and compound-Cy5 bound to high-molecular 
weight structures. 
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6.3. Experimental procedures 
 
6.3.1. Cells and Reagents 
 
The human cervical carcinoma cell line HeLa was obtained from the American Type Culture 
Collection (ATCC) (Manassas, VA, USA). T-Rex-293 cells, the T-Rex vector pcDNA4/TO, 
Zeocin , Blasticidin and TetraSpeck microspheres were purchased from Invitrogen (Carlsbad, 
USA). Effectene Transfection Reagent and QIAquick PCR Purification Kits were obtained 
from QIAGEN (Hagen, Germany). The Phusion DNA Polymerase Kit supplied by Finnzymes 
(Woburn, USA). PAGE- and HPLC-purified RhG- and Cy5-labeled primers were obtained 
from Thermo Electron GmbH (Ulm, Germany). Tissue culture media and fetal calf serum 
(FCS) were purchased from PAN biotech (Aidenbach, Germany), the Cy5 monofunctional 
reactive dye from GE Healthcare (Little Chalfont, UK). The electroporation kits Cell Line 
Nucleofector Kit V and Cell Line Nucleofector Kit R were obtained from Lonza Cologne 
(Cologne, Germany). The dye S0387 was purchased from FEW Chemicals (Bitterfeld-
Wolfen, Germany), the dye sodium fluorescein was obtained from Fluka (Deisenhofen, 
Germany). 
 
 
6.3.2. Generation of the doubly-labeled FCCS standard 
 
In order to determine the exact spectral overlap of the detection volumes of both channels a 
doubly-labeled FCCS standard of 109 bp (≈37 nm) was generated by means of PCR. The 
Src homology 2 domain containing adaptor protein B (SHB) was employed as template DNA. 
The forward primer was labeled with the fluorescent dye Cy5 (5´-Cy5-ATA TGG TAT CAC 
GGA GCC ATC AG-3´), the reverse primer was labeled with Rhodamine Green (RhG) (5´-
RhG-TAG TCA TGC TTG CTG GTC TGG-3´). For the amplification a Phusion DNA 
Polymerase Kit was used according to the supplier‟s manual. The PCR reaction was 
conducted in a GeneAmp PCR System 9700 (PE Applied Biosystems Weiterstadt, Germany) 
(Scheme 6.2.). Subsequently, the FCCS standard was purified by a QIAquick PCR 
Purification Kit according to the supplier‟s manual, analyzed by gel electrophoresis, diluted 
20-fold in PBS buffer and finally stored in glass vials at -20°C. Additionally, un- and mono-
labeled standards were generated to characterize the spectral properties of the standard. 
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Scheme 6.2. Settings of the PCR system. 
 
 
6.3.3. Synthesis of labeled compounds 
 
Compounds carrying a 5-PEG linker with a terminal amino group were synthesized at GPC 
Biotech. 500 nmol of these conjugates were dissolved in 100 L dimethyl sulfoxide and 0.7 
L N,N-diisopropylethylamine. The solution was added to one aliquot of Cy5 monofunctional 
reactive dye and incubated in the dark at RT for 20 h. Subsequently, purification was 
performed by preparative RP-HPLC (Gilson, Middleton, USA) using a linear gradient of water 
(0.1 % trifluoroacetic acid) - acetonitrile (0.1 % trifluoroacetic acid). The identity of the Cy5-
labeled compounds was confirmed by mass spectrometry. 
 
 
6.3.4. Tissue culture 
 
Hek293 and HeLa wild type cell lines were grown in RPMI1640 medium containing 5% fetal 
calf serum at 37°C and 5% CO2. The cell lines T-Rex-293 and HeLa-T-Rex stably transfected 
with the vector pcDNA4/TO were grown in RPMI1640 medium containing 10% fetal calf 
serum and the selection factors 100 g/ml Zeocin and 5 g/ml Blasticidin at 37°C and 5% 
CO2. 
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6.3.5. Generation of stable T-Rex-293 and HeLa-T-Rex cell lines 
expressing ABL1-GFP and DHFR-GFP 
 
5 x 106 T-Rex-293 cells and 2 x 106 HeLa cells were transfected with 2 µg of the respective 
plasmids encoding GFP-tagged target proteins and a Zeocin resistance cassette using 
Effectene Transfection Reagent. Transfected cells were selected using Zeocin at a 
concentration of 0.1 mg/ml over a period of several weeks, eliminating all cells that did not 
express the Zeocin resistance gene at sufficient amounts. The polyclonal T-Rex-293 and 
HeLa-T-Rex strains were kept under selective pressure of 100 g/ml Zeocin and 5 g/ml 
Blasticidin throughout the experiment. 
 
 
6.3.6. Cellular import of drug molecules 
 
T-Rex-293 cells expressing low amounts of ABL1-GFP were detached by Trypsin/EDTA and 
washed in medium. Subsequently, different concentrations of PD-Cy5 were electroporated 
into the cells (single pulse, 130 V, 500 F, Fischer Electroporator, Heidelberg, Germany). For 
analysis of the direct uptake of PD-Cy5 without electroporation, T-Rex-293 cells expressing 
ABL1-GFP were grown in 8-well chambered coverglass slides (Nunc, Rochester, USA) and 
incubated with different concentrations of PD-Cy5 for 3h at 37°C. 
For analysing the interaction of MTX-Cy5 with DHFR-GFP, T-Rex-293 cells stably 
transfected with DHFR-GFP were detached by Trypsin/EDTA, washed in medium and 
resuspended in 100 L Nucleofector Solution R containing 4 µM MTX-Cy5. MTX-Cy5 was 
imported by electroporation (Nucleofector, Lonza Cologne) using the electroporation method 
I-013 according to the recommendations of the manufacturer. Subsequently, 500 L RPMI 
medium were added carefully and the cells were incubated for 10 min at 37°C. 
Subsequently, the cell suspension was washed in medium twice by centrifugation. The cells 
were seeded in 8-well chambered coverglass slides (Nunc, Rochester, USA). 
HeLa-T-Rex cells expressing low amounts of DHFR-GFP were detached by Trypsin/EDTA 
and washed in medium. Cells were electroporated in a solution of 1 M MTX-Cy5 in RPMI 
medium (single pulse, 130 V, 500 F, Fischer Electroporator). The cells were washed three 
times with medium and finally seeded in a 8-well chambered coverglass slide. 
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6.3.7. Intracellular FCCS measurements 
 
FCCS measurements were performed with a TCS SP5 confocal microscope/dual channel 
fluorescence correlation spectroscopy unit equipped with an HCX PL APO 63x N.A. 1.2 
water immersion lens (Leica Microsystems, Mannheim, Germany) and with a ConfoCor2 
fluorescence correlation spectroscopy unit connected to an Axiovert 100M equipped with a 
C-Apochromat 40x N.A. 1.2 water immersion lens (Carl Zeiss, Jena, Germany). In case of 
the TCS SP5, fluorescence was split by a BS 625 beam splitter. Fluorescence in the green 
channel was detected using a BP 500-550 band pass filter, fluorescence in the red channel 
with a BP 647-703 band pass filter. For the ConfoCor2, fluorescence was split by an NFT 
610 beam splitter, green fluorescence was detected with a BP 500-550 IR band pass filter, 
red fluorescence with an LP 650 long pass filter. The GFP fusion proteins were excited with 
the 488 nm laser line of an argon-ion laser, Cy5 with a 633 helium-neon laser. In order to 
avoid high background signals resulting from autofluorescence and minimize bleaching, the 
power of both lasers was adjusted to a low intensity. The argon-ion laser was adjusted to 20 
W and 11 W for the TCS SP5 and the ConfoCor2, respectively, the helium-neon laser to 
19 W and 8 W, measured with an X1-1 laser power meter equipped with an LSM-9901 
Luminous Flux detector head (Gigahetz-Optik, Puchheim, Germany) at the exit aperture of 
the lens. 
For each setup these parameters led to comparable molecular brightness (fluorescence per 
molecule – fpm) in both channels. Solution measurements were carried out with a sample 
volume of 20 L in a 384-well plate (175 m, low-base design, MMI, Eching, Germany). The 
short wavelength channel was calibrated with a 10 nM sodium fluorescein solution. For 
measurements of GFP fusion proteins, the structure parameter corresponding to the ratio of 
the radii of the detection volume along the optical axis and in the focal plane S = z0/ 0 was 
fixed to the value determined by fitting the autocorrelation function for this measurement. The 
structure parameter S for the long-wavelength channel was determined by an autocorrelation 
measurement of a 10 nM S0387 solution. This indocyanine dye has spectral properties 
comparable to Cy5 (Mader et al., 2004). The spectral overlap of the detection volumes was 
determined by a cross-correlation measurement of a doubly-labeled FCCS standard, 
terminally labeled with Rhodamine Green (RhG) and Cy5, similar to a standard described 
previously (Baudendistel et al., 2005). Cells with low expression of GFP fusion proteins were 
selected by confocal imaging. The detection volume for the FCCS measurements was 
placed inside the cytosol near to the nucleus. The signal of immobile molecules was 
removed by a pre-bleaching pulse of a few seconds at the same laser power employed for 
the subsequent measurements, followed by recording of either 5 to 60 autocorrelation 
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functions of 1 s each for the ConfoCor2 or 5 to 10 measurements of 5 s each for the TCS 
SP5. Autocorrelation functions not affected by strong fluctuations of fluorescence as caused 
by diffusion of vesicles were averaged for each cell for further analysis. 
Autocorrelation functions of Cy5-labeled compounds were fitted with a 3D Gaussian 
algorithm containing two diffusing components and a triplet term. Either the diffusional 
autocorrelation times D and fractions of both components were variable or the D of the fast 
component was fixed to the value determined for the respective Cy5-labeled compound in 
solution multiplied by a factor of four in order to account for the higher viscosity of the 
cytoplasm (Ellis, 2001; Berland et al., 1995). 
For the analysis of cross-correlation functions, the structure parameters S in both channels 
were fixed to the values determined by measurements of fluorescein and S0387, 
respectively. The triplet times of GFP and Cy5 were fixed to values derived from 
measurements in solution. For the cross-correlation curve no triplet term was included in the 
fitting algorithm. 
The autocorrelation amplitudes of the GFP channel Ggreen(0) and the Cy5 channel Gred(0) and 
the cross-correlation amplitude GCC(0) were determined. The ratio CC(measured) between 
Ggreen(0) and GCC(0) represented the fraction of the Cy5-labeled compounds that formed a 
complex with GFP fusion proteins (Schwille et al., 1997). The results were normalized by the 
value CC(max) determined for the doubly-labeled FCCS standard in the same experiment. 
Here, the device-dependent values were between 41 and 45 %. Due to the wavelength 
dependence of diffraction this value can maximally amount to 54 % in a perfectly adjusted 
microscope (Weidemann et al., 2002). The fraction of the Cy5-labeled compound bound to 
the GFP-tagged target protein CC(corr.) was corrected by 
(max)
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The particle number N derived from the autocorrelation functions was corrected for non-
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Deviations of the fpm from values measured in solution indicated the presence of 
fluorescence energy transfer (FRET) and quenching (Weidemann et al., 2002; Földes-Papp, 
2005) or poor overlap of the detection volume with the cell. 
The number of Cy5-labeled drug molecules bound to their respective GFP-target proteins 
Nred-bound was calculated according to 
 
Nred-bound =  Ncorrected ∙ CC(corr.)        (6.4)
 
 
With knowledge of the size of the detection volumes, which were approximately 0.3 fl for the 
detection volume of the green and 0.6 fl for the detection volume of the red channel, the 
concentrations of Cy5-labeled compounds and GFP-tagged target protein could be 
calculated. The determination of detection volumes was based on experimentally determined 
point spread functions using TetraSpeck microspheres of 0.1 m. 
Assuming thermodynamic equilibrium for the interaction of compound and target 
 
Ccompound-Cy5, free + CProtein-GFP, free  Ccomplex      (6.5) 
 
the dissociation constant Kd could be determined by 
 
Kd = Ccompound-Cy5, free ∙ CProtein-GFP, free ∙ Ccomplex
-1      (6.6) 
 
Here, the concentration of unbound compound-Cy5 (Ccompound-Cy5, free) was deduced from the 
fraction of free molecules obtained from two-component fits of the autocorrelation functions. 
The concentration of the compound-Cy5:target protein-GFP complex (Ccomplex) was 
determined by cross-correlation measurements and the concentration of unbound GFP 
fusion protein (Cprotein-GFP, free) was calculated by the substraction of Ccomplex from the total 
concentration of the GFP fusion protein. 
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6.4. Results 
 
6.4.1. Characterization of the doubly-labeled FCCS standard 
 
Solutions of the doubly-labeled FCCS standards were analyzed by agarose gel 
electrophoresis. According to a DNA-based molecular weight standard the detected DNA 
fragments had a size of about 100 bp. Larger DNA fragments such as template strands or 
other impurities could not be detected (Fig 6.1.A). Furthermore, FCCS measurements were 
conducted. Optical effects such as spectral cross-talk and FRET were quantified by mono-
labeled DNA standards. At laser powers of 10.7 W for the 488 nm line of an argon-ion laser 
and 7.6 W for the helium-neon laser at 633 nm comparable molecular brightnesses were 
obtained in both channels. A weak cross-talk of the RhG emission spectrum (mono-labeled 
RhG-standard) into the red detection channel of 3.5 % could detected. Furthermore the 
argon-ion laser excited the mono-labeled Cy5-standard leading to an intensity of 1.7 % 
relative to the Cy5 signal upon excitation with the helium-neon laser. In summary, cross-talk 
effects and cross-excitation contributed 5.2 %. The doubly-labeled standard also showed 5.2 
% cross-talk and cross-excitation upon excitation with the argon-ion laser only. This clearly 
indicated that no FRET was detectable. Moreover, an unlabeled standard did not show 
detectable autofluorescence. Upon excitation with both lasers the doubly-labeled FCCS 
standard showed cross-correlation amplitudes between 44 and 48 % (Fig 6.1.B). Due to 
dependence of the detection volume on the excitation and emission wavelengths the 
maximal spatial overlap of the detection volumes and thus also the theoretical maximum of 
the cross-correlation amplitude is 54 %. 
 
Fig. 6.1. Properties of the doubly-labeled FCCS standard. (A) The purity of the FCCS standard was 
controlled by gel electrophoresis. (B) The standard was measured by FCCS. The height of the cross-
correlation amplitude (black curve, small arrow) was referred to the height of the autocorrelation 
amplitude of the RhG channel (green curve, large arrow). 
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6.4.2. Synthesis of Cy5-labeled drug molecules 
 
The pentamethine indocyanine dye Cy5 was selected as a fluorophore for the labeling of the 
drug molecules. With an emission maximum of around 670 nm, the fluorescence of this 
molecule shows very little spectral overlap with the emission of the green fluorescent protein 
(Southwick et al., 1990). For the conjugation to drug molecules, functional groups had to be 
selected that are not part of the pharmacophore. Methotrexate was labeled at the free 
carboxyl group of the glutamate residue as described before (Gapski et al., 1975). For the 
compounds PD173956 and purvalanol B the position for labeling was based on preceding 
SAR studies, that verified that the conjugated compounds maintained their specific activity 
(Becker et al., 2004; Caligiuri et al., 2005). 
In order to further minimize interference of the fluorophore with the binding of the compounds 
and to prevent FRET, the fluorophore was coupled via a polyethylene glycol (PEG) spacer. 
Due to its hydrophilicity, the PEG spacer should promote the solubility of the compounds and 
minimize hydrophobic interactions with membranes and proteins. Cy5 was employed as a 
commercially available, preactivated succinimidyl active ester (Scheme 1.A). 
 
 
6.4.3. Intracellular distribution of the Cy5-labeled compounds 
 
First, we were interested to explore the intracellular distribution of the compounds. When 
using fluorescently labeled analogs, an influence of the fluorophore on the distribution of the 
molecule of interest is an important concern. HeLa and Hek293 wild type cells were 
incubated with 5 M of the respected compounds for 90 min. In comparison to previous 
studies the incubation time with methotrexate was rather short (Kaufman et al., 1978). This 
short incubation time was mainly chosen to prevent unintended effects on cell viability. 
The hydrophobic compounds PD-Cy5 and Pur-Cy5 were taken up efficiently into HeLa and 
Hek293 cells. Both conjugates were primarily localized in membranes and vesicular 
structures. In contrast, the uptake efficiency of the hydrophilic drug MTX-Cy5 was lower and 
its localization was more diffuse (Fig. 6.2). 
While these results do not fully exclude an influence of the fluorophore on the characteristics 
of the compounds, they clearly show that the compound is decisive for the subcellular 
pharmacokinetics of the conjugates. As we had stable cell lines expressing GFP-tagged 
DHFR and the Abl1 kinase domain under the control of a tetracyclin-inducible promoter in 
our hands, the labeled compounds MTX-Cy5 and PD-Cy5 were selected for further 
experiments to address intracellular interactions by FCS and FCCS. 
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Fig. 6.2. Intracellular localization of three Cy5-labeled representative anti-cancer drugs. (A-C) HeLa 
cells and (D-F) Hek293 cells were treated with each 5 M of (A and D) PD-Cy5, (B and E) MTX-Cy5 
and (C and F) Pur-Cy5 for 90 min at 37°C. The scale bars denote 20 m. 
 
 
6.4.4. Intracellular interactions of MTX-Cy5 in DHFR-GFP-expressing 
HeLa cells 
 
Confocal microscopy is very instructive to study the subcellular distribution of molecules 
(Pygall et al., 2007). However, the method provides little information on the possible 
association of compounds with homogenously distributed intracellular structures. Moreover, 
information on concentrations is very difficult to obtain. Fluorescence recovery after 
photobleaching (FRAP) (Meyvis et al., 1999), a method frequently used to study association 
and mobility of molecules inside cells does not provide sufficient temporal resolution to 
analyze the mobility of small molecules and/or very low concentrations of fluorescent 
molecules (Lippincott-Schwartz et al., 2001). Therefore, for the analysis of the association of 
small molecules with subcellular structures at low concentrations, FCS and FCCS are the 
methods-of-choice. 
When using low micromolar concentrations of Cy5-MTX for 90 min, we failed to acquire 
intracellular autocorrelation functions. It has been shown previously, that the cellular uptake 
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of fluorescein-labeled MTX is slow, requiring several hours before reaching equilibrium 
(Kaufman et al., 1978). In order to avoid potential negative pharmacologic effects of the 
antimetabolite methotrexate on viability, the cells were not incubated with MTX-Cy5 for such 
a long period of time. Instead, we explored the use of electroporation for the cytoplasmic 
import of the conjugate. Electroporation achieves a cytoplasmic import of solutes by 
application of short high-voltage pulses that induce transient pore formation in the plasma 
membrane (Gehl, 2003).  
 
 
Fig. 6.3. Interaction of MTX-Cy5 in HeLa-TREx cells expressing DHFR-GFP. (A) Characteristic 
autocorrelation functions for DHFR-GFP (dashed line) and MTX-Cy5 (dotted line) and the cross-
correlation function for the DHFR-GFP:MTX-Cy5 complex (solid line). (B) Scatter plots of relative 
contributions to the autocorrelation function versus diffusional autocorrelation times derived from fits to 
the autocorrelation functions with an algorithm comprising two diffusing components in which the 
diffusion time D of the low-molecular weight fraction was fixed to 200 s. Averages (cross) and 
standard deviations are indicated. 
 
 
Subsequently, FCCS measurements were performed with a combined FCCS/confocal 
microscope while the cells were still not entirely flattened and attached to the bottom. 
Confocal imaging enabled a precise placement of the confocal measurement volume for 
FCCS measurements in three dimensions (Scheme 1B-F). In the slightly rounded cells the 
confocal volume could be placed inside the cytosol more easily than in entirely attached 
cells.  
HeLa-T-Rex cells expressing low concentrations of DHFR-GFP in the absence of tetracycline 
were electroporated with the compound. In the absence of tetracycline the DHFR-GFP 
concentration was in the range of 313 ±187 nM, indicating a considerable leakiness of the 
promotor. Still, the use of an inducible promoter was by far superior to the use of a 
constitutive promoter, which typically yields too high expression levels for FCS 
measurements. A 1 M solution of MTX-Cy5 was electroporated into the cells, yielding 
typical intracellular MTX-Cy5 concentrations of approximately 40-70 nM, thus, in a 
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concentration range in which standard microscopy techniques fail to provide suitable results. 
The concentrations were derived from the amplitudes of the autocorrelation functions. In 
FCS, the amplitude is inversely correlated to the average number of molecules in the 
detection volume. Using experimentally determined detection volumes for both channels, 
these molecule numbers were converted into concentrations. 
Dividing the fluorescence by the number of molecules yields the fluorescence-per-molecule 
(fpm). For cellular FCS measurements large variations of this value between individual 
measurements indicate inhomogeneities in the sample or cell movement. Moreover, the fpm 
may vary in dependence of the molecular environment of a fluorophore. 
The molecular brightness fpm of GFP was highly constant within the samples and was 
approximately 4.0 ± 1.2 kHz. The intracellular molecular brightness (fpm) of MTX-Cy5 was 
slightly lower than the extracellular fpm indicating that in the cytosol no significant quenching 
occurred. 
In most cases, the first two measurements of a consecutive series of measurements in a 
single cell were affected by bleaching of immobilized MTX-Cy5 and therefore were omitted 
from the further analysis. The autocorrelation functions for MTX-Cy5 were fitted with two 
diffusing components and a triplett term (Fig. 6.3.A). The diffusional autocorrelation time D 
reflects the average time that a fluorophore needs to diffuse through the detection volume. 
This time is directly correlated with the radius of the molecule. Therefore, the larger the 
molecule the bigger D. The ability to describe the autocorrelation functions with two 
components does not imply that MTX-Cy5 was only present in two molecular forms, as for 
example free drug molecule and in a molecular complex of a defined molecular weight. 
Given the fact that the molecular radius correlates with the cubic root of the molecular weight 
of a molecule, which means that it is rather little depends on the molecular weight, especially 
the high molecular weight form may represent multiple different complexes. 
The D of the fast component was fixed to 200 s. This value was based on the D of MTX-
Cy5 in PBS buffer of approximately 50 s, in comparison to 35 s of the free dye, 
considering that the viscosity of the cytoplasm is about 4-fold higher in comparison to an 
aqueous buffer. In order to represent the variation between individual measurements, a 
graphical presentation according to (Brock et al., 1999) was chosen (Fig. 6.3.B). Here, for 
each fraction, the relative contribution to the autocorrelation amplitude is plotted versus the 
diffusional autocorrelation time D.  
The bound MTX-Cy5 fraction accounted for approximately 83 ± 11 % and had an average 
diffusional autocorrelation time D of 1.7 ± 0.5 ms. The diffusional autocorrelation time D of 
the DHFR-GFP was 1.3 ± 0.6 ms. Assuming identical mobilities for the DHFR-GFP and the 
MTX-Cy5, the MTX-Cy5 should have a diffusional autocorrelation time of about 2.2 ms. This 
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estimate is based on the larger dimensions of the detection volume due to the wavelength 
dependence of diffraction (Weidemann et al., 2002) and the  proportionality of D ~ x y, 
where x and y  represent the lateral extensions of the detection volume (Schwille et al., 
1997). The exact dimensions of the latter were determined by measuring the point spread 
function of the objective using sub-resolution fluorescent microspheres. 
In addition to the autocorrelation functions of MTX-Cy5 and DHFR-GFP, the cross-correlation 
functions were calculated. For the HeLa-T-Rex cells cross-correlation amplitudes of 19.0 ± 
6.4 % in comparison to the autocorrelation amplitude of the DHFR-GFP channel were 
obtained. By relating this value to the maximum attainable cross-correlation amplitude of 45 
% if all molecules were in a complex, these data showed that on average approximately 42 
% of the MTX-Cy5 was bound to the specific target protein DHFR-GFP. This in turn means 
that on average about 51 % of the MTX-Cy5 molecules that were bound to high-molecular 
targets were in complex with DHFR-GFP. Based on these numbers, the dissociation 
constant Kd for the interaction of MTX-Cy5 with DHFR-GFP was calculated. The dissociation 
constant of MTX-Cy5:DHFR-GFP determined in 10 HeLa-T-Rex cells was 125 ± 54 nM.  
 
 
6.4.5. Intracellular interactions of MTX-Cy5 in DHFR-GFP-expressing 
HEK293 cells 
 
In order to investigate to which degree this interaction pattern was a characteristic of the 
specific cell type, we next performed a corresponding set of measurements in HEK293 cells, 
expressing the DHFR-GFP fusion protein under control of the tetracycline promotor.  
In the absence of tetracycline, an intracellular DHFR-GFP concentration of 27 ± 14 nM was 
obtained. The concentrations were considerably lower than in HeLa-T-Rex cells, indicating 
that the tetracycline repressor was less leaky in HEK293 cells.  
Due to a lower electroporation efficiency, in this case the cells were electroporated with a 
solution containing 4 M MTX-Cy5. This led to typical cytosolic concentrations in the range of 
20-50 nM as determined by FCS.  
Again, the molecular brightness of GFP was highly constant within the samples and was 
approximately 2.3 ± 0.4 kHz. The fpm of the MTX-Cy5 varied between independent 
measurements. This variation was likely due to the interactions of the compound with high-
molecular weight structures that partially perturbed the autocorrelation measurements. The 
differences in fpm between HeLa and Hek cells most likely reflect the fact that both cell types 
were measured with different instruments. 
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For the analysis of the autocorrelation functions (Fig. 6.4.A), first the D of the fast component 
was fixed again to 200 s. In this case, the fast fraction accounted for 62 % of the 
autocorrelation amplitude; the slow component accounted for 38 % of MTX-Cy5 with a D of 
5.8 ± 2.6 ms (Fig. 6.4.B). The D of the slow component had a much stronger variation than 
for the HeLa cells. Therefore, the autocorrelation functions were also fitted with both 
diffusional autocorrelation times D kept variable. In that case, the fast fraction had an 
average D of 437 s representing 65 ± 20 % of the total amount of MTX-Cy5, the slow-
diffusing fraction a D of 132 ms (35 % of the total amount) (Fig. 6.4.C). The comparability of 
results obtained with both fitting procedures strongly indicates that the rapidly diffusing 
component corresponds to free compound and that in this case, more than half of the 
molecules diffused freely in the cytoplasm.  
The diffusional autocorrelation time D of the DHFR-GFP was 972 ± 294 s and thus slightly 
shorter than the one measured for HeLa cells. Thus, DHFR-GFP-bound MTX-Cy5 should 
have a diffusional autocorrelation time of about 1.6 ms. However, the bound compound 
showed a clearly higher diffusion time than expected for MTX-Cy5 bound to its 48 kDa target 
protein DHFR-GFP.  
The cross-correlation functions had amplitudes in the range of 7.2 ± 1.9 % of the one of the 
DHFR-GFP channel. These data indicated that on average a fraction of approximately 16 % 
of the MTX-Cy5 molecules were bound to the specific target protein DHFR-GFP. Given the 
total fraction of bound molecules of 38 % this result showed that on average only about 42 % 
of the MTX-Cy5 molecules bound to high-molecular targets was bound to DHFR-GFP, 
considerably less than for the HeLa cells. The average dissociation constant determined 
from measurements in 18 cells was 86 ± 45 nM. The Kd value as determined in the above 
experiments was measured in the presence of intrinsic dihydrofolate which competes with 
MTX-Cy5 for the binding sites on DHFR-GFP; thus the calculated binding constants are 
regarded as apparent Kd-values, that may differ from values determined in biochemical 
assays. 
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Fig. 6.4. Interactions of MTX-Cy5 in T-Rex-293 cells expressing DHFR-GFP. (A) Characteristic 
autocorrelation functions for DHFR-GFP (dashed line), MTX-C5 (dotted line) and the respective cross-
correlation function (solid line). (B,C) Dot plots of the relative fractions of each component versus the 
diffusional autocorrelation D of MTX-Cy5 derived from two-component fits with averages (cross) and 
standard deviations, in which the fast component was fixed to 200 s (B) or both diffusional 
autocorrelation times were allowed to vary (C). 
 
 
6.4.6. Intracellular binding of PD-Cy5 to high-molecular target structures 
in T-Rex-293 cells 
 
Finally, we were interested to investigate the intracellular interaction pattern for the 
hydrophobic compound PD-Cy5. T-Rex-293 cells expressed low amounts of ABL1-GFP in 
the range of 50-130 nM. The cells were electroporated with 0.2 M Parke-Davis compound. 
This led to PD-Cy5 concentrations of 320 ± 165 nM. These concentrations were significantly 
higher than the concentrations determined for MTX-Cy5. Also in measurements in which 
cells were directly incubated with the compound, much higher intracellular concentrations 
were reached. These results indicate that PD-Cy5 enters cells much more efficiently than 
MTX-Cy5 and that also during the electroporation procedure, for this hydrophobic compound, 
a direct crossing of the plasma membrane greatly contributed to cell entry. 
Again, the autocorrelation functions were analyzed with two-component fits in which the 
diffusion time D of the low-molecular weight component was fixed to 200 s. The determined 
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diffusion time D of the high-molecular weight fraction was high, mostly >10 ms, indicating an 
interaction between the compound and cellular structures that were significantly larger in 
molecular weight than the 60 kDa ABL1-GFP molecule. The diffusion time D of the ABL1-
GFP was 541 ± 112 s, and therefore shorter than the one for the DHFR-GFP. The high-
molecular fraction accounted for 70 ± 10 % of the total PD-Cy5 fraction. Additionally, a large 
fraction PD-Cy5 was bleached within the first seconds of the measurements indicating 
complete immobilization or trapping in vesicular structures. This strong bleaching of immobile 
fluorescence is therefore consistent with the distribution of fluorescence seen by confocal 
microscopy. 
 
 
Fig. 6.5. Interaction of PD-Cy5 in cells. (A,B) T-Rex-293 cells expressing ABL1-GFP were 
electroporated with PD-Cy5. (A) Characteristic autocorrelation functions for ABL1-GFP (dashed line) 
and PD-Cy5 (dotted line) and the cross-correlation function (solid line). (B) Dot plot of the relative 
contribution to the autocorrelation amplitude versus diffusional autocorrelation time D for PD-Cy5 with 
the fast component fixed to 200 s with averages (cross) and standard deviations.  
 
 
Interestingly, no cross-correlation could be observed in the cells, although previous 
experiments had shown a high affinity of binding in cell lysate with Kd values in the lower 
nanomolar range. Varying of the concentrations of the PD-Cy5 used for electroporation did 
not improve the result. The measurements with MTX-Cy5 had demonstrated the possibility to 
determine dissociation constants inside cells at a similar total degree of drug binding, as 
determined by FCS. Apparently, the fraction of molecules binding to their target was below 
the detection limit. We therefore conclude that off-target binding to other proteins and/or 
membranes inside the cell plays a much stronger role for PD-Cy5 than for MTX-Cy5. 
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6.5. Conclusions 
 
At present, detailed molecular analyses of the biological activity of drugs and drug 
candidates are restricted to in vitro tests. Cellular assays typically report on the activity of a 
compound in a very complex molecular context. Molecular interactions with the drug target 
and off-target binding are not addressed explicitly. In this work, we achieved such an 
analysis for small molecule anti-cancer drugs using laser scanning microscopy and a 
combination of fluorescence correlation spectroscopy (FCS) and fluorescence cross-
correlation spectroscopy (FCCS). For this purpose, Cy5-labeled molecules were 
synthesized. To our knowledge Cy5 has not been used for the labeling of small molecule 
drugs and their application in intracellular studies before. 
Confocal microscopy revealed that Pur-Cy5 and PD-Cy5 were taken up into HeLa and 
Hek293 cells efficiently, but localized in vesicular structures, whereas MTX-Cy5 entered the 
cells poorly, but showed a homogenous intracellular distribution. The localization and poor 
uptake for such short incubation times were consistent with results reported for Fluorescein-
MTX before (Kaufman et al., 1978). The subcellular distribution of PD and Pur demonstrated 
that sequestration in membranes and vesicular structures should be a limiting factor for the 
intracellular bioavailability of these compounds. Indeed, FCS revealed that a considerable 
fraction of the compound PD-Cy5 was bound to high-molecular weight structures. Cross-
correlations, reflecting an interaction of PD-Cy5 with with the ABL1-GFP target molecule 
could not be detected. If such particles were present their fraction in comparison to the non-
interacting molecules was too low to give rise to a cross-correlation amplitude. A too high 
number of non-interacting molecules limits the detectability of molecular interactions in FCCS 
as these lead to a decrease in the amplitude of the cross-correlation function. The ability of 
PD-Cy5 to interact with the target was confirmed in lysates of cells strongly overexpressing 
the fusion protein. However, in these cell lysates, a significant fraction of membranes had 
been removed by centrifugation prior to the FCCS measurements. 
In contrast to PD-Cy5, the interaction of the hydrophilic drug methotrexate MTX-Cy5 with its 
specific molecular target DHFR could be detected in living cells. The Kd values determined in 
the T-Rex-293 and HeLa-T-Rex cells were highly comparable, even though expression levels 
of the target protein varied by one order of magnitude and the overall interaction pattern was 
also different. In T-Rex cells, more than one third of the molecules were freely diffusive, in 
contrast to only 17 % in HeLa cells. Moreover, in T-Rex-293 cells, a lower fraction of MTX-
Cy5 specifically bound to DHFR-GFP. This reduced binding was accompanied by increased 
off-target binding to high molecular weight intracellular structures, as indicated by the longer 
and more heterogeneous D values.  
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It is a particular strength of FCCS to directly provide information on all molecular species in 
equilibrium. Therefore, a dissociation constant can be derived from one single measurement. 
In this case, in which off-target binding also occurred, the combination of FCS and FCCS 
proved to be highly powerful. Both measurement modalities provided complementary 
information on the fraction of bound molecules. With FCS, total binding of the compound was 
determined. FCCS selectively reported on those MTX-Cy5 molecules specifically bound to 
DHFR-GFP.  
The dissociation constants were about two orders of magnitude higher than the values 
determined in vitro for purified DHFR (Rajagopalan et al., 2002; Mayer et al., 1986; Remy 
and Michnick, 2001). A major reason for this difference will be the presence of endogenous 
dihydrofolate (DHF). Whereas in resting cells the intracellular DHF concentration is in the 
lower nanomolar range, it can increase over several orders of magnitudes in proliferating 
cells (Assaraf, 2007). Both, Hek293 and HeLa cells are highly proliferating cell lines, so it is 
reasonable to assume a rather high DHF concentration. 
Next to the fusion protein, endogenous DHFR is also present inside the cells. However, since 
the binding of MTX-Cy5 to DHFR-GFP was measured in equilibrium, this endogenous 
protein will not affect the apparent Kd values measured for DHFR-GFP:MTX-Cy5 by FCCS. 
Instead, we may assume that endogenous DHFR may account at least for a fraction of the 
off-target binding, determined by the differences of bound fraction determined with FCS and 
FCCS. 
In summary, this study demonstrates the potential of a combination of FCS and FCCS to 
define target and off-target binding profiles of drugs inside cells. Exploitation of the leakiness 
of inducible promoters turned out as an important technical detail to reliably achieve low 
expression levels of fusion proteins also in only transiently transfected cells. 
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7. Appendix 
 
7.1. Macro for the quantification of cellular fluorescence 
 
The macro was set up on ImageJ 1.41 based on Java 1.6.0_10. The threshold (8th row from 
the top) was adjusted according to each experiment independently. 
 
close(); 
run("Duplicate...", "title=1"); 
run("Smooth"); 
run("Duplicate...", "title=2"); 
run("Set Scale...", "distance=0 known=1 pixel=1 unit=cm global"); 
setAutoThreshold(); 
//run("Threshold..."); 
setThreshold(6, 255); 
run("Analyze Particles...", "size=3000-infinity circularity=0.00-1.00 show=Masks"); 
run("Watershed"); 
run("Analyze Particles...", "size=3000-infinity circularity=0.00-1.00 show=Masks 
add"); 
selectWindow("1"); 
setOption("Show All",true); 
run("Set Measurements...", "area mean standard min circularity median redirect=None 
decimal=3"); 
roiManager("Measure"); 
saveAs("Measurements", "C:\\Documents and 
Settings\\z718203\\Desktop\\Results.xls"); 
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Fig 7.1. Automatized image analysis procedure. The (A) raw image is smoothed (B). A threshold is set 
in order to distinguish between cells and background (C). From these data a binary mask is generated 
(D) and a minimal size threshold is set in order to exclude single bright pixels from being detected as 
cells. The conduction of a watershed fit enables to distinguish between adjacent cells (E). The cells 
are identified as single objects in the binary mask (F). Finally, the mask is applied on the smoothed 
original image (G) and the cellular brightness of the particles is determined. 
 
8. REFERENCES 
 
139 
8. References 
 
 1.  Almela, M. J., Torres, P. A., Lozano, S. und Herreros, E. (2009). Characterization of 
the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives. Toxicol.In 
Vitro. 
 2.  Amyere, M., Mettlen, M., Van Der, S. P., Platek, A., Payrastre, B., Veithen, A. und 
Courtoy, P. J. (2002). Origin, originality, functions, subversions and molecular 
signalling of macropinocytosis. Int.J.Med.Microbiol., 291, 487-494. 
 3.  Anderson, B. F., Baker, H. M., Norris, G. E., Rumball, S. V. und Baker, E. N. (1990). 
Apolactoferrin structure demonstrates ligand-induced conformational change in 
transferrins. Nature, 344, 784-787. 
 4.  Assaraf, Y. G. (2007). Molecular basis of antifolate resistance. Cancer Metastasis 
Rev., 26, 153-181. 
 5.  Augustinus (398). Confessiones, Liber XI. caput 24. 
 6.  Bacia, K., Kim, S. A. und Schwille, P. (2006). Fluorescence cross-correlation 
spectroscopy in living cells. Nat.Methods, 3, 83-89. 
 7.  Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., 
Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., 
Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, 
B. und Drewes, G. (2007). Quantitative chemical proteomics reveals mechanisms of 
action of clinical ABL kinase inhibitors. Nat.Biotechnol.. 
 8.  Bareford, L. M. und Swaan, P. W. (2007). Endocytic mechanisms for targeted drug 
delivery. Adv.Drug Deliv.Rev., 59, 748-758. 
 9.  Barr, A. J., Ugochukwu, E., Lee, W. H., King, O. N., Filippakopoulos, P., Alfano, I., 
Savitsky, P., Burgess-Brown, N. A., Muller, S. und Knapp, S. (2009). Large-scale 
structural analysis of the classical human protein tyrosine phosphatome. Cell, 136, 
352-363. 
 10.  Baudendistel, N., Muller, G., Waldeck, W., Angel, P. und Langowski, J. (2005). Two-
hybrid fluorescence cross-correlation spectroscopy detects protein-protein 
interactions in vivo. Chemphyschem., 6, 984-990. 
 11.  Becker, F., Murthi, K., Smith, C., Come, J., Costa-Roldan, N., Kaufmann, C., Hanke, 
U., Degenhart, C., Baumann, S., Wallner, W., Huber, A., Dedier, S., Dill, S., Kinsman, 
D., Hediger, M., Bockovich, N., Meier-Ewert, S., Kluge, A. F. und Kley, N. (2004). A 
three-hybrid approach to scanning the proteome for targets of small molecule kinase 
inhibitors. Chem.Biol., 11, 211-223. 
8. REFERENCES 
 
140 
 12.  Bellamy, W., Takase, M., Yamauchi, K., Wakabayashi, H., Kawase, K. und Tomita, 
M. (1992). Identification of the bactericidal domain of lactoferrin. 
Biochim.Biophys.Acta, 1121, 130-136. 
 13.  Berg, T. (2008). Small-molecule inhibitors of protein-protein interactions. 
Curr.Opin.Drug Discov.Devel., 11, 666-674. 
 14.  Berland, K. M., So, P. T. und Gratton, E. (1995). Two-photon fluorescence correlation 
spectroscopy: method and application to the intracellular environment. Biophys.J., 68, 
694-701. 
 15.  Boskey, A. L., Camacho, N. P., Mendelsohn, R., Doty, S. B. und Binderman, I. 
(1992). FT-IR microscopic mappings of early mineralization in chick limb bud 
mesenchymal cell cultures. Calcif.Tissue Int., 51, 443-448. 
 16.  Bracci, L., Falciani, C., Lelli, B., Lozzi, L., Runci, Y., Pini, A., De Montis, M. G., 
Tagliamonte, A. und Neri, P. (2003). Synthetic peptides in the form of dendrimers 
become resistant to protease activity. J Biol.Chem., 278, 46590-46595. 
 17.  Brandner, G., Mueller, N., Graessmann, A., Graessmann, M., Niebel, J. und 
Hoffmann, H. (1974). Inhibition by interferon of SV40 tumor antigen formation in cells 
injected with SV40 cRNA transcribed in vitro. FEBS Lett., 39, 249-251. 
 18.  Bray, B. L. (2003). Large-scale manufacture of peptide therapeutics by chemical 
synthesis. Nat.Rev.Drug Discov., 2, 587-593. 
 19.  Brinckerhoff, L. H., Kalashnikov, V. V., Thompson, L. W., Yamshchikov, G. V., Pierce, 
R. A., Galavotti, H. S., Engelhard, V. H. und Slingluff, C. L., Jr. (1999). Terminal 
modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) 
peptide: implications for peptide vaccines. Int.J Cancer, 83, 326-334. 
 20.  Brock, Fischer, Fotin-Mleczek and Hufnagel. (2007) "Peptides Useful as Cell-
Penetrating Peptides".  European Patent [EP1966240] 
 21.  Brock, R., Hink, M. A. und Jovin, T. M. (1998). Fluorescence correlation microscopy 
of cells in the presence of autofluorescence. Biophys.J., 75, 2547-2557. 
 22.  Brock, R. und Jovin, T. M. (1998). Fluorescence correlation microscopy (FCM)-
fluorescence correlation spectroscopy (FCS) taken into the cell. Cell Mol.Biol.(Noisy.-
le-grand), 44, 847-856. 
 23.  Brock, R., Vamosi, G., Vereb, G. und Jovin, T. M. (1999). Rapid characterization of 
green fluorescent protein fusion proteins on the molecular and cellular level by 
fluorescence correlation microscopy. Proc.Natl.Acad.Sci U.S.A, 96, 10123-10128. 
 24.  Buffy, J. J., Waring, A. J., Lehrer, R. I. und Hong, M. (2003). Immobilization and 
aggregation of the antimicrobial peptide protegrin-1 in lipid bilayers investigated by 
solid-state NMR. Biochemistry, 42, 13725-13734. 
8. REFERENCES 
 
141 
 25.  Buschmann, Kramer, Koberling, Macdonald and Ruttinger. (2007) "Quantitative FCS: 
Determination of the Confocal Volume by FCS and Bead Scanning with the 
MicroTime 200".  PicoQuant, AppNote Quantitative FCS , 1-8 
 26.  Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A. und 
Sutherland, R. L. (2008). Cell cycle machinery: links with genesis and treatment of 
breast cancer. Adv.Exp.Med.Biol., 630, 189-205. 
 27.  Caligiuri, M., Becker, F., Murthi, K., Kaplan, F., Dedier, S., Kaufmann, C., Machl, A., 
Zybarth, G., Richard, J., Bockovich, N., Kluge, A. und Kley, N. (2005). A proteome-
wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of 
cell cycle progression. Chem.Biol., 12, 1103-1115. 
 28.  Capdeville, R., Buchdunger, E., Zimmermann, J. und Matter, A. (2002). Glivec 
(STI571, imatinib), a rationally developed, targeted anticancer drug. Nat.Rev.Drug 
Discov., 1, 493-502. 
 29.  Casnellie, J. E. (1991). Assay of protein kinases using peptides with basic residues 
for phosphocellulose binding. Methods Enzymol., 200, 115-120. 
 30.  Celis, J. E. (1984). Microinjection of somatic cells with micropipettes: comparison with 
other transfer techniques. Biochem.J., 223, 281-291. 
 31.  Chang, M., Chou, J. C. und Lee, H. J. (2005). Cellular internalization of fluorescent 
proteins via arginine-rich intracellular delivery peptide in plant cells. Plant Cell Physiol, 
46, 482-488. 
 32.  Chapman, E. und Wong, C. H. (2002). A pH sensitive colorometric assay for the high-
throughput screening of enzyme inhibitors and substrates: a case study using 
kinases. Bioorg.Med.Chem, 10, 551-555. 
 33.  Chauhan, S. S., Liang, X. J., Su, A. W., Pai-Panandiker, A., Shen, D. W., Hanover, J. 
A. und Gottesman, M. M. (2003). Reduced endocytosis and altered lysosome 
function in cisplatin-resistant cell lines. Br.J.Cancer, 88, 1327-1334. 
 34.  Chaurand, P., Schwartz, S. A., Reyzer, M. L. und Caprioli, R. M. (2005). Imaging 
mass spectrometry: principles and potentials. Toxicol.Pathol., 33, 92-101. 
 35.  Chen, R. F. und Knutson, J. R. (1988). Mechanism of fluorescence concentration 
quenching of carboxyfluorescein in liposomes: energy transfer to nonfluorescent 
dimers. Anal.Biochem., 172, 61-77. 
 36.  Cheng, Y. und Prusoff, W. H. (1973). Relationship between the inhibition constant 
(K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an 
enzymatic reaction. Biochem.Pharmacol., 22, 3099-3108. 
 37.  Choi, M., Rolle, S., Wellner, M., Cardoso, M. C., Scheidereit, C., Luft, F. C. und 
Kettritz, R. (2003). Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide 
accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. 
Blood, 102, 2259-2267. 
8. REFERENCES 
 
142 
 38.  Chorev, M., Shavitz, R., Goodman, M., Minick, S. und Guillemin, R. (1979). Partially 
modified retro-inverso-enkephalinamides: topochemical long-acting analogs in vitro 
and in vivo. Science, 204, 1210-1212. 
 39.  Chrisman, T. D., Sobo, G. E. und Exton, J. H. (1984). The Mg2+ requirements of 
nonactivated and activated rat liver phosphorylase kinase. Inhibition of the activated 
form by free Mg2+. FEBS Lett., 167, 295-300. 
 40.  Chugh, A. und Eudes, F. (2007). Translocation and nuclear accumulation of 
monomer and dimer of HIV-1 Tat basic domain in triticale mesophyll protoplasts. 
Biochim.Biophys.Acta, 1768, 419-426. 
 41.  Chugh, A. und Eudes, F. (2008). Cellular uptake of cell-penetrating peptides pVEC 
and transportan in plants. J.Pept.Sci., 14, 477-481. 
 42.  Clegg, R. M. (1995). Fluorescence resonance energy transfer. Curr.Opin.Biotechnol., 
6, 103-110. 
 43.  Conner, S. D. und Schmid, S. L. (2003). Regulated portals of entry into the cell. 
Nature, 422, 37-44. 
 44.  Cooper, M. A. (2002). Optical biosensors in drug discovery. Nat.Rev.Drug Discov., 1, 
515-528. 
 45.  Cooper, W. J. und Waters, M. L. (2005). Molecular recognition with designed peptides 
and proteins. Curr.Opin.Chem.Biol., 9, 627-631. 
 46.  Cory, S., Huang, D. C. und Adams, J. M. (2003). The Bcl-2 family: roles in cell 
survival and oncogenesis. Oncogene, 22, 8590-8607. 
 47.  Davies, S. P., Reddy, H., Caivano, M. und Cohen, P. (2000). Specificity and 
mechanism of action of some commonly used protein kinase inhibitors. Biochem.J., 
351, 95-105. 
 48.  Dawson, P. E., Muir, T. W., Clark-Lewis, I. und Kent, S. B. (1994). Synthesis of 
proteins by native chemical ligation. Science, 266, 776-779. 
 49.  de Lange, J. H., Schipper, N. W., Schuurhuis, G. J., ten Kate, T. K., van Heijningen, 
T. H., Pinedo, H. M., Lankelma, J. und Baak, J. P. (1992). Quantification by laser 
scan microscopy of intracellular doxorubicin distribution. Cytometry, 13, 571-576. 
 50.  De, S. K. und Contreras, R. (2005). Human antimicrobial peptides: defensins, 
cathelicidins and histatins. Biotechnol.Lett., 27, 1337-1347. 
 51.  Derossi, D., Joliot, A. H., Chassaing, G. und Prochiantz, A. (1994). The third helix of 
the Antennapedia homeodomain translocates through biological membranes. J 
Biol.Chem, 269, 10444-10450. 
8. REFERENCES 
 
143 
 52.  Digman, M. A., Wiseman, P. W., Horwitz, A. R. und Gratton, E. (2009). Detecting 
protein complexes in living cells from laser scanning confocal image sequences by 
the cross correlation raster image spectroscopy method. Biophys.J., 96, 707-716. 
 53.  Ding, H., Prodinger, W. M. und Kopecek, J. (2006). Identification of CD21-binding 
peptides with phage display and investigation of binding properties of HPMA 
copolymer-peptide conjugates. Bioconjug.Chem., 17, 514-523. 
 54.  Doherty, T., Waring, A. J. und Hong, M. (2008). Dynamic structure of disulfide-
removed linear analogs of tachyplesin-I in the lipid bilayer from solid-state NMR. 
Biochemistry, 47, 1105-1116. 
 55.  Donovan, M. D., Flynn, G. L. und Amidon, G. L. (1990a). Absorption of polyethylene 
glycols 600 through 2000: the molecular weight dependence of gastrointestinal and 
nasal absorption. Pharm.Res., 7, 863-868. 
 56.  Donovan, M. D., Flynn, G. L. und Amidon, G. L. (1990b). The molecular weight 
dependence of nasal absorption: the effect of absorption enhancers. Pharm.Res., 7, 
808-815. 
 57.  Drews, J. (2000). Drug discovery: a historical perspective. Science, 287, 1960-1964. 
 58.  Drews, J. und Ryser, S. (1997). The role of innovation in drug development. 
Nat.Biotechnol., 15, 1318-1319. 
 59.  Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B. und Papahadjopoulos, D. 
(1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. 
Pharmacol.Rev., 51, 691-743. 
 60.  Du, C., Fang, M., Li, Y., Li, L. und Wang, X. (2000). Smac, a mitochondrial protein 
that promotes cytochrome c-dependent caspase activation by eliminating IAP 
inhibition. Cell, 102, 33-42. 
 61.  Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. und Brock, R. (2007). A 
comprehensive model for the cellular uptake of cationic cell-penetrating peptides. 
Traffic., 8, 848-866. 
 62.  Duncan, R. (2003). The dawning era of polymer therapeutics. Nat.Rev Drug Discov., 
2, 347-360. 
 63.  Duncan, R., Coatsworth, J. K. und Burtles, S. (1998). Preclinical toxicology of a novel 
polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum.Exp.Toxicol., 
17, 93-104. 
 64.  Dupont, E., Prochiantz, A. und Joliot, A. (2007). Identification of a signal peptide for 
unconventional secretion. Journal of Biological Chemistry, 282, 8994-9000. 
8. REFERENCES 
 
144 
 65.  El-Andaloussi, S., Johansson, H. J., Lundberg, P. und Langel, U. (2006). Induction of 
splice correction by cell-penetrating peptide nucleic acids. J.Gene Med., 8, 1262-
1273. 
 66.  Elass-Rochard, E., Roseanu, A., Legrand, D., Trif, M., Salmon, V., Motas, C., 
Montreuil, J. und Spik, G. (1995). Lactoferrin-lipopolysaccharide interaction: 
involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding 
to Escherichia coli 055B5 lipopolysaccharide. Biochem.J., 312 ( Pt 3), 839-845. 
 67.  Ellis, R. J. (2001). Macromolecular crowding: obvious but underappreciated. Trends 
Biochem.Sci., 26, 597-604. 
 68.  Elson, E. L. und Webb, W. W. (1975). Concentration correlation spectroscopy: a new 
biophysical probe based on occupation number fluctuations. Annu.Rev 
Biophys.Bioeng., 4, 311-334. 
 69.  Ertl, P., Rohde, B. und Selzer, P. (2000). Fast calculation of molecular polar surface 
area as a sum of fragment-based contributions and its application to the prediction of 
drug transport properties. J.Med.Chem., 43, 3714-3717. 
 70.  Esposito, P., Barbero, L., Caccia, P., Caliceti, P., D'Antonio, M., Piquet, G. und 
Veronese, F. M. (2003). PEGylation of growth hormone-releasing hormone (GRF) 
analogues. Adv.Drug Deliv.Rev., 55, 1279-1291. 
 71.  Fasano, A. und Uzzau, S. (1997). Modulation of intestinal tight junctions by Zonula 
occludens toxin permits enteral administration of insulin and other macromolecules in 
an animal model. J.Clin.Invest, 99, 1158-1164. 
 72.  Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B. und Barsoum, J. 
(1994). Tat-mediated delivery of heterologous proteins into cells. 
Proc.Natl.Acad.Sci.U.S.A, 91, 664-668. 
 73.  Fischer, P. M., Krausz, E. und Lane, D. P. (2001). Cellular delivery of impermeable 
effector molecules in the form of conjugates with peptides capable of mediating 
membrane translocation. Bioconjug.Chem., 12, 825-841. 
 74.  Fischer, R., Fotin-Mleczek, M., Hufnagel, H. und Brock, R. (2005). Break on through 
to the other side-biophysics and cell biology shed light on cell-penetrating peptides. 
Chembiochem., 6, 2126-2142. 
 75.  Fischer, R., Kohler, K., Fotin-Mleczek, M. und Brock, R. (2004). A stepwise dissection 
of the intracellular fate of cationic cell-penetrating peptides. Journal of Biological 
Chemistry, 279, 12625-12635. 
 76.  Fischer, R., Mader, O., Jung, G. und Brock, R. (2003). Extending the applicability of 
carboxyfluorescein in solid-phase synthesis. Bioconjug.Chem., 14, 653-660. 
 77.  Fischer, R., Waizenegger, T., Kohler, K. und Brock, R. (2002). A quantitative 
validation of fluorophore-labelled cell-permeable peptide conjugates: fluorophore and 
cargo dependence of import. Biochim.Biophys.Acta, 1564, 365-374. 
8. REFERENCES 
 
145 
 78.  Flanagan, M. T. und Pantell, R. H. (1984). Surface plasmon resonance and 
immunosensors. Electron Lett., 968-970. 
 79.  Foerg, C. und Merkle, H. P. (2008). On the biomedical promise of cell penetrating 
peptides: limits versus prospects. J Pharm.Sci., 97, 144-162. 
 80.  Földes-Papp, Z. (2005). How the Molecule Number Is Corectly Quantified in Two-
Color Fluorescence Cross-Correlating Spectroscopy: Corrections for Cross-Talk and 
Quenching in Experiments. Curr.Pharmaceutical Biotechnology, 6, 437-444. 
 81.  Fotin-Mleczek, M., Fischer, R. und Brock, R. (2005a). Endocytosis and cationic cell-
penetrating peptides--a merger of concepts and methods. Curr.Pharm.Des, 11, 3613-
3628. 
 82.  Fotin-Mleczek, M., Welte, S., Mader, O., Duchardt, F., Fischer, R., Hufnagel, H., 
Scheurich, P. und Brock, R. (2005b). Cationic cell-penetrating peptides interfere with 
TNF signalling by induction of TNF receptor internalization. J Cell Sci, 118, 3339-
3351. 
 83.  Frackenpohl, J., Arvidsson, P. I., Schreiber, J. V. und Seebach, D. (2001). The 
outstanding biological stability of beta- and gamma-peptides toward proteolytic 
enzymes: an in vitro investigation with fifteen peptidases. Chembiochem., 2, 445-455. 
 84.  Fuchs, S. M. und Raines, R. T. (2004). Pathway for polyarginine entry into 
mammalian cells. Biochemistry, 43, 2438-2444. 
 85.  Fulda, S., Wick, W., Weller, M. und Debatin, K. M. (2002a). Smac agonists sensitize 
for Apo2L/T. Nat.Med., 8, 808-815. 
 86.  Fulda, S., Wick, W., Weller, M. und Debatin, K. M. (2002b). Smac agonists sensitize 
for Apo2L/Trail- or anticancer drug-induced apoptosis and induce regression of 
malignant glioma in vivo. Nat.Med., 8, 808-815. 
 87.  Gapski, G. R., Whiteley, J. M., Rader, J. I., Cramer, P. L., Henderson, G. B., Neef, V. 
und Huennekens, F. M. (1975). Synthesis of a fluorescent derivative of amethopterin. 
J.Med.Chem., 18, 526-528. 
 88.  Gehl, J. (2003). Electroporation: theory and methods, perspectives for drug delivery, 
gene therapy and research. Acta Physiol Scand., 177, 437-447. 
 89.  Ghose, A. K., Viswanadhan, V. N. und Wendoloski, J. J. (1999). A knowledge-based 
approach in designing combinatorial or medicinal chemistry libraries for drug 
discovery. 1. A qualitative and quantitative characterization of known drug databases. 
J.Comb.Chem., 1, 55-68. 
 90.  Gifford, J. L., Hunter, H. N. und Vogel, H. J. (2005). Lactoferricin: a lactoferrin-derived 
peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell 
Mol.Life Sci., 62, 2588-2598. 
8. REFERENCES 
 
146 
 91.  Gohlke, H. und Klebe, G. (2002). Approaches to the description and prediction of the 
binding affinity of small-molecule ligands to macromolecular receptors. 
Angew.Chem.Int.Ed Engl., 41, 2644-2676. 
 92.  Goldberg, M. und Gomez-Orellana, I. (2003). Challenges for the oral delivery of 
macromolecules. Nat.Rev.Drug Discov., 2, 289-295. 
 93.  Goldsmith, K. C., Liu, X., Dam, V., Morgan, B. T., Shabbout, M., Cnaan, A., Letai, A., 
Korsmeyer, S. J. und Hogarty, M. D. (2006). BH3 peptidomimetics potently activate 
apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene, 25, 
4525-4533. 
 94.  Goodwin, R. J., Pennington, S. R. und Pitt, A. R. (2008). Protein and peptides in 
pictures: imaging with MALDI mass spectrometry. Proteomics., 8, 3785-3800. 
 95.  Gordon, D. J., Sciarretta, K. L. und Meredith, S. C. (2001). Inhibition of beta-
amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-
amyloid congeners containing N-methyl amino acids at alternate residues. 
Biochemistry, 40, 8237-8245. 
 96.  Gotter, B., Faubel, W. und Neubert, R. H. (2008). Optical methods for measurements 
of skin penetration. Skin Pharmacol.Physiol, 21, 156-165. 
 97.  Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. 
H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S. H., Lockhart, D. J. und 
Schultz, P. G. (1998). Exploiting chemical libraries, structure, and genomics in the 
search for kinase inhibitors. Science, 281, 533-538. 
 98.  Griffith, O. W. (1986). Beta-amino acids: mammalian metabolism and utility as alpha-
amino acid analogues. Annu.Rev Biochem, 55, 855-878. 
 99.  Groenink, J., Walgreen-Weterings, E., van 't, H. W., Veerman, E. C. und Nieuw 
Amerongen, A. V. (1999). Cationic amphipathic peptides, derived from bovine and 
human lactoferrins, with antimicrobial activity against oral pathogens. FEMS 
Microbiol.Lett., 179, 217-222. 
 100.  Gschwendt, M., Muller, H. J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G. und 
Marks, F. (1994). Rottlerin, a novel protein kinase inhibitor. Biochem.Biophys.Res 
Commun., 199, 93-98. 
 101.  Haag, R. und Vogtle, F. (2004). Highly branched macromolecules at the interface of 
chemistry, biology, physics, and medicine. Angew.Chem Int.Ed Engl., 43, 272-273. 
 102.  Hällbrink, Kilk, Elmquist, Lundberg, Lindgren, Jiang, Pooga, Soomets and Langel. 
(2005) "Prediction of cell-penetrating peptides".  Int.J.Pep.Res.Ther. 11, 249-259 
 103.  Harris, J. M. und Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. 
Nat.Rev.Drug Discov., 2, 214-221. 
8. REFERENCES 
 
147 
 104.  Herman, S., Zurgil, N. und Deutsch, M. (2005). Low dose methotrexate induces 
apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a 
greater extent than in monocytic lines. Inflamm.Res., 54, 273-280. 
 105.  Hink, M. A., Griep, R. A., Borst, J. W., van, H. A., Eppink, M. H., Schots, A. und 
Visser, A. J. (2000). Structural dynamics of green fluorescent protein alone and fused 
with a single chain Fv protein. Journal of Biological Chemistry, 275, 17556-17560. 
 106.  Hintersteiner, M. und Auer, M. (2008). Single-bead, single-molecule, single-cell 
fluorescence: technologies for drug screening and target validation. 
Ann.N.Y.Acad.Sci., 1130, 1-11. 
 107.  Horejsi, V., Zhang, W. und Schraven, B. (2004). Transmembrane adaptor proteins: 
organizers of immunoreceptor signalling. Nat.Rev.Immunol., 4, 603-616. 
 108.  Hruby, V. J. und Balse, P. M. (2000). Conformational and topographical 
considerations in designing agonist peptidomimetics from peptide leads. 
Curr.Med.Chem., 7, 945-970. 
 109.  Huang, W., Lee, S. L. und Yu, L. X. (2009). Mechanistic approaches to predicting oral 
drug absorption. AAPS.J., 11, 217-224. 
 110.  Hunter, H. N., Demcoe, A. R., Jenssen, H., Gutteberg, T. J. und Vogel, H. J. (2005). 
Human lactoferricin is partially folded in aqueous solution and is better stabilized in a 
membrane mimetic solvent. Antimicrob.Agents Chemother., 49, 3387-3395. 
 111.  Imming, P., Sinning, C. und Meyer, A. (2006). Drugs, their targets and the nature and 
number of drug targets. Nat.Rev.Drug Discov., 5, 821-834. 
 112.  IUPAC (1984). IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). 
Nomenclature and symbolism for amino acids and peptides. Recommendations 1983. 
Eur.J.Biochem., 138, 9-37. 
 113.  Jarver, P., Langel, K., El Andaloussi, S. und Langel, U. (2007). Applications of cell-
penetrating peptides in regulation of gene expression. Biochem.Soc.Trans., 35, 770-
774. 
 114.  Kapp, T., Muller, S. und Gust, R. (2006). Dinuclear alkylamine platinum(II) complexes 
of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): influence of endocytosis and 
copper and organic cation transport systems on cellular uptake. ChemMedChem., 1, 
560-564. 
 115.  Kastrup, L., Blom, H., Eggeling, C. und Hell, S. W. (2005). Fluorescence fluctuation 
spectroscopy in subdiffraction focal volumes. Phys.Rev.Lett., 94, 178104. 
 116.  Kaufman, R. J., Bertino, J. R. und Schimke, R. T. (1978). Quantitation of dihydrofolate 
reductase in individual parental and methotrexate-resistant murine cells. Use of a 
fluorescence activated cell sorter. Journal of Biological Chemistry, 253, 5852-5860. 
8. REFERENCES 
 
148 
 117.  Kawamoto, T. (1990). Light microscopic autoradiography for study of early changes in 
the distribution of water-soluble materials. J.Histochem.Cytochem., 38, 1805-1814. 
 118.  Kawamura, K. S., Sung, M., Bolewska-Pedyczak, E. und Gariepy, J. (2006). Probing 
the impact of valency on the routing of arginine-rich peptides into eukaryotic cells. 
Biochemistry, 45, 1116-1127. 
 119.  Kelly, S. M., Jess, T. J. und Price, N. C. (2005). How to study proteins by circular 
dichroism. Biochim.Biophys.Acta, 1751, 119-139. 
 120.  Kim, S. A., Heinze, K. G. und Schwille, P. (2007). Fluorescence correlation 
spectroscopy in living cells. Nat.Methods, 4, 963-973. 
 121.  Knight, D. E. und Scrutton, M. C. (1986). Gaining access to the cytosol: the technique 
and some applications of electropermeabilization. Biochem.J., 234, 497-506. 
 122.  Knight, Z. A. und Shokat, K. M. (2005). Features of selective kinase inhibitors. Chem 
Biol., 12, 621-637. 
 123.  Kohler, K., Ganser, A., Andre, T., Roth, G., Grosse-Hovest, L., Jung, G. und Brock, R. 
(2008). Stimulus dependence of the action of small-molecule inhibitors in the 
CD3/CD28 signalling network. ChemMedChem., 3, 1404-1411. 
 124.  Koopman, W. J., Hink, M. A., Verkaart, S., Visch, H. J., Smeitink, J. A. und Willems, 
P. H. (2007). Partial complex I inhibition decreases mitochondrial motility and 
increases matrix protein diffusion as revealed by fluorescence correlation 
spectroscopy. Biochim.Biophys.Acta, 1767, 940-947. 
 125.  Kopecek, J. und Bazilova, H. (1973). Poly[N-(2-hydroxypropyl)methacrylamide] I. 
Radical polymerisation and copolymerisation. Eur.Polym., 9, 7-14. 
 126.  Kopecek, J., Kopeckova, P., Minko, T. und Lu, Z.-R. (2000). HPMA copolymer-
anticancer drug conjugates: design, activity, and mechanism of action. European 
Journal of Pharmaceutics and Biopharmaceutics, 50, 61-81. 
 127.  Koppel, D. E. (1974). Statistical accuracy in fluorescence correlation spectroscopy. 
Phys.Rev.A, 10, 1938-1945. 
 128.  Korn, K. und Krausz, E. (2007). Cell-based high-content screening of small-molecule 
libraries. Curr.Opin.Chem.Biol., 11, 503-510. 
 129.  Kosuge, M., Takeuchi, T., Nakase, I., Jones, A. T. und Futaki, S. (2008). Cellular 
internalization and distribution of arginine-rich peptides as a function of extracellular 
Peptide concentration, serum, and plasma membrane associated proteoglycans. 
Bioconjug.Chem., 19, 656-664. 
 130.  Kovar, M., Strohalm, J., Etrych, T., Ulbrich, K. und Rihova, B. (2002). Star structure of 
antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric 
8. REFERENCES 
 
149 
conjugate for targeted drug delivery with potent antitumor effect. Bioconjug.Chem, 13, 
206-215. 
 131.  Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D. und Moore, 
C. W. (2000). Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-
d]pyrimidine tyrosine kinase inhibitors. Biochem.Pharmacol., 60, 885-898. 
 132.  Kroczek, R. A., Mages, H. W. und Hutloff, A. (2004). Emerging paradigms of T-cell 
co-stimulation. Curr.Opin.Immunol., 16, 321-327. 
 133.  Kubinyi, H. (1994). [The key and the lock. I. The basis of drug action]. Pharm.Unserer 
Zeit, 23, 158-168. 
 134.  Kuwana, T., Mackey, M. R., Perkins, G., Ellisman, M. H., Latterich, M., Schneiter, R., 
Green, D. R. und Newmeyer, D. D. (2002). Bid, Bax, and lipids cooperate to form 
supramolecular openings in the outer mitochondrial membrane. Cell, 111, 331-342. 
 135.  Lang, P., Yeow, K., Nichols, A. und Scheer, A. (2006). Cellular imaging in drug 
discovery. Nat.Rev.Drug Discov., 5, 343-356. 
 136.  Langel, U. 2002. Cell Penetrating Peptides: Processes and Applications., Boca 
Raton: CRC Press. 
 137.  Lankelma, J., Dekker, H., Luque, F. R., Luykx, S., Hoekman, K., van, d., V, van Diest, 
P. J. und Pinedo, H. M. (1999). Doxorubicin gradients in human breast cancer. 
Clin.Cancer Res., 5, 1703-1707. 
 138.  Lasch, P. und Naumann, D. (2006). Spatial resolution in infrared microspectroscopic 
imaging of tissues. Biochim.Biophys.Acta, 1758, 814-829. 
 139.  Law, B., Quinti, L., Choi, Y., Weissleder, R. und Tung, C. H. (2006). A mitochondrial 
targeted fusion peptide exhibits remarkable cytotoxicity. Mol.Cancer Ther., 5, 1944-
1949. 
 140.  Leader, B., Baca, Q. J. und Golan, D. E. (2008). Protein therapeutics: a summary and 
pharmacological classification. Nat.Rev.Drug Discov., 7, 21-39. 
 141.  Lee, K. C., Moon, S. C., Park, M. O., Lee, J. T., Na, D. H., Yoo, S. D., Lee, H. S. und 
DeLuca, P. P. (1999). Isolation, characterization, and stability of positional isomers of 
mono-PEGylated salmon calcitonins. Pharm.Res., 16, 813-818. 
 142.  Legrand, D., Mazurier, J., Elass, A., Rochard, E., Vergoten, G., Maes, P., Montreuil, 
J. und Spik, G. (1992). Molecular interactions between human lactotransferrin and the 
phytohemagglutinin-activated human lymphocyte lactotransferrin receptor lie in two 
loop-containing regions of the N-terminal domain I of human lactotransferrin. 
Biochemistry, 31, 9243-9251. 
 143.  Legrand, D., Pierce, A., Elass, E., Carpentier, M., Mariller, C. und Mazurier, J. (2008). 
Lactoferrin structure and functions. Adv.Exp.Med.Biol., 606, 163-194. 
8. REFERENCES 
 
150 
 144.  Lehel, C., niel-Issakani, S., Brasseur, M. und Strulovici, B. (1997). A 
chemiluminescent microtiter plate assay for sensitive detection of protein kinase 
activity. Anal.Biochem., 244, 340-346. 
 145.  Levay, P. F. und Viljoen, M. (1995). Lactoferrin: a general review. Haematologica, 80, 
252-267. 
 146.  Leveugle, B., Mazurier, J., Legrand, D., Mazurier, C., Montreuil, J. und Spik, G. 
(1993). Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. 
Eur.J Biochem., 213, 1205-1211. 
 147.  Lewin, M., Carlesso, N., Tung, C. H., Tang, X. W., Cory, D., Scadden, D. T. und 
Weissleder, R. (2000). Tat peptide-derivatized magnetic nanoparticles allow in vivo 
tracking and recovery of progenitor cells. Nat.Biotechnol., 18, 410-414. 
 148.  Li, S. S. (2005). Specificity and versatility of SH3 and other proline-recognition 
domains: structural basis and implications for cellular signal transduction. Biochem.J., 
390, 641-653. 
 149.  Liebecq, C. Ed. 1992. Biochemical Nomenclature and Related Documents. 
 150.  Lipinski, C. A., Lombardo, F., Dominy, B. W. und Feeney, P. J. (2001). Experimental 
and computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv.Drug Deliv.Rev., 46, 3-26. 
 151.  Lippincott-Schwartz, J., Snapp, E. und Kenworthy, A. (2001). Studying protein 
dynamics in living cells. Nat.Rev.Mol.Cell Biol., 2, 444-456. 
 152.  Liu, B. A., Jablonowski, K., Raina, M., Arce, M., Pawson, T. und Nash, P. D. (2006). 
The human and mouse complement of SH2 domain proteins-establishing the 
boundaries of phosphotyrosine signaling. Mol.Cell, 22, 851-868. 
 153.  Lobley, A., Whitmore, L. und Wallace, B. A. (2002). DICHROWEB: an interactive 
website for the analysis of protein secondary structure from circular dichroism 
spectra. Bioinformatics., 18, 211-212. 
 154.  Lundin, P., Johansson, H., Guterstam, P., Holm, T., Hansen, M., Langel, U. und El, A. 
S. (2008). Distinct uptake routes of cell-penetrating peptide conjugates. 
Bioconjug.Chem., 19, 2535-2542. 
 155.  Luxembourg, S. L., Vaezaddeh, A. R., Amstalden, E. R., Zimmermann-Ivol, C. G., 
Hochstrasser, D. F. und Heeren, R. M. (2006). The molecular scanner in microscope 
mode. Rapid Commun.Mass Spectrom., 20, 3435-3442. 
 156.  Mader, O., Reiner, K., Egelhaaf, H. J., Fischer, R. und Brock, R. (2004). Structure 
property analysis of pentamethine indocyanine dyes: identification of a new dye for 
life science applications. Bioconjug.Chem., 15, 70-78. 
8. REFERENCES 
 
151 
 157.  Maeda, H. (2001). SMANCS and polymer-conjugated macromolecular drugs: 
advantages in cancer chemotherapy. Adv.Drug Deliv.Rev., 46, 169-185. 
 158.  Magzoub, M., Kilk, K., Eriksson, L. E., Langel, U. und Graslund, A. (2001). Interaction 
and structure induction of cell-penetrating peptides in the presence of phospholipid 
vesicles. Biochim.Biophys.Acta, 1512, 77-89. 
 159.  Magzoub, M., Pramanik, A. und Graslund, A. (2005). Modeling the endosomal 
escape of cell-penetrating peptides: transmembrane pH gradient driven translocation 
across phospholipid bilayers. Biochemistry, 44, 14890-14897. 
 160.  Malkov, D., Angelo, R., Wang, H. Z., Flanders, E., Tang, H. und Gomez-Orellana, I. 
(2005). Oral delivery of insulin with the eligen technology: mechanistic studies. 
Curr.Drug Deliv., 2, 191-197. 
 161.  Malugin, A., Kopeckova, P. und Kopecek, J. (2004). HPMA copolymer-bound 
doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-
independent pathway. Mol.Pharm., 1, 174-182. 
 162.  Mammen, M., Choi, S.-K. und Whitesides, G. M. (1998). Polyvalente 
Wechselwirkungen in biologischen Systemen: Auswirkungen auf das Design und die 
Verwendung multivalenter Liganden und Inhibitoren. Angew.Chem., 110, 2908-2953. 
 163.  Manning, G., Whyte, D. B., Martinez, R., Hunter, T. und Sudarsanam, S. (2002). The 
protein kinase complement of the human genome. Science, 298, 1912-1934. 
 164.  Matsuzaki, K., Yoneyama, S., Fujii, N., Miyajima, K., Yamada, K., Kirino, Y. und 
Anzai, K. (1997). Membrane permeabilization mechanisms of a cyclic antimicrobial 
peptide, tachyplesin I, and its linear analog. Biochemistry, 36, 9799-9806. 
 165.  Mayer, R. J., Chen, J. T., Taira, K., Fierke, C. A. und Benkovic, S. J. (1986). 
Importance of a hydrophobic residue in binding and catalysis by dihydrofolate 
reductase. Proc.Natl.Acad.Sci.U.S.A, 83, 7718-7720. 
 166.  Melvik, J. E., Pettersen, E. O., Gordon, P. B. und Seglen, P. O. (1986). Increase in 
cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization 
of the plasma membrane in cultured human NHIK 3025 cells. Eur.J.Cancer 
Clin.Oncol., 22, 1523-1530. 
 167.  Meseth, U., Wohland, T., Rigler, R. und Vogel, H. (1999). Resolution of fluorescence 
correlation measurements. Biophys.J., 76, 1619-1631. 
 168.  Metz-Boutigue, M. H., Jolles, J., Mazurier, J., Schoentgen, F., Legrand, D., Spik, G., 
Montreuil, J. und Jolles, P. (1984). Human lactotransferrin: amino acid sequence and 
structural comparisons with other transferrins. Eur.J.Biochem., 145, 659-676. 
 169.  Meyvis, T. K., De Smedt, S. C., Van, O. P. und Demeester, J. (1999). Fluorescence 
recovery after photobleaching: a versatile tool for mobility and interaction 
measurements in pharmaceutical research. Pharm.Res., 16, 1153-1162. 
8. REFERENCES 
 
152 
 170.  Michaelis, L. und Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochem.Z., 
49, 333-369. 
 171.  Miller, L. W. und Cornish, V. W. (2005). Selective chemical labeling of proteins in 
living cells. Curr.Opin.Chem.Biol., 9, 56-61. 
 172.  Miller, L. W., Sable, J., Goelet, P., Sheetz, M. P. und Cornish, V. W. (2004). 
Methotrexate conjugates: a molecular in vivo protein tag. Angew.Chem.Int.Ed Engl., 
43, 1672-1675. 
 173.  Miller, M. L., Jensen, L. J., Diella, F., Jorgensen, C., Tinti, M., Li, L., Hsiung, M., 
Parker, S. A., Bordeaux, J., Sicheritz-Ponten, T., Olhovsky, M., Pasculescu, A., 
Alexander, J., Knapp, S., Blom, N., Bork, P., Li, S., Cesareni, G., Pawson, T., Turk, B. 
E., Yaffe, M. B., Brunak, S. und Linding, R. (2008). Linear motif atlas for 
phosphorylation-dependent signaling. Sci.Signal., 1, ra2. 
 174.  Mir, L. M., Banoun, H. und Paoletti, C. (1988). Introduction of definite amounts of 
nonpermeant molecules into living cells after electropermeabilization: direct access to 
the cytosol. Exp.Cell Res., 175, 15-25. 
 175.  Mitchell, D. J., Kim, D. T., Steinman, L., Fathman, C. G. und Rothbard, J. B. (2000). 
Polyarginine enters cells more efficiently than other polycationic homopolymers. J 
Pept.Res., 56, 318-325. 
 176.  Mizuno, T., Miyashita, M. und Miyagawa, H. (2009). Cellular internalization of 
arginine-rich peptides into tobacco suspension cells: a structure-activity relationship 
study. J.Pept.Sci., 15, 259-263. 
 177.  Nagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A., Latham, D. G., Lissy, N. 
A., Becker-Hapak, M., Ezhevsky, S. A. und Dowdy, S. F. (1998). Transduction of full-
length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. 
Nat.Med., 4, 1449-1452. 
 178.  Nekhotiaeva, N., Elmquist, A., Rajarao, G. K., Hallbrink, M., Langel, U. und Good, L. 
(2004). Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. 
FASEB J., 18, 394-396. 
 179.  Neumann, E., Schaefer-Ridder, M., Wang, Y. und Hofschneider, P. H. (1982). Gene 
transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J., 1, 
841-845. 
 180.  Nielsen, C. U., Andersen, R., Brodin, B., Frokjaer, S., Taub, M. E. und Steffansen, B. 
(2001). Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity 
for and transport via hPepT1 in the human intestinal Caco-2 cell line. J.Control 
Release, 76, 129-138. 
 181.  Nolan, G. P. (2007). What's wrong with drug screening today. Nat.Chem.Biol., 3, 187-
191. 
8. REFERENCES 
 
153 
 182.  Noor, F., Kinscherf, R., Bonaterra, G. A., Walczak, S., Wolfl, S. und Metzler-Nolte, N. 
(2009). Enhanced Cellular Uptake and Cytotoxicity Studies of Organometallic 
Bioconjugates of the NLS Peptide in Hep G2 Cells. Chembiochem., 10, 493-502. 
 183.  Nori, A., Jensen, K. D., Tijerina, M., Kopeckova, P. und Kopecek, J. (2003). Tat-
conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human 
ovarian carcinoma cells. Bioconjug.Chem., 14, 44-50. 
 184.  Oehlke, J., Wallukat, G., Wolf, Y., Ehrlich, A., Wiesner, B., Berger, H. und Bienert, M. 
(2004). Enhancement of intracellular concentration and biological activity of PNA after 
conjugation with a cell-penetrating synthetic model peptide. Eur.J.Biochem., 271, 
3043-3049. 
 185.  Oesch, F., Fabian, E., Oesch-Bartlomowicz, B., Werner, C. und Landsiedel, R. 
(2007). Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev., 
39, 659-698. 
 186.  Omelyanenko, V., Kopeckova, P., Gentry, C. und Kopecek, J. (1998). Targetable 
HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular 
fate. J.Control Release, 53, 25-37. 
 187.  Pace, C. N., Vajdos, F., Fee, L., Grimsley, G. und Gray, T. (1995). How to measure 
and predict the molar absorption coefficient of a protein. Protein Sci., 4, 2411-2423. 
 188.  Pawson, T. und Nash, P. (2003). Assembly of cell regulatory systems through protein 
interaction domains. Science, 300, 445-452. 
 189.  Pedersen, P. L. (2007). Transport ATPases into the year 2008: a brief overview 
related to types, structures, functions and roles in health and disease. 
J.Bioenerg.Biomembr., 39, 349-355. 
 190.  Pellecchia, M., Sem, D. S. und Wuthrich, K. (2002). NMR in drug discovery. 
Nat.Rev.Drug Discov., 1, 211-219. 
 191.  Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F. und Altschuler, S. J. 
(2004). Multidimensional drug profiling by automated microscopy. Science, 306, 
1194-1198. 
 192.  Peterson, N. A., Anderson, B. F., Jameson, G. B., Tweedie, J. W. und Baker, E. N. 
(2000). Crystal structure and iron-binding properties of the R210K mutant of the N-
lobe of human lactoferrin: implications for iron release from transferrins. Biochemistry, 
39, 6625-6633. 
 193.  Piehler, J., Brecht, A., Geckeler, K. E. und Gauglitz, G. (1996). Surface modification 
for direct immunoprobes. Biosens.Bioelectron., 11, 579-590. 
 194.  Poon, G. M. und Gariepy, J. (2007). Cell-surface proteoglycans as molecular portals 
for cationic peptide and polymer entry into cells. Biochem.Soc.Trans., 35, 788-793. 
8. REFERENCES 
 
154 
 195.  Postema, M. und Gilja, O. H. (2007). Ultrasound-directed drug delivery. 
Curr.Pharm.Biotechnol., 8, 355-361. 
 196.  Powell, M. S., Barnes, N. C., Bradford, T. M., Musgrave, I. F., Wines, B. D., Cambier, 
J. C. und Hogarth, P. M. (2006). Alteration of the Fc gamma RIIa dimer interface 
affects receptor signaling but not ligand binding. J.Immunol., 176, 7489-7494. 
 197.  Provencher, S. W. und Glockner, J. (1981). Estimation of globular protein secondary 
structure from circular dichroism. Biochemistry, 20, 33-37. 
 198.  Pygall, S. R., Whetstone, J., Timmins, P. und Melia, C. D. (2007). Pharmaceutical 
applications of confocal laser scanning microscopy: the physical characterisation of 
pharmaceutical systems. Adv.Drug Deliv.Rev., 59, 1434-1452. 
 199.  Rademann, J. und Jung G (2000). Drug discovery - Integrating combinatorial 
synthesis and bioassays. Science, 287, 1947-1948. 
 200.  Rajagopalan, P. T., Zhang, Z., McCourt, L., Dwyer, M., Benkovic, S. J. und Hammes, 
G. G. (2002). Interaction of dihydrofolate reductase with methotrexate: ensemble and 
single-molecule kinetics. Proc.Natl.Acad.Sci.U.S.A, 99, 13481-13486. 
 201.  Ram, N., Aroui, S., Jaumain, E., Bichraoui, H., Mabrouk, K., Ronjat, M., Lortat-Jacob, 
H. und De, W. M. (2008). Direct peptide interaction with surface glycosaminoglycans 
contributes to the cell penetration of maurocalcine. J.Biol.Chem., 283, 24274-24284. 
 202.  Ramamoorthy, A., Thennarasu, S., Tan, A., Gottipati, K., Sreekumar, S., Heyl, D. L., 
An, F. Y. und Shelburne, C. E. (2006). Deletion of all cysteines in tachyplesin I 
abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide 
selective binding. Biochemistry, 45, 6529-6540. 
 203.  Rao, M. und Alving, C. R. (2000). Delivery of lipids and liposomal proteins to the 
cytoplasm and Golgi of antigen-presenting cells. Adv.Drug Deliv.Rev., 41, 171-188. 
 204.  Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Jarvinen, T. und 
Savolainen, J. (2008). Prodrugs: design and clinical applications. Nat.Rev.Drug 
Discov., 7, 255-270. 
 205.  Reichmann, D., Rahat, O., Cohen, M., Neuvirth, H. und Schreiber, G. (2007). The 
molecular architecture of protein-protein binding sites. Curr.Opin.Struct.Biol., 17, 67-
76. 
 206.  Remy, I. und Michnick, S. W. (2001). Visualization of biochemical networks in living 
cells. Proc.Natl.Acad.Sci.U.S.A, 98, 7678-7683. 
 207.  Rigler, R., Mets, U., Widengren, J. und Kask, P. (1993). Fluorescence corelation 
spectroscopy with high count rate and low background: Analysis of translational 
diffusion. Eur.Biophys.J., 22, 169-175. 
8. REFERENCES 
 
155 
 208.  Robinson, J. A., Demarco, S., Gombert, F., Moehle, K. und Obrecht, D. (2008). The 
design, structures and therapeutic potential of protein epitope mimetics. Drug 
Discov.Today, 13, 944-951. 
 209.  Rohrbach, S., Muller-Werdan, U., Werdan, K., Koch, S., Gellerich, N. F. und Holtz, J. 
(2005). Apoptosis-modulating interaction of the neuregulin/erbB pathway with 
anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J.Mol.Cell Cardiol., 
38, 485-493. 
 210.  Rojas, M., Donahue, J. P., Tan, Z. und Lin, Y. Z. (1998). Genetic engineering of 
proteins with cell membrane permeability. Nat.Biotechnol., 16, 370-375. 
 211.  Roodhart, J. M., Langenberg, M. H., Witteveen, E. und Voest, E. E. (2008). The 
molecular basis of class side effects due to treatment with inhibitors of the 
VEGF/VEGFR pathway. Curr.Clin.Pharmacol., 3, 132-143. 
 212.  Rouquayrol, M., Gaucher, B., Roche, D., Greiner, J. und Vierling, P. (2002). 
Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, 
indinavir, and nelfinavir across Caco-2 cell monolayers. Pharm.Res., 19, 1704-1712. 
 213.  Ruijtenbeek, R., Kruijtzer, J. A., van de, W. W., Fischer, M. J., Fluck, M., Redegeld, F. 
A., Liskamp, R. M. und Nijkamp, F. P. (2001). Peptoid - peptide hybrids that bind Syk 
SH2 domains involved in signal transduction. Chembiochem., 2, 171-179. 
 214.  Russell-Jones, G. J., Westwood, S. W. und Habberfield, A. D. (1995). Vitamin B12 
mediated oral delivery systems for granulocyte-colony stimulating factor and 
erythropoietin. Bioconjug.Chem., 6, 459-465. 
 215.  Ruttekolk, I. R., Duchardt, F., Fischer, R., Wiesmuller, K. H., Rademann, J. und 
Brock, R. (2008). HPMA as a scaffold for the modular assembly of functional peptide 
polymers by native chemical ligation. Bioconjug.Chem., 19, 2081-2087. 
 216.  Ryser, H. J. und Shen, W. C. (1978). Conjugation of methotrexate to poly(L-lysine) 
increases drug transport and overcomes drug resistance in cultured cells. 
Proc.Natl.Acad.Sci.U.S.A, 75, 3867-3870. 
 217.  Ryser, H. J., Shen, W. C. und Merk, F. B. (1978). Membrane transport of 
macromolecules: new carrier functions of proteins and poly(amino acids). Life Sci., 
22, 1253-1260. 
 218.  Sandanaraj, B. S., Vutukuri, D. R., Simard, J. M., Klaikherd, A., Hong, R., Rotello, V. 
M. und Thayumanavan, S. (2005). Noncovalent modification of chymotrypsin surface 
using an amphiphilic polymer scaffold: implications in modulating protein function. J 
Am.Chem Soc., 127, 10693-10698. 
 219.  Santra, S., Yang, H., Holloway, P. H., Stanley, J. T. und Mericle, R. A. (2005a). 
Synthesis of water-dispersible fluorescent, radio-opaque, and paramagnetic 
CdS:Mn/ZnS quantum dots: a multifunctional probe for bioimaging. J.Am.Chem.Soc., 
127, 1656-1657. 
8. REFERENCES 
 
156 
 220.  Santra, S., Yang, H., Stanley, J. T., Holloway, P. H., Moudgil, B. M., Walter, G. und 
Mericle, R. A. (2005b). Rapid and effective labeling of brain tissue using TAT-
conjugated CdS:Mn/ZnS quantum dots. Chem.Commun.(Camb.), 3144-3146. 
 221.  Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A., Greene, A. 
K., Corfas, G. und Folkman, J. (2004). Targeting angiogenesis with a conjugate of 
HPMA copolymer and TNP-470. Nat.Med., 10, 255-261. 
 222.  Schmidt, M. C., Rothen-Rutishauser, B., Rist, B., Beck-Sickinger, A., Wunderli-
Allenspach, H., Rubas, W., Sadee, W. und Merkle, H. P. (1998). Translocation of 
human calcitonin in respiratory nasal epithelium is associated with self-assembly in 
lipid membrane. Biochemistry, 37, 16582-16590. 
 223.  Schwarze, S. R., Ho, A., Vocero-Akbani, A. und Dowdy, S. F. (1999). In vivo protein 
transduction: delivery of a biologically active protein into the mouse. Science, 285, 
1569-1572. 
 224.  Schwille, P., Haupts, U., Maiti, S. und Webb, W. W. (1999). Molecular dynamics in 
living cells observed by fluorescence correlation spectroscopy with one- and two-
photon excitation. Biophys.J, 77, 2251-2265. 
 225.  Schwille, P., Meyer-Almes, F. J. und Rigler, R. (1997). Dual-color fluorescence cross-
correlation spectroscopy for multicomponent diffusional analysis in solution. 
Biophys.J, 72, 1878-1886. 
 226.  Searle, F., Gac-Breton, S., Keane, R., Dimitrijevic, S., Brocchini, S., Sausville, E. A. 
und Duncan, R. (2001). N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-
aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo 
evaluation. Bioconjug.Chem, 12, 711-718. 
 227.  Seethala, R. und Menzel, R. (1997). A homogeneous, fluorescence polarization 
assay for src-family tyrosine kinases. Anal.Biochem., 253, 210-218. 
 228.  Selsted, M. E. (2004). Theta-defensins: cyclic antimicrobial peptides produced by 
binary ligation of truncated alpha-defensins. Curr.Protein Pept.Sci., 5, 365-371. 
 229.  Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K. und 
Duncan, R. (1995). Influence of molecular weight on passive tumour accumulation of 
a soluble macromolecular drug carrier. Eur.J.Cancer, 31A, 766-770. 
 230.  Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J. und Duncan, R. (1990). The 
pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol., 39, 1125-
1131. 
 231.  Shen, W. C. und Ryser, H. J. (1978). Conjugation of poly-L-lysine to albumin and 
horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. 
Proc.Natl.Acad.Sci.U.S.A, 75, 1872-1876. 
 232.  Shi, X., Foo, Y. H., Sudhaharan, T., Chong, S. W., Korzh, V., Ahmed, S. und 
Wohland, T. (2009). Determination of dissociation constants in living zebrafish 
8. REFERENCES 
 
157 
embryos with single wavelength fluorescence cross-correlation spectroscopy. 
Biophys.J., 97, 678-686. 
 233.  Signor, L., Varesio, E., Staack, R. F., Starke, V., Richter, W. F. und Hopfgartner, G. 
(2007). Analysis of erlotinib and its metabolites in rat tissue sections by MALDI 
quadrupole time-of-flight mass spectrometry. J.Mass Spectrom., 42, 900-909. 
 234.  So, A., Hadaschik, B., Sowery, R. und Gleave, M. (2007). The role of stress proteins 
in prostate cancer. Curr.Genomics, 8, 252-261. 
 235.  Sonnevend, A., Knoop, F. C., Patel, M., Pal, T., Soto, A. M. und Conlon, J. M. (2004). 
Antimicrobial properties of the frog skin peptide, ranatuerin-1 and its [Lys-8]-
substituted analog. Peptides, 25, 29-36. 
 236.  Sorscher, S. M., Bartholomew, J. C. und Klein, M. P. (1980). The use of fluorescence 
correlations spectroscopy to probe chromatin in the cell nucleus. 
Biochim.Biophys.Acta, 610, 28-46. 
 237.  Southwick, P. L., Ernst, L. A., Tauriello, E. W., Parker, S. R., Mujumdar, R. B., 
Mujumdar, S. R., Clever, H. A. und Waggoner, A. S. (1990). Cyanine dye labeling 
reagents--carboxymethylindocyanine succinimidyl esters. Cytometry, 11, 418-430. 
 238.  Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., 
Blumberg, R. S. und Lencer, W. I. (2002). Receptor-mediated immunoglobulin G 
transport across mucosal barriers in adult life: functional expression of FcRn in the 
mammalian lung. J.Exp.Med., 196, 303-310. 
 239.  Steinhilber/Schubert-Zsilavecz/Roth 2005. Medizinische Chemie - Targets und 
Arzneistoffe, Deutscher Apotheker Verlag Stuttgart. 
 240.  Stephens, D. J. und Pepperkok, R. (2001). The many ways to cross the plasma 
membrane. Proc.Natl.Acad.Sci.U.S.A, 98, 4295-4298. 
 241.  Stoevesandt, O., Elbs, M., Kohler, K., Lellouch, A. C., Fischer, R., Andre, T. und 
Brock, R. (2005a). Peptide microarrays for the detection of molecular interactions in 
cellular signal transduction. Proteomics., 5, 2010-2017. 
 242.  Stoevesandt, O., Kohler, K., Fischer, R., Johnston, I. C. und Brock, R. (2005b). One-
step analysis of protein complexes in microliters of cell lysate. Nat.Methods, 2, 833-
835. 
 243.  Stoevesandt, O. und Taussig, M. J. (2007). Affinity reagent resources for human 
proteome detection: initiatives and perspectives. Proteomics., 7, 2738-2750. 
 244.  Strasser, A., Jost, P. J. und Nagata, S. (2009). The many roles of FAS receptor 
signaling in the immune system. Immunity., 30, 180-192. 
 245.  Stumpf, W. E. (2005). Drug localization and targeting with receptor microscopic 
autoradiography. J.Pharmacol.Toxicol.Methods, 51, 25-40. 
8. REFERENCES 
 
158 
 246.  Stumpf, W. E., Hayakawa, N. und Bidmon, H. J. (2008). Skin research and drug 
localization with receptor microscopic autoradiography. Exp.Dermatol., 17, 133-138. 
 247.  Sun, X. L., Baker, H. M., Shewry, S. C., Jameson, G. B. und Baker, E. N. (1999). 
Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta 
Crystallogr.D.Biol.Crystallogr., 55, 403-407. 
 248.  Suzuki, Y. A., Lopez, V. und Lonnerdal, B. (2005). Mammalian lactoferrin receptors: 
structure and function. Cell Mol.Life Sci., 62, 2560-2575. 
 249.  Swaan, P. W., Hillgren, K. M., Szoka, F. C., Jr. und Oie, S. (1997). Enhanced 
transepithelial transport of peptides by conjugation to cholic acid. Bioconjug.Chem., 8, 
520-525. 
 250.  Takeshima, K., Chikushi, A., Lee, K.-K., Yonehara, S. und Matsuzaki, K. (2003). 
Translocation of analogues of the antimicrobial peptides Magainin and Buforin across 
human cell membranes. J.Biol.Chem., 278, 1310-1315. 
 251.  Tam, J. P., Xu, J. und Eom, K. D. (2001). Methods and strategies of peptide ligation. 
Biopolymers, 60, 194-205. 
 252.  Testa, B. (2009). Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. 
Curr.Opin.Chem.Biol.. 
 253.  Testa, B. und Kramer, S. D. (2009). The biochemistry of drug metabolism--an 
introduction: part 5. Metabolism and bioactivity. Chem.Biodivers., 6, 591-684. 
 254.  Thanou, M., Verhoef, J. C. und Junginger, H. E. (2001). Oral drug absorption 
enhancement by chitosan and its derivatives. Adv.Drug Deliv.Rev., 52, 117-126. 
 255.  Tirlapur, U. K. und Konig, K. (2002). Targeted transfection by femtosecond laser. 
Nature, 418, 290-291. 
 256.  Toke, O. (2005). Antimicrobial peptides: new candidates in the fight against bacterial 
infections. Biopolymers, 80, 717-735. 
 257.  Tunnemann, G., Martin, R. M., Haupt, S., Patsch, C., Edenhofer, F. und Cardoso, M. 
C. (2006). Cargo-dependent mode of uptake and bioavailability of TAT-containing 
proteins and peptides in living cells. FASEB J., 20, 1775-1784. 
 258.  Tunnemann, G., Ter-Avetisyan, G., Martin, R. M., Stockl, M., Herrmann, A. und 
Cardoso, M. C. (2008). Live-cell analysis of cell penetration ability and toxicity of 
oligo-arginines. J.Pept.Sci., 14, 469-476. 
 259.  Turner, J. J., Ivanova, G. D., Verbeure, B., Williams, D., Arzumanov, A. A., Abes, S., 
Lebleu, B. und Gait, M. J. (2005). Cell-penetrating peptide conjugates of peptide 
nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. 
Nucleic Acids Res., 33, 6837-6849. 
8. REFERENCES 
 
159 
 260.  Turner, M. und Billadeau, D. D. (2002). VAV proteins as signal integrators for multi-
subunit immune-recognition receptors. Nat.Rev.Immunol., 2, 476-486. 
 261.  Tyagi, M., Rusnati, M., Presta, M. und Giacca, M. (2001). Internalization of HIV-1 tat 
requires cell surface heparan sulfate proteoglycans. J.Biol.Chem., 276, 3254-3261. 
 262.  Unnamalai, N., Kang, B. G. und Lee, W. S. (2004). Cationic oligopeptide-mediated 
delivery of dsRNA for post-transcriptional gene silencing in plant cells. FEBS Lett., 
566, 307-310. 
 263.  Valenti, P. und Antonini, G. (2005). Lactoferrin: an important host defence against 
microbial and viral attack. Cell Mol.Life Sci., 62, 2576-2587. 
 264.  van de Ven, M., van Ginkel, G. und Levine, Y. K. (1984). Angle resolved fluorescence 
depolarisation of 1,6-diphenyl-1,3,5 hexatriene (DPH) in unsaturated digalactosyl 
diacylglycerol (DGDG) lipid bilayers. Biochem Biophys.Res.Commun., 123, 352-357. 
 265.  van de Waterbeemd, H. (1998). The fundamental variables of the biopharmaceutics 
classification system (BCS): a commentary. Eur.J.Pharm.Sci., 7, 1-3. 
 266.  van Kuppevelt, T. H., Dennissen, M. A., van Venrooij, W. J., Hoet, R. M. und 
Veerkamp, J. H. (1998). Generation and application of type-specific anti-heparan 
sulfate antibodies using phage display technology. Further evidence for heparan 
sulfate heterogeneity in the kidney. J Biol.Chem., 273, 12960-12966. 
 267.  van, S., I, Spoelder, H. J., Bloemendal, M., van, G. R. und Groen, F. C. (1990). 
Estimation of protein secondary structure and error analysis from circular dichroism 
spectra. Anal.Biochem., 191, 110-118. 
 268.  Verma, A., Uzun, O., Hu, Y., Hu, Y., Han, H. S., Watson, N., Chen, S., Irvine, D. J. 
und Stellacci, F. (2008). Surface-structure-regulated cell-membrane penetration by 
monolayer-protected nanoparticles. Nat.Mater., 7, 588-595. 
 269.  Veronese, F. M. (2001). Peptide and protein PEGylation: a review of problems and 
solutions. Biomaterials, 22, 405-417. 
 270.  Vicent, M. J. und Duncan, R. (2006). Polymer conjugates: nanosized medicines for 
treating cancer. TRENDS in Biotechnology, 24, 39-47. 
 271.  Vives, E., Brodin, P. und Lebleu, B. (1997). A truncated HIV-1 Tat protein basic 
domain rapidly translocates through the plasma membrane and accumulates in the 
cell nucleus. J Biol.Chem, 272, 16010-16017. 
 272.  Wachsmuth, M., Waldeck, W. und Langowski, J. (2000). Anomalous diffusion of 
fluorescent probes inside living cell nuclei investigated by spatially-resolved 
fluorescence correlation spectroscopy. J.Mol.Biol., 298, 677-689. 
8. REFERENCES 
 
160 
 273.  Wadhwani, P., Afonin, S., Ieronimo, M., Buerck, J. und Ulrich, A. S. (2006). Optimized 
protocol for synthesis of cyclic gramicidin S: starting amino acid is key to high yield. 
J.Org.Chem., 71, 55-61. 
 274.  Wadia, J. S., Stan, R. V. und Dowdy, S. F. (2004). Transducible TAT-HA fusogenic 
peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. 
Nat.Med., 10, 310-315. 
 275.  Wagner, G. und Laufer, S. (2006). Small molecular anti-cytokine agents. 
Med.Res.Rev., 26, 1-62. 
 276.  Walensky, L. D., Pitter, K., Morash, J., Oh, K. J., Barbuto, S., Fisher, J., Smith, E., 
Verdine, G. L. und Korsmeyer, S. J. (2006). A stapled BID BH3 helix directly binds 
and activates BAX. Mol.Cell, 24, 199-210. 
 277.  Ward, P. P. und Conneely, O. M. (2004). Lactoferrin: role in iron homeostasis and 
host defense against microbial infection. Biometals, 17, 203-208. 
 278.  Washtien, W. L. (1982). Thymidylate synthetase levels as a factor in 5-
fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. 
Mol.Pharmacol., 21, 723-728. 
 279.  Weidemann, T., Wachsmuth, M., Tewes, M., Rippe, K. und Langowski, J. (2002). 
Analysis of Ligand Binding by Two-Colour Fluorescence Cross-Corelation 
Spectroscopy. Single Mol., 1, 49-61. 
 280.  Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L. und 
Rothbard, J. B. (2000). The design, synthesis, and evaluation of molecules that 
enable or enhance cellular uptake: peptoid molecular transporters. 
Proc.Natl.Acad.Sci U.S.A, 97, 13003-13008. 
 281.  Westphal, V. und Hell, S. W. (2005). Nanoscale resolution in the focal plane of an 
optical microscope. Phys.Rev.Lett., 94, 143903. 
 282.  Whitmore, L. und Wallace, B. A. (2004). DICHROWEB, an online server for protein 
secondary structure analyses from circular dichroism spectroscopic data. Nucleic 
Acids Res., 32, W668-W673. 
 283.  Willis, S. N. und Adams, J. M. (2005). Life in the balance: how BH3-only proteins 
induce apoptosis. Curr.Opin.Cell Biol., 17, 617-625. 
 284.  Witt, J. J. und Roskoski, R., Jr. (1975). Rapid protein kinase assay using 
phosphocellulose-paper absorption. Anal.Biochem., 66, 253-258. 
 285.  Wolf, Y., Pritz, S., Abes, S., Bienert, M., Lebleu, B. und Oehlke, J. (2006). Structural 
requirements for cellular uptake and antisense activity of peptide nucleic acids 
conjugated with various peptides. Biochemistry, 45, 14944-14954. 
8. REFERENCES 
 
161 
 286.  Wu, G., Chai, J., Suber, T. L., Wu, J. W., Du, C., Wang, X. und Shi, Y. (2000). 
Structural basis of IAP recognition by Smac/DIABLO. Nature, 408, 1008-1012. 
 287.  Wu, M. und Hancock, R. E. (1999). Interaction of the cyclic antimicrobial cationic 
peptide bactenecin with the outer and cytoplasmic membrane. Journal of Biological 
Chemistry, 274, 29-35. 
 288.  Yaffe, M. B. (2002). Phosphotyrosine-binding domains in signal transduction. 
Nat.Rev.Mol.Cell Biol., 3, 177-186. 
 289.  Yamamoto, A., Tatsumi, H., Maruyama, M., Uchiyama, T., Okada, N. und Fujita, T. 
(2001). Modulation of intestinal permeability by nitric oxide donors: implications in 
intestinal delivery of poorly absorbable drugs. J.Pharmacol.Exp.Ther., 296, 84-90. 
 290.  Yaroslavov, A. A., Sitnikova, T. A., Rakhnyanskaya, A. A., Yaroslavova, E. G., 
Davydov, D. A., Burova, T. V., Grinberg, V. Y., Shi, L. und Menger, F. M. (2009). 
Biomembrane Sensitivity to Structural Changes in Bound Polymers. J.Am.Chem.Soc.. 
 291.  Yen, W. C. und Lee, V. H. (1995). Role of Na+ in the asymmetric paracellular 
transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across 
rabbit colonic segments and Caco-2 cell monolayers. J.Pharmacol.Exp.Ther., 275, 
114-119. 
 292.  Zhang, W. und Smith, S. O. (2005). Mechanism of penetration of Antp(43-58) into 
membrane bilayers. Biochemistry, 44, 10110-10118. 
 293.  Zhang, Y. und Yu, L. C. (2008). Microinjection as a tool of mechanical delivery. 
Curr.Opin.Biotechnol., 19, 506-510. 
 
 
9. ACADEMIC TEACHERS 
 
162 
9. Academic teachers 
 
K. Albert, E.O. Bayer, C.F. Bardele, H. Bisswanger, K.W. Bock, P. Bohley, U. Breyer-Pfaff, R. 
Brock, A. Buchmann, M. Duszenko, H.-J. Egelhaaf, K. Eisele, G. Gaugliz, G. Häfelinger, B. 
Hamprecht, H. Kalbacher, C. Köhle, S. Laufer, E. Lindner, F. Madeo, W. Maier, P.A. Münzel, 
H. Ninnemann, H. Oberhammer, H. Pommer, K. Reutter, H. Schott, M. Schwarz, G. 
Steinbrück, R. Süssmuth, J. Strähle, S. Verleysdonk, J. Werringloer, U. Weser, K.-H. 
Wiesmüller, K.-P. Zeller 
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10.1. LEBENSLAUF (DEUTSCH) 
IVO ROBERT RUTTEKOLK, GEBOREN AM 14. JULI 1980 IN SOLINGEN 
 
PROMOTIONSTÄTIGKEIT  
  
August 2007 - November 2009 Fortsetzung der Arbeit in Nijmegen (Niederlande) 
"Untersuchung zur Zellulären Pharmakologie von peptidischen und 
nichtpeptidischen Wirkstoffmolekülen", betreut durch Prof. Dr. R. Brock, 
Nijmegen Centre of Molecular Life Sciences (NCMLS), und Prof. Dr. S. 
Laufer, Institut für Pharmazeutische Chemie, Tübingen 
August 2007 Umzug der Arbeitsgruppe in die Niederlande 
April 2006 - Juli 2007 Beginn der Promitionstätigkeit in Tübingen 
 
BIOCHEMIESTUDIUM 
 
  
März 2006 Biochemiediplom (Wahlfächer: Toxikologie, Analytische Chemie)  
Juli 2005 - März 2006 Diplomarbeit "Synthese, Charakterisierung und zelluläre Testung 
polymerkonjugierter, funktioneller Peptide“, Prof. Dr. K.-H. Wiesmüller, 
EMC microcollections GmbH und Institut für Organische Chemie und 
Dr. R. Brock, Institut für Zellbiologie, Tübingen 
April 2001 - März 2006 Biochemiestudium in Tübingen (Vordiplom: Juli 2003) 
 
SANITÄTSDIENST DER BUNDESWEHR  
 
  
Juli 2000 - März 2001 sanitätsdienstliche und organisatorische Aufgaben 
 
 
SCHULAUSBILDUNG 
 
  
September 1991 - Juni 2000 Gymnasium August-Dicke-Schule, Solingen, Abschluss: Abitur  
 
INDUSTRIEERFAHRUNG 
 
  
Januar - April 2008 dreimonatiger Laboraufenthalt bei EVONIK Industries (Industriepark 
Marl) 
Mai 2007 - September 2009 Zusammenarbeit mit EVONIK Industries (Marl/Darmstadt), 
April 2006 - September 2009  enge Zusammenarbeit mit den deutschen Biotechnologieunternehmen 
gpc-biotech (München) und Intana Bioscience (München), 
Mai - Juli 2008 Kooperation mit dem Technologieunternehmen Lonza (Köln), 
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10.2. CURRICULUM VITAE (ENGLISH) 
IVO R. RUTTEKOLK, BORN ON JULY 14TH, 1980 IN SOLINGEN 
 
PHD THESIS  
  
August 2007 - November 2009 Completion of the PhD thesis in Nijmegen (The Netherlands) 
"Investigation of the Cellular Pharmacology of Peptidic and Non-
Peptidic Compounds", supervised by Prof. Dr. R. Brock, Nijmegen 
Centre of Molecular Life Sciences (NCMLS), and Prof. Dr. S. Laufer, 
Institute for Pharmaceutical Chemistry, Tübingen 
since August 2007 Move of the workgroup to The Netherlands 
April 2006 - July 2007 Start of the PhD thesis in Tübingen 
 
STUDIES OF BIOCHEMISTRY 
 
  
March 2006 Diploma in biochemistry (specialization: toxicology, analytical 
chemistry)  
July 2005 - March 2006 Diploma thesis "Synthesis, Characterization and Cellular Testing of 
Polymer-Conjugated, Functional Peptides“, supervised by Prof. Dr. K.-
H. Wiesmüller, EMC microcollections GmbH and Institute for Organic 
Chemistry and Dr. R. Brock, Institute for Cell Biology, Tübingen 
April 2001 - March 2006 Studies in Biochemistry, Tübingen (July 2003: prediploma) 
 
MILITARY DUTY IN THE MEDICAL SERVICE  
 
  
July 2000 - March 2001 Medical and organisational practice 
 
EDUCATION 
 
  
September 1991 - June 2000 Gymnasium August-Dicke-Schule, Solingen, graduation: Abitur 
 
INDUSTRIAL EXPERIENCE 
 
  
January - April 2008 Full-time internship with EVONIK Industries (Industrial Centre Marl),  
May 2007 - September 2009 Cooperation with EVONIK Industries (Marl/Darmstadt): 
April 2006 - September 2009 Tight cooperation with the German biotechnological company gpc 
biotech (Munich) and Intana Bioscience (Munich) 
May - September 2008 Conjoint project with the technological company Lonza (Cologne) 
 
